Graduate Theses, Dissertations, and Problem Reports
2015

Decellularized matrix and cartilage regeneration: A focus on
developing a matrix with anti-inflammation and micromechanical
properties
Ying Zhang

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Zhang, Ying, "Decellularized matrix and cartilage regeneration: A focus on developing a matrix with antiinflammation and micromechanical properties" (2015). Graduate Theses, Dissertations, and Problem
Reports. 7035.
https://researchrepository.wvu.edu/etd/7035

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

DECELLULARIZED MATRIX AND CARTILAGE
REGENERATION: A FOCUS ON DEVELOPING A MATRIX
WITH ANTI-INFLAMMATION AND MICROMECHANICAL
PROPERTIES
Ying Zhang
Dissertation submitted to the Benjamin M. Statler College of
Engineering and Mineral Resources at West Virginia University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
Ming Pei, M.D., Ph.D., Chair
Cerasela Zoica Dinu, Ph.D.
Victor H. Mucino, Ph.D.
Konstantinos A. Sierros, Ph.D.
Nithi T. Sivaneri, Ph.D.
Nianqiang Wu, Ph.D.

in the Department of Mechanical and Aerospace Engineering
Morgantown, West Virginia
2015

Key words: Decellularized extracellular matrix, Anti-inflammation,
Chondrogenesis, Biomechanics
Copyright 2015 Ying Zhang

Abstract
DECELLULARIZED MATRIX AND CARTILAGE
REGENERATION: A FOCUS ON DEVELOPING A MATRIX
WITH ANTI-INFLAMMATION AND MICROMECHANICAL
PROPERTIES
Ying Zhang
Osteoarthritis (OA) is predicted to be the fourth leading cause of disability worldwide by the
year 2020. Stem cell-based therapy is a promising biological approach for the treatment of
cartilage defects. However, adult stem cells tend to become replicatively senescent when they
are expanded on conventional plastic flasks. Decellularized extracellular matrix (dECM)
provides an expansion system to rejuvenate and maintain the chondrogenic phenotype of stem
cells for cartilage repair. In addition, joints with cartilage defects normally have inflammation
to some extent; several stimuli, such as Reactive Oxygen Species (ROS) and Interleukin-1
(IL-1), reportedly induce apoptosis of chondrocytes. The tolerance of transplanted cells to a
harsh environment is a key determinant for successful cartilage repair. dECM expansion gives
adult stem cells an ability to resist inflammation and oxidants. This anti-inflammatory effect
was further optimized by the combined use of small molecules in inflammation-related
signaling pathways. Furthermore, dECM is a three-dimensional nanofiber structure with
unique micromechanical properties. The influence of dECM elasticity on expanded stem
cells’ chondrogenic differentiation has been studied. Our long-term goal is to develop an in
vitro stem cell matrix with optimized micromechanical properties to enhance stem cell
proliferation and boost chondrogenic differentiation in order to treat cartilage defects and OA.
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Specific Aims
Articular cartilage has a limited ability to self-heal because it is a unique hypocellular, and
avascular tissue and often accompanied with inflammation especially after trauma and
degenerative disease [1]. Mesenchymal stem cell (MSC) is a promising cell source for
cartilage regeneration because they are easily obtainable in high numbers and expanded in
vitro without losing their differentiation potential. A reconstructed in vitro three dimensional
(3D) stem cell microenvironment was found to dramatically increase cell numbers and greatly
enhanced chondrogenic capacities were observed, which inspired us to develop an efficient in
vitro cell expansion system with proliferation and chondrogenic differentiation rejuvenating
capacities [2]. The potential impact of this study is that the optimization of ex vivo stem cell
protocols with decellularized extracellular matrix for maintaining stemness and facilitating
chondrogenesis will provide high quality and a large quantity of cells for cartilage
regeneration in clinic. The understanding of the rejuvenation mechanisms including its
biochemical and biophysical mechanisms by matrixes will advance the knowledge of
cartilage regeneration and benefit the development of cartilage defect treatment.
The objectives of this dissertation were to: (1) Develop a 3D stem cell-derived decellularized
extracellular matrix (dECM), including surface characterization, expanded cell morphology,
functional analysis on its chondrogenesis, as well as biochemical signals. (2) Define novel
properties of dECM, focusing on its antioxidant and anti-inflammatory properties, which will
be promising for the application of osteoarthritis (OA) treatment. (3) Explore potential
mechanisms of dECM from biophysical (especially on substrate Young’s modulus)
perspective.
The central hypothesis was that dECM deposited by human stem cells can be optimized
biochemically and biophysically to serve as ex vivo expansion system to beter promote
cartilage regeneration in the inflammatory environment.
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Introduction
Current progress in cartilage repair
Osteoarthritis (OA), also called osteoarthrosis or degenerative joint disease, is a chronic joint
disease characterized by cartilage destruction, subchondral bone sclerosis, osteophyte
formation, synovial inflammation, and degeneration of ligaments. OA is the most common
type of arthritis, affecting nearly 27 million people in the United States alone [1]. In the latestage of OA when the disease progresses and the symptoms increase, surgical intervention
may be required. The treatment for cartilage injury remains a clinical challenge despite
advances in surgical techniques. Indeed, the oxidative and inflammatory environment of the
joints may induce telomere instability and chondrocyte senescence, leading to the formation
of fibrocartilage, which is inferior to hyaline cartilage in respect to biochemical and
biomechanical characteristics [2].
Traditional surgical methods for articular cartilage repair such as the transplantation of
osteochondral grafts, microfracturing, and autologous chondrocyte implantation (ACI) can
repair or replace damaged cartilage; however, these procedures do not completely restore the
normal structure composition and function of cartilage [3]. ACI has undergone considerable
development since its inception and it is now an established form of treatment for
symptomatic osteochondral defects [4]. However, several limitations make it an inferior
application when compared to other cell-based cartilage repair therapies, including cell
senescence [5] and dedifferentiation [6] which may contribute to insufficient numbers of
viable chondrocytes and inferior fibrocartilage at the defect site [6, 7]. Adult mesenchymal
stem cells (MSCs) have the ability to differentiate into cells of chondrogenic lineage and have
emerged as an ideal cell type for cell-based articular cartilage repair technology [8]. The
potential for guided chondrogenesis, and the ease with which they can be isolated and
expanded in vitro without phenotypic change before lineage-specific differentiation [9], make
MSCs attractive candidates for cartilage tissue engineering.
Recently, in vivo investigations of stem cell niches have suggested the importance of
developing an in vitro stem cell microenvironment for cell expansion and tissue-specific
3

differentiation. To successfully translate human adult stem cells into applications in cartilage
repair, it is important to create a functional in vitro stem cell niche that consists entirely of
known, xeno-free, and chemically defined factors and molecules [10]. Despite synthetic
matrices providing the highly controlled composition and structure, an in vitro niche derived
from stem cell is more physiologically and serves as a “natural” reservoir of growth factors
and cytokines [11], therefore enhancing cell attachment, proliferation, and differentiation.

The applications of dECM in resisting oxidative and inflammatory
environment in osteoarthritis treatment
To guarantee successful cell-based therapy or tissue engineering, measures must be taken to
control the inflammatory and oxidative environment in which cartilage is regenerated.
Scaffolds made by materials with natural anti-inflammatory characteristics not only provide
mechanical support for stem cells to attach, migrate, and proliferate, but also suppress
inflammatory reaction in cartilage repair. Since bioengineered cartilage constructs will
eventually be transplanted into arthritic joints in which elevated levels of pro-inflammatory
cytokines exist, it is especially important to select scaffolds that support the stability of
bioengineered cartilage in an inflammatory environment. To this end, many ECM-based
scaffolds are hypothesized to meet the requirements of cartilage repair.
dECM provides an in vitro microenvironment for synovium-dervied stem cell (SDSC)
rejuvenation in terms of enhancing expanded cells’ proliferation and chondrogenic potential
[12, 13]. Recent findings indicated that dECM expansion decreases expanded cells’ reactive
oxygen species (ROS) levels [14]. Furthermore, microarray data suggested that dECM
expansion could upregulate SDSCs’ antioxidant gene expressions, indicating that dECM
expansion may benefit SDSCs by increasing their resistance to oxidative stress and promoting
chondrogenic capability [15]. A study in mini-pigs successfully proved its resurfacing effect
on partial-thickness cartilage defects after intra-articular injection of dECM-expanded
allogeneic SDSCs [16]. Developed as an expansion system to provide a number of highquality cell sources ready for cartilage tissue engineering, the dECM model also demonstrated
4

anti-inflammatory capabilities, which is of great potential for the treatment of OA patients
with cartilage defects.

Preconditioning

stem

cells

with

small

molecules

targeting

inflammation signals
The control of stem cell fate and function is an important step for clinical applications in
regenerative medicine. Understanding and controlling the fate and function of adult stem cells
is a challenge for developing better therapeutic approaches to regenerative medicine. Among
various approaches in controlling stem cell fate, small molecules are considered a good
strategy, because small molecules targeting specific signaling pathways affect various cellular
events, such as DNA replication, proliferation, differentiation, and apoptosis. Proinflammatory factors such as IL-1β, tumor necrosis factor α (TNFα) and oxidative stress
induce phosphorylation-dependent signaling pathways, such as p38 MAPK and NF-κB, which
regulates synthesis of several inflammatory cytokines and matrix metalloproteinases (MMPs),
which play major roles in pathways that are activated during the OA process. Widely used as
an anti-inflammatory drug in cartilage repair, most of the p38 MAPK inhibitor was applied in
the cell differentiation phase, in which stem cells experienced the committed chondrogenesis
under appropriate induction conditions. However, p38 MAPK inhibitor also blocks
chondrogenesis [17], adverse effects of p38 MAPK inhibitors resulting from undesired
pharmacological activity are still a major concern for clinical application [18].

Biomechanics in chondrogenic differentiation of stem cells
Stem cell biologists have long appreciated the regulatory roles of soluble stem cell niche
signals (e.g., growth factors and cytokines) in regulating stem cell fate. Recent evidence
demonstrated that mechanical and topographical cues that exist in stem cell niche can also be
sensed and transduced into intracellular biochemical and functional responses by stem cells, a
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process known as mechanotransduction [19, 20]. Mechanical forces generated intrinsically
within the cell in response to its extracellular environment, and extrinsic mechanical signals
from extracellular environment, play a critical role in determining stem cell fate. There are
two different methods of mechanotransduciton: “inside-out” or “outside-in” sensing. For the
active “inside-out” sensing, the generation of internal forces allows for “measurement” of the
extracellular environment, for example, changes in extracellular matrix stiffness, surface
topography, and ligand density will be felt and responded to by cells through generating
varying traction forces. Passive “outside-in” sensing is where the cell responds to a force
imparted upon itself, for example, compression, tension, or pressure [21].
Cells are regarded to differentiate optimally on the tissue level’s elasticity, which was
confirmed by Engler et al. studies showing that mesenchymal stem cells differentiate into
neurogenic, myogenic, and osteogenic precursor cells through cultivation on substrates with
the respective elasticity [22]. However, little is known about the influence of elasticity on
chondrocyte behaviors and chondrogenic differentiation fate.
dECM is an effective expansion tool for harvesting a large amount of high-quality
chondrocytes for cell-based cartilage repair. The fact that stem cells maintained better
chondrogenic potentials on dECM with lower elasticity suggested that during in vitro cell
expansion, dECM could be designed with an appropriate elasticity in order to better maintain
its chondrogenic potential. By controlling dECM elasticity, or changing the nanotopography
of dECM, stem cells could be steered specifically toward chondrogenic differentiation.
Moreover, extrinsic mechanical forces (e.g. compression, hydrostatic pressure, fluid flow) can
also be applied to change stem cell properties from cellular levels, which might further
influence its chondrogenic fate. However, studies of influences of mechanical properties of
the in vitro microenvironment on chondrogenesis of stem cells are still in their infancy and the
underlying mechanisms need to be explored further.
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Abstract
Cartilage defects are normally concomitant with posttraumatic inflammation and pose a major
challenge in cartilage repair. Due to the avascular nature of cartilage and its inability to
surmount an inflammatory response, the cartilage is easily attacked by pro-inflammatory
factors and oxidative stress; if left untreated, osteoarthritis may develop. Suppression of
inflammation has always been a crux for cartilage repair. Pharmacological drugs have been
successfully applied in cartilage repair; however, they cannot optimally work alone. This
review paper will summarize current pharmacological drugs and their application in cartilage
repair. The development of extracellular matrix-based scaffolds and preconditioned tissuespecific stem cells will be emphasized because both of these tissue engineering components
could contribute to an enhanced ability not only for cartilage regeneration but also for antiinflammation. These strategies could be combined to boost cartilage repair under
inflammatory conditions.
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Introduction
Joint injuries are common in the young and active population and often result in cartilage or
osteochondral lesions. If left untreated, these defects might lead to joint swelling and pain, eventually
progressing toward osteoarthritis (OA). Over 27 million Americans are affected by OA, introducing
huge clinical and socioeconomic burdens [1]. Traditional cartilage repair methods include the
transplantation of osteochondral grafts [2], microfracturing, and autlogolous chondrocyte implantation
(ACI) [3]; however, none of these cartilage repair strategies have generated long-lasting hyaline
cartilage that meets functional demands. The causes of cartilage impairment are diverse, including
inflammation, hypertrophy, and senescence (Fig. 1) [4, 5]. Excessive mechanical surface contact
stress can directly damage articular cartilage and subchondral bone and adversely alter chondrocyte
function [6] while the disruption of the homeostasis of chondrocytes may gradually develop into OA
[7]. In the early phase of OA, disease-modifying interventions targeting inflammatory processes
might be most efficacious for the prevention and treatment of OA [8]. To this end, many antiinflammatory strategies have been discovered, such as growth factor applications, exertion of anticytokines or anti-inflammatory drugs, and stem cell-based therapies.
Growth factors are utilized to improve clinical cartilage repair by altering the local biological
environment at the site of cartilage damage. Inflammation at the damage site may disrupt the balance
between catabolic and anabolic factors; growth factors that target specific catabolic pro-inflammatory
mediators such as cytokines or nitric oxide synthase (NOS), or that affect anabolism are potential
candidates in slowing down the structural progression of the disease. The production and activities of
many pro-inflammatory factors, such as cytokines, chemokines, growth factors, and various immune
response regulators, are controlled by different signaling systems, such as nuclear factor-kappa B
(NF-κB), mitogen-activated protein kinases (MAPK), and Janus kinase/signal transducers and
activators of transcription (JAK/STAT). Novel small molecule regulators targeting specific signal
pathways as well as related precursor molecules have received a great deal of attention as potential
candidates for treatment of inflammatory diseases (Fig. 2).
The development of stem cell technology provides the possibility of biotherapy for cartilage repair
(Fig. 3). The availability of large quantities of mesenchymal stem cells (MSCs) and their multilineage
differentiation potential, especially for chondrogenic differentiation, have made MSCs the ideal
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progenitor source for cartilage engineering and regeneration. Cell-based therapies using
undifferentiated or pre-chondrogenic stem cells in biodegradable three-dimensional (3D) scaffolds for
transplantation into focal lesions could regenerate hyaline-like cartilage [9, 10]. Since bioengineered
cartilage constructs will eventually be transplanted into arthritic joints in which elevated levels of proinflammatory cytokines exist, it is especially important to select scaffolds that support the stability of
bioengineered cartilage in an inflammatory environment. To this end, many extracellular matrix
(ECM)-based scaffolds are hypothesized to meet the requirements of cartilage repair (Fig. 3).
Recently, decellularized ECM deposited by stem cells (DSCM) has attracted attention due to its
excellent rejuvenation of expanded stem cells’ chondrogenic potential, which has been reviewed [11].
Furthermore, DSCM expanded human synovium-derived stem cells (SDSCs) demonstrated in vitro
antioxidant and anti-inflammatory capabilities [12]. A study in mini-pigs successfully proved its
resurfacing effect on partial-thickness cartilage defects after intra-articular injection of DSCMexpanded allogeneic SDSCs [13]. In this review paper, the strategies using pharmacologic drugs,
biomechanical stimulation, tissue-specific stem cells, and ECM-based scaffolds are summarized. An
emerging strategy using a DSCM preconditioning approach to rejuvenate tissue-specific stem cells in
both cell amount and chondrogenic potential is emphasized for its vital role in cartilage repair and
anti-inflammation (Fig. 3). Future goals include the utilization of 3D ECM scaffolds, in conjunction
with other combined strategies, including the use of preconditioned tissue-specific stem cells in a
more favorable microenvironment to reduce the inflammation in cartilage repair.

Pharmacologic strategy
Growth factors
In articular cartilage, numerous growth factors work in concert throughout life to regulate
development and homeostasis of articular cartilage [14]. Disruption in the balance of regulatory
factors may hinder tissue maintenance and repair, ultimately resulting in reduced synthesis of ECM,
tissue degeneration, and consequently, an accelerated erosion of the articular surface [15]. Bioactive
growth factors are considered promising candidates for enhanced healing of chondral injuries and
modification of the arthritic disease process. Members of the transforming growth factor beta (TGF-
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β)/bone morphogenetic protein (BMP) family, insulin-like growth factor-I (IGF-I), and fibroblast
growth factors (FGFs) are considered to be major anabolic factors for cartilage formation. They may
stimulate chondrocyte synthesis of proteoglycans, aggrecan, and type II collagen, inducing cell
proliferation, driving stem cell chondrogenic differentiation, and decreasing the catabolic effects of
cytokines [16, 17]. Overexpression of the growth factor progranulin (PGRN), for example, has been
implicated in the stimulation of chondrocyte proliferation; PGRN also acts as a physiological
antagonist of tumor necrosis factor alpha (TNFα) signaling and disturbs the binding of TNFα and
TNF receptor [18], potentially inhibiting cartilage degradation [19]. Cytokines such as TNFα can
stimulate vascular endothelial growth factor (VEGF) expression [20]. Therefore, some antiinflammatory strategies inhibit inflammation-induced angiogenesis although it remains unclear to
what extent angiogenesis inhibition mediates their therapeutic effects [21].
By exerting influence over inflammation, growth factors can modulate the microenvironment of
chondrocytes to improve the local residence and provide a more ideal atmosphere for cartilage
regeneration. For instance, growth factors such as platelet-derived growth factor (PDGF) and TGF-β
obtained from platelet-rich plasma (PRP) decreased interleukin 1 beta (IL-1β)-induced NF-κB
activation, a major pathway involved in the pathogenesis of OA (Fig. 2) [22, 23]. Furthermore, in
activated PRP, Bendinelli et al. observed increases in hepatocyte growth factor (HGF), IL-4, and
TNFα; HGF and TNFα, by disrupting NF-κB-transactivating activity through the enhanced cellular
IκBα expression, were important for the anti-inflammatory function of activated PRP [24].
Paradoxically, platelet lysate (PL), a PRP derivative, was thought to play a role as a proinflammatory
agent, acting synergistically with the canonical proinflammatory cytokines such as IL-1α, thus
enhancing the initial inflammatory response; surprisingly, PL also contributes to the down-regulation
of the NF-κB signal pathway and cyclooxygenase 2 (COX-2) expression, thus triggering the
resolution of the inflammation [25]. The anti-inflammatory role of PRP was also demonstrated in an
in vivo study. In the antigen-induced arthritis (AIA) porcine model, the intra-articular injection of PRP
attenuated the subsequent inflammatory response [26]. The use of PRP may also improve the
integration of an osteochondral graft at the cartilage interface and decreased degeneration in an in vivo
rabbit model [27].
The strategy combining growth factors and 3D scaffolds demonstrated a huge impact on tissue
regeneration. Because of PRP’s prominent role in anti-inflammation and fewer immunogenic as well
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as more biocompatible characteristics, the cell-free polyglycolic acid (PGA)-hyaluronan scaffold
combined with PRP led to cartilage repair and improved patient-reported outcomes (the Knee injury
and Osteoarthritis Score, KOOS) during 12 months of follow-up [28]. Moreover, TGF-β, delivered
together with calcium alginate to the sites of osteochondral defects, improved the repair of
osteochondral defects in the rabbit knee [29]. However, the local production of osteophytes has been
observed in clinical trials, therefore caution is advised because some growth factors favor the
dedifferentiation of stem cells and promote the endochondral ossification process [30].

Anti-cytokine therapy
Like growth factors, cytokines can also be produced in joint tissues and released into the synovial
fluid; they influence the surrounding cells in an “autocrine-paracrine” manner (Fig. 1). Low levels of
factors are necessary for normal homeostasis; however, inflammatory or oxidative stress conditions
may disrupt normal homeostasis, driving the pathogenesis of OA. Among the vast number of
cytokines, IL-1β and TNFα seem quite prominent and of major importance to cartilage destruction
[31]. Treatment strategies targeting major inflammatory factors have been developed (Fig. 2). Specific
inhibitors of production/activity of IL-1, such as recombinant human IL-1 receptor antagonist (IL1ra), can block the actions of IL-1 without any detectable agonist activity [32]. The use of monoclonal
antibodies against IL-1 or against type I IL-1 receptor (IL-1RI) represents another possible approach
in neutralization of the cytokine [33]. Pharmacologic reagents which down-regulate the production
and activity of active pro-inflammatory and pro-catabolic IL-1β is also a feasible approach [34]. One
such example is to apply the rhein, an active metabolite of the semi-synthetic anthraquinone
derivative diacerein, to down-regulate the production and activity of IL-1β in both the cartilage layer
and synovial membrane [35]. Etanercept, a recombinant soluble p75 TNF receptor, has a high affinity
for TNFα, preventing it from binding with its receptor [36]. A recent report indicates that etanercept
enhanced preservation of osteochondral allograft viability [37]. An in vivo study showed that
subcutaneous injection of etanercept promoted repair of osteochondral defects in the rabbit knee [38].
Application of anti-TNFα monoclonal antibody in polyarthritic transgenic mice demonstrated reversal
of cartilage degradation in the young mice [39].
Besides IL-1β and TNFα, pro-inflammatory cytokines, such as IL-6 [40], leukemia inhibitory factor
(LIF) [41], and the chemokine IL-8 [42], may modulate the direct catabolic effects of some cytokines.
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They usually synergize with TNFα or IL-1β in the catabolic process of cartilage [43]. Interference
with those pro-inflammatory factors is another direction for anti-inflammatory therapy in cartilage
repair. A number of anti-inflammatory cytokines, such as IL-4, IL-10, IL-11, and IL-13, were found in
increased levels in the synovial fluid of OA patients [44]. They decrease the production and/or activity
of the pro-inflammatory cytokines in vitro [45], thus have been classified as anti-inflammatory
cytokines. Endogenous IL-4 and IL-10 have been shown not only to reduce local IL-1 but may also
have direct stimulatory or protective effects on chondrocyte metabolism [46, 47]. Since the early
phase of OA is the most effective period to inhibit inflammation, administration of cytokine
antagonists following cartilage repair is a safe strategy for not only promotion of cartilage integration
but also the prevention of inflammation occurrence.

Chondroprotective drugs
Among pharmacological treatments, symptomatic slow-acting drugs have been largely studied over
the last decade. Recently there has been an increase in the use of symptomatic slowacting/chondroprotective drugs such as glucosamine sulfate (GS), chondroitin sulfate (CS), hyaluronic
acid (HA), and diacerein. Glucosamine decreased the activation of NF-κB in rat chondrocytes when
treated with IL-1β [48]. In normal human articular chondrocytes, GS inhibited IL-1β and TNFα
induced nitric oxide (NO) production, which is a major contributor for the inflammatory reaction in
arthritis [49]. Natural sulfated glycosaminoglycan (GAG), in particular CS, seemed to have beneficial
effects on the pathophysiology of OA by reducing blood markers of inflammation and the activity of
destructive proteases like matrix metalloproteinases (MMPs), diminishing pain as well as improving
the function of the affected joint [50, 51, 52]. In chondrocytes, CS diminished IL-1β-induced
increases in p38 MAPK and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, and
decreased NF-κB nuclear translocation and as a consequence, reduced the formation of proinflammatory cytokines, IL-1β and TNFα, and pro-inflammatory enzymes, such as phospholipase A2
(PLA2), COX-2, and inducible NOS (iNOS) [53]. However, other reports suggested that chondroitin4-sulfate inhibited the enhanced expression of COX-2 and prostaglandin E (PGE) synthases 1 but had
no effect on the IL-1β-induced decrease of I-κB α and nuclear translocation of NF-κB [54]; the extent
of sulfation influenced the responsiveness of inflammation [55].
Synthetically sulfated HA was at first characterized as an inhibitor of TNFα [56]. Hyaluronic acid is
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an anionic, non-sulfated GAG which acts as a crucial structural component of ECM and as an
important mediator of leukocyte adhesion and migration [57]. Hyaluronic acid is widely used in the
treatment of OA and exerts significant chondroprotective effects. An in vitro report showed that HA
altered the profile of inflammatory mediators, shifting the balance between cell matrix synthesis and
degradation away from degradation [58]. An in vivo rabbit study showed that three weekly intraarticular injections of HA had a positive effect on the repair tissue that formed within the chondral
defect at the early follow-up time point [59]. Chondroitin sulfate, diacereine, GS, and HA
demonstrated pain reduction and physical function improvement with very low toxicity in OA
treatment, and could be of potential interest for the symptomatic management of OA [60]. Slowingacting drugs avoid interrupting the normal cellular function and toxicity to cells, thus could provide an
anti-inflammatory strategy for cartilage repair (Fig. 2). However, high concentrations of
chondroprotective drugs are not presumably attained via oral administration; intra-articular injections
may represent a feasible and effective approach [61]. With the application of tissue engineering in
cartilage repair, slow-acting drugs serve as a basic unit of a 3D scaffold and, together with stem cells,
demonstrated the potential of modulating inflammatory chemokines/receptors and catabolic/inhibiting
factors [62].

Small molecules targeting inflammation signals
Strategies for generating functional small molecules of synthetic and natural products targeting
inflammatory signals have been considered effective in the suppression of inflammation [63]. Primary
pro-inflammatory factors IL-1β and TNFα have the capacity to activate a diverse array of intracellular
signaling pathways; upon activation they can induce phosphorylation-dependent signaling pathways,
such as NF-κB, p38 MAPK, and c-Jun N-terminal kinase (JNK), which regulate the synthesis of
several inflammatory cytokines and MMPs, many of which play major roles in the process of OA
formation (Fig. 2) [64].
The NF-κB signaling pathway mediates critical events in the inflammatory response by chondrocytes,
leading to progressive ECM damage and cartilage destruction. There are an increasing number of
reports about NF-κB inhibitors, such as glucocorticoids, cyclosporine A, and tacrolinmus (FK-506)
[65]. IκB kinase beta (IKKβ) has also become a particularly appealing target because of its crucial
role in the activation of the NF-κB pathway [66]. A recent report showed that a novel butanoylated
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GlcNAc derivative, 3,4,6-O-Bu3GlcNAc, an inhibitor of NF-κB activity, has the potential to stimulate
new tissue production and reduce inflammation in IL-1β-induced chondrocytes with utility for OA
and other forms of inflammatory arthritis [67]. One concern about inhibiting several of these
components of the NF-κB pathway is the specificity of such drugs. For example, the proteasome
which is responsible for IκB degradation has many other important functions. Thus, inhibition of
proteasome activity could potentially cause severe side effects. Also it may not be feasible to block
the NF-κB pathway for prolonged periods, since NF-κB plays an important role in the maintenance of
host defense responses [68].
Two MAPKs, p38 MAPK and JNK, are frequently activated by a wide range of environmental
stresses and cytokines to induce inflammation and joint destruction, hence the name stress-activated
protein kinases (SAPKs). p38 MAPK positively regulates the expression of many genes involved in
inflammation, such as those coding for TNFα, IL-1β, IL-6, IL-8, COX-2, and collagenase-1 and -3
[69]. Many small molecule inhibitors of p38 MAPK such as Cannabidiol [70], SB203580,
Doramapimod (BIRB-796) [71], VX-702 [72], RO-3201195 [73], and SB-242235 [74] have
demonstrated positive anti-inflammatory effects. Among all these p38 MAPK inhibitors currently in
clinical trials, SB203580 appears to be the most potent compound in terms of anti-inflammatory
activity. For instance, inhibition of the p38 MAPK signaling pathway with SB203580 showed antiinflammatory effects in both cartilage explants [75] and animal models [76]. However, there is a
conflicting report showing that inhibition of the p38 MAPK pathway using SB203580 leads to OAlike changes in a rat animal model [77]. Similarly, the JNKs are activated in macrophages after
stimulation with lipopolysaccharide [78]. Inhibition of the JNK signaling pathway has shown
preventive effects with regard to bone and cartilage destruction in rheumatoid arthritis (RA) [79] and
down-regulation of IL-1-induced MMP-13 expression in OA chondrocytes [80].

Small molecules targeting specific enzymes
Small molecules which target specific enzymes involved in OA have been developed as a possible
way to alleviate inflammation in cartilage repair (Fig. 2). MMPs are synthesized and secreted by
chondrocytes in response to stimulants such as IL-1 and TNF [81]. Inappropriate expression of MMP
activity constitutes part of the pathogenic mechanism associated with the destruction of cartilage and
bone in OA. Possible strategies include impeding the production of MMPs, blocking the active site of
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MMPs, and increasing endogenous production of tissue inhibitors of metalloproteinases (TIMPs) [82].
Another representative member of cyclooxygenase, the COX-2 enzyme is primarily associated with
inflammation. Cytokines and growth factors increase the expression of COX-2, mainly at
inflammatory sites, producing prostaglandins that mediate inflammation, pain, and fever [83].
Targeting cyclooxygenase, non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib play a
major role in the management of inflammation and pain caused by arthritis [84, 85]. However, nonselective NSAIDs cause gastrointestinal complications in a significant number of patients, and COX-2
inhibitors have recently raised concerns regarding cardiovascular side effects/risks [86].
The possible roles of NO in OA pathophysiology have been supported by a study showing that
selective inhibition of the iNOS could reduce the progression of structural changes in experimental
OA in dogs, partly related to a reduction in the levels of synovial inflammation [81]. Many of these
small molecule compounds have already been launched on the market as drugs acting against
inflammatory conditions. For example, leflunomide was found to significantly inhibit IL-4 and IL-13enhanced production of chemokine (C-C motif) ligand (CCL)-26 [88].

Biomechanical Strategy
Biomechanical factors play an important role in the health of diarthrodial joints. Under normal
physiological loading, because articular cartilage provides a nearly frictionless surface for the
transmission and distribution of joint loads, moderate mechanical loading exhibits little or no wear
over decades of use. In reality, moderate loading is necessary to maintain healthy articular cartilage.
Through a variety of mechanisms, including ion channels and integrin-mediated connections to the
ECM that involves membrane, cytoskeletal, and intracellular deformation, chondrocytes in cartilage
may perceive physical signals from the outside environment. Altered joint loading, which might be
associated with obesity, malalignment, trauma, or joint instability, is a critical risk factor for joint
degeneration and OA occurrence.
Biomechanical influences on cartilage are complex. Depending on the way cartilage is loaded, the
effects on cartilage homeostasis can vary. An overload of mechanical stress may lead to acute joint
injury such as posttraumatic OA (PTOA), which is also caused by gradual onset of structural damage

8

and cartilage compositional degradation due to chronic overloading of injured joints [89]. Cartilage
explants subjected to static compression exhibit a significant suppression of metabolic activity that is
dependent on the magnitude of applied stress [90]. High magnitude mechanical strain is proinflammatory and initiates cartilage destruction while inhibiting matrix synthesis, both of which are
involved in the NF-κB-related signal pathway [91, 92].
It has been reported that low magnitude mechanical strain inhibits inflammation by suppressing IL-1β
and TNFα-induced transcription of multiple pro-inflammatory mediators involved in cartilage
degradation [91]. It is noteworthy, however, that the influences of mechanical stress are not
independent; many mechanical and physiochemical factors that are known to affect chondrocytes are
inextricably coupled to one another within the cartilage ECM. Ramachandran et al. reported that
treatment with C-type natriuretic peptide (CNP) and dynamic compression increased anabolic
activities and blocked catabolic effects induced by IL-1β [93]. For cyclic loading, however, the
cartilage reaction is different; low frequencies and amplitudes do not appear to affect biosynthesis
rates. Some studies suggested that, above a certain threshold frequency, cyclic loading increases the
synthesis of components of ECM, such as aggrecans, cartilage oligomeric matrix protein, and
fibronectin [90].
There is increasing evidence showing that muscle function is closely related to OA. Muscle, lying
anatomically adjacent to cartilage, provides the cartilage with a biomechanical stimulation that
promotes nutrient distribution and maintains homeostasis [92]. Muscle loss [94] and reduced muscle
strength [95] have been shown to be risk factors for knee OA. On the other hand, patients with knee
OA were found to have impaired muscle function; quadriceps, hamstring, and hip muscles are
significantly impaired in subjects with knee OA compared with age-matched controls [96]. Recent
studies showed that a rat chondrocyte cell line co-cultured with muscle cells or cultured in muscle
cell-conditioned medium in a monolayer demonstrated enhanced resistance to pro-inflammatory
factors such as IL-1β and TNFα, suggesting that non-loading biochemical effects of muscle cells have
a significant influence on cartilage homeostasis and a preventative role in OA formation [97].
Mechanistically, it is known that the pro-inflammatory cytokines IL-1β and TNFα are major
inflammation initiators in cartilage by inducing the expression of MMPs, promoting chondrocyte
hypertrophy, and reducing the synthesis of cartilage matrix genes. However, muscle cell-derived
factors or myokines inhibited the mRNA expression of MMPs as well as hypertrophic markers in
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bioengineered cartilage; it could also rescue IL-1β-induced chondrocyte growth arrest through
regulating the cell cycle. The beneficial role of muscle cells on OA indicated muscle strengthening
exercises could be a potential intervention for OA [98].

Mesenchymal stem cell strategy
Inherent anti-inflammatory properties
Despite being the most advanced and promising approach for cartilage repair, chondrocyte-based
cartilage repair has some disadvantages, such as morbidity caused by damage to the donor-site
articular surface and cell senescence during ex vivo expansion [4]. Furthermore, the inflammatory
synovial fluid microenvironment triggers human chondrocytes to actively take part in inflammatory
processes, particularly during the initiation and progression of inflammatory joint diseases and in the
disruption of cartilage repair mechanisms resulting in cartilage degradation [99]. Unlike chondrocytes,
MSCs are not limited by an intrinsic tendency to lose their phenotype and dedifferentiate during
expansion [100]. MSCs also play an important role in immunomodulation and tissue regeneration by
secretion of soluble factors [101, 102]. In an inflammatory environment, MSCs secrete factors which
cause multiple anti-inflammatory effects and influence matrix turnover in synovium and cartilage
explants [103]. MSCs have also been revealed as robust sources of TIMP-mediated MMP-inhibition,
capable of protecting the perivascular niche from high levels of destructive MMPs, even under
pathological conditions [104].
Due to their potential to modulate the local microenvironment via anti-inflammatory and
immunosuppressive functions, MSCs have an additional advantage for allogeneic application (Fig. 3).
Moreover, by secreting various bioactive soluble factors, MSCs can protect the cartilage from further
tissue destruction and facilitate regeneration of the remaining progenitor cells in situ [105]. The joint
resurfacing function of MSCs was also demonstrated in in vivo studies. After intra-articular injection
of autologous MSCs into a caprine OA model (complete excision of the medial meniscus and
resection of the anterior cruciate ligament), there was evidence of marked regeneration of the medial
meniscus and implanted cells were detected in the newly formed tissue. Degeneration of the articular
cartilage, osteophytic remodeling, and subchondral sclerosis were reduced in cell-treated joints
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compared with joints treated with vehicle alone without cells [106]. A clinical case report
demonstrated that, 24 weeks after the injection of autologous MSCs into a knee with symptomatic and
radiographic degenerative joint disease, there was significant cartilage growth, decreased pain, and
increased joint mobility in the patient [107]. As a result, MSCs could be used in cartilage repair as a
potential anti-inflammatory strategy especially in the context of allogeneic transplantation.

Acquired anti-inflammatory capacity
Treatment strategies focused on both reducing inflammation and increasing tissue production are
necessary to effectively treat OA from a tissue-engineering perspective. Despite their multi-lineage
differentiation potential and immunomodulatory properties as well as anti-inflammatory abilities,
MSCs’ survival after transplantation is still very low, thereby hindering their therapeutic efficacy
[108].
Recent studies found that MSCs could be rejuvenated by preconditioning strategies which enhance
their post-transplantation survival and functionality [109]. The concept of preconditioning was
established in 1986 by Murry and colleagues, who found ischemic preconditioning of cardiomyocytes
led to the activation of survival signaling [110]. In theory, any factors that might influence the
proliferation and differentiation of therapeutic cells can be an advantage. For instance, hypoxic
preconditioning not only has pro-survival and cytoprotective effects, it also helps the cells maintain
their stemness and promote proliferation and differentiation potential post-engraftment [111]. When
referring to a cartilage engineering application, preconditioning of MSCs can be derived from
microenvironment factors such as low oxygen [112], growth factors [113], or potentially
pharmacological substances targeting specific signal pathways involved in MSC chondrogenesis such
as the MAPK [114, 115] and Wnt signal pathways [114, 116].

DSCM-mediated stem cell preconditioning
The stem cell niche is a specialized microenvironment that helps sustain the stem cell pool within
each tissue or organ system. It is hypothesized that stem cells can create their own microenvironment;
in such a microenvironment, adult stem cells are expected to greatly expand while retaining their
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stemness for a tissue-specific lineage. In 2009, He et al. utilized porcine SDSCs, a tissue-specific stem
cell for chondrogenesis [117], as a model to reconstruct an in vitro 3D stem cell microenvironment, in
which expanded SDSCs produced a drastic increase in cell number and chondrogenic potential [118].
Later on, this DSCM-mediated stem cell preconditioning was also demonstrated to be effective in
rejuvenating human bone marrow stromal cells, in terms of enhanced proliferation and chondrogenic
hypertrophy [119]. Interestingly, this DSCM-mediated expansion system also works for primary
chondrocytes, such as articular chondrocytes [120, 121] and nucleus pulposus cells [122, 123].
The regulation of intracellular reactive oxygen species (ROS) is crucial for cell survival in a harsh
environment and guarantees successful cell therapy [124]. DSCM preconditioning could decrease
expanded stem cell ROS level [119, 125], and protect human SDSCs from oxidative stress-induced
cell senescence, as it applies to cell proliferation and differentiation capacity [12]. Furthermore, our
recent data showed that human SDSCs expanded on DSCM exhibited an increased chondrogenic
potential as well as heightened protection against IL-1β-induced inflammation [126]. The adaptive
capacity in a harsh environment was also validated in a minipig study, in which DSCM-expanded
SDSCs exhibited an enhanced in vivo cartilage regeneration capacity post-injection, evidenced by
intensely stained type II collagen and sulfated GAGs in the partial-thickness cartilage defects with
negligible staining of type I collagen [13], indicating that DSCM preconditioned SDSCs have the
ability to resist inflammation. In contrast, the existence of type I collagen in the regenerated cartilage
from the plastic flask-expanded SDSC groups suggested fibrocartilage formation [13], which might be
explained by dedifferentiation caused by inflammatory stress [127].

Low oxygen and FGF-2 contribute to DSCM-mediated stem cell
preconditioning
Low oxygen tension (hypoxia) maintains undifferentiated states of MSC phenotypes and also
influences proliferation and cell-fate commitment [128]. There is increasing evidence suggesting that
hypoxia (or, more appropriately, physiological hypoxia) can stimulate chondrogenesis [129, 130].
Hypoxic preconditioning can boost the expression of genes favoring MSC proliferation and growth
prolongation by inducing the expression of pro-survival and pro-angiogenic markers in MSCs [131].
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Recently, hypoxia-inducible factors (HIFs) have been shown to activate specific signaling pathways
such as Notch and the expression of transcription factors such as octamer-binding transcription factor
4 (Oct4) which is responsible for controlling stem cell self-renewal and multipotency [132]. This
finding suggests that modulation of oxygen availability and HIF expression can influence stem cell
fate. Our recent report suggested that the combination of hypoxia and FGF-2 significantly enhanced
DSCM-expanded SDSC proliferation and chondrogenic potential [133].This micro-ecosystem
apparently reconciled the contradiction of “Quantity” versus “Quality”, a predicament often met in
stem cell-based cartilage repair. In vivo, numerous growth factors and morphogens are immobilized
by directly binding to the ECM through specific heparin-binding domains, by direct binding to ECM
molecules such as collagen, or by direct anchoring to cell membranes [134]. By immobilizing growth
factors in a concentrated area, DSCM helps to amplify the effects of growth factors and reduce the
inflammation reaction leading to improved proliferation and differentiation of stem cells [102].

Small molecules targeting inflammation signals contribute to DSCMmediated stem cell preconditioning
Widely used as an anti-inflammatory drug in cartilage repair, p38 MAPK inhibitor also blocks
chondrogenesis [135], indicating that p38 MAPK inhibitor has some disadvantages in the treatment of
cartilage damage with concomitant inflammation. Considering its adverse effects for clinical
treatment of OA, MSCs pretreated by SB203580 in the DSCM expansion phase were assumed to
avoid this dilemma. Preconditioning using SB203580 significantly enhanced DSCM-expanded human
SDSC chondrogenic potential; this rejuvenation of chondrogenic capacity, instilled in SDSCs by
SB203580, gave the stem cell the ability to resist the influence of IL-1-induced inflammation [136].

Extracellular matrix strategy
Compared to natural biomaterials, synthetic polymers are more controllable and predicable in their
chemical and physical properties, holding some promise of success in tissue engineering and
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regenerative medicine. Of the synthetic polymers, those derived from poly(α-hydroxy esters),136
poly(propylene fumarates) [137], polyurethanes [138], PGA [139], and poly(lactide-co-glycolide)
[140] have been used for cartilage regeneration; however, inflammatory reaction due to synthetic
scaffolds that impaired the quality of regenerated cartilage has also been reported in some studies
[141, 142].

Natural matrix scaffolds
Naturally occurring polymers as scaffolds offer options for cartilage tissue engineering due to
biocompatibility, biodegradability, low toxicity of degradation byproducts, and plasticity in processing
into a variety of material formats [143]. In an attempt to repair articular cartilage, allografted articular
chondrocytes, embedded in collagen gel, were transplanted into full-thickness defects in rabbit
articular cartilage; 24 weeks after implantation, the defects were filled with hyaline cartilage,
synthesized type II collagen, and exhibited no signs of immunologic rejection and degeneration of the
reparative tissue [144, 145]. Rahfoth et al. found that the transplantation of allograft chondrocytes
embedded in agarose gel was a suitable method to repair articular cartilage defects in rabbits because
there were no signs of graft-versus-host rejection or infiltration by immune cells [146]. Other natural
polymers that have been explored as bioactive scaffolds for cartilage tissue engineering include but
are not limited to silk [147], hyaluronan [148], and chitosan [149]. In a recent study, the responses of
articular chondrocytes under inflammatory conditions were compared after seeding within three
polymeric scaffolding materials [silk, collagen, and polylactic acid (PLA)]; Kwon et al. found that
chondrocytes grown in the silk and collagen scaffolds exhibited higher levels of cartilage matrix gene
expression than those in the PLA scaffolds [150]. When using a PGA scaffold for treatment of fullthickness defects, however, there appears to be a moderate immunoreaction as evidenced by
lymphocytes in transplanted joints [9, 151].

Chondrocyte sheets
A cell-sheet technique developed in 1993 [152] shows promise in cartilage repair with concomitant
inflammation. Hamahashi et al. reported that a layered chondrocyte sheet produced the most humoral
factors including PGE2, which plays a key role in its anti-inflammatory function [153]. In
chondrocyte sheets, catabolic factors such as MMP3, MMP13, and a disintegrin and metalloproteinase
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with thrombospondin motifs 5 (ADAMTS5) were also observed to decrease while the expression of
TIMP1 with antagonistic actions against MMP3 increased [154]. In a rabbit model with partialthickness cartilage defects, layered chondrocyte sheets were able to maintain the cartilaginous
phenotype, and could be attached to the site of cartilage damage, acting as a barrier to prevent a loss
of proteoglycan from these sites and to protect them from catabolic factors in the joint [154]. This
technique might have great potential for OA treatment and inflammatory prevention in cartilage
repair.

Decellularized tissue matrix
In contrast to the DSCM described above, which attempts to rejuvenate expanded stem cells’
chondrogenic potential as well as anti-inflammatory capacity, decellularized tissue matrix influences
tissue engineering directly, providing a carrier (or scaffold) and chondrogenically induced growth
factors as well as an anti-inflammatory function. The use of ECM derived from decellularized tissue is
increasingly common in regenerative medicine and tissue engineering [155]. By virtue of physical,
chemical, or enzymatic approaches, organ decellularization removes all cellular material without
adversely affecting the composition, biologic activity, or mechanical integrity of the remaining 3D
matrix [156]. The molecules that constitute ECM are largely and highly conserved across species and
are well tolerated even by xenogeneic recipients. The effects of xenogeneic ECM on the innate
immune response, specifically the responding macrophages, may elicit a necessary M2 phenotypic
profile to support a constructive remodeling response for the scaffold [157]. In the field of cartilage
regeneration, many decellularized tissue scaffolds showed positive effects and reparative capability
for cartilage defects [158]. For example, the combined use of cells with decellularized aortic scaffold
was able to prevent the generation of a strong inflammatory response and improve overall tracheal
cartilage regeneration [159]. Compared to a PGA scaffold, an ECM scaffold derived from porcine
cartilage not only strongly supported chondrogenic differentiation of rabbit MSCs, but also helped
maintain its phenotype in vivo [160].
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Summary
The treatment of cartilage injury remains a clinical challenge despite the advancements in surgical
procedures and techniques. An important hurdle is the concomitant inflammation during cartilage
repair. Pharmacological drugs have been successfully applied in cartilage repair; however, they cannot
optimally work alone [161]. With the development of ECM-based scaffolds and preconditioned
tissue-specific stem cells, both tissue engineering components could not only contribute to an
enhanced ability in anti-inflammation but also to cartilage regeneration. All of these strategies could
combine to boost cartilage repair under inflammatory conditions.
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Figure1. 1 Inflammation in cartilage repair.
Abnormally high contact stresses such as mechanical overload transmitted to focal areas of articular
cartilage result in cartilage defects and release cartilage fragments. This process stimulates the
synovial membrane, leading to the activation of macrophages and inflammatory cells such as T cells,
which produce interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNFα). In an “autocrineparacrine” manner, these activated inflammatory factors may stimulate chondrocytes to secrete
degradative enzymes like proteinases, such as matrix metalloproteinases (MMPs) and a disintegrin
and metalloprotease with thrombospondin motifs (ADAMTS), which are directly involved in
degradation of type II collagen and aggrecans in cartilage matrix. In the meantime, chondrocytes can
change phenotype and size in response to stimulation from inflammatory factors and undergo
hypertrophy, which is an essential step in the endochondral ossification process.
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Figure1. 2 Schematic representation of key signaling pathways in the inflammatory process and
potential strategies for inflammatory inhibition in cartilage repair.
Use of anti-cytokine and chondroprotective drugs against IL-1, TNFα, or against their receptors is a
direct and effective approach in the suppression of inflammation. Strategies targeting disturbance or
intervention of key signal pathways in cytosol have been developed such as blocking the MAPK
signal pathways or the NF-κB pathway. Using inhibitors for downstream products of degradative
enzymes, such as MMPs, COX-2, iNOS, and ADAMTS, can also effectively protect cartilage from
degradation and inflammation. Growth factors such as FGF-2, IGF-I, or TGF-β may interfere with
inflammation by blocking the associated signal pathways. Use of growth factors is a possible antiinflammatory strategy in cartilage repair despite the fact that growth factors can promote neo-cartilage
formation.
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Figure1. 3 Therapeutic strategies for cartilage damage utilizing preconditioned stem cell and
three-dimensional matrix.
After ex vivo expansion of adult stem cells extracted from the human body, two strategies can be used
for the treatment of cartilage defects: direct intra-articular injection or transplant of cells in a threedimensional (3D) scaffold. For full-thickness cartilage defects, the second strategy is normally used.
3D scaffolds can be made of ECM materials. A structurally and mechanically stable scaffold allows
for infiltration and attachment of bioactive molecules (IGF-I, FGF-2, and/or TGF-β) which can exert
their anti-inflammatory effects on the surrounding environment. For partial thickness cartilage
defects, direct intra-articular injection of expanded stem cells is an option. Mesenchymal stem cells
can secrete growth factors, which may exert their anti-inflammatory and anti-oxidative effects in the
microenvironment where MSCs reside. These growth factors also benefit tissue regeneration. A recent
finding suggests that decellularized stem cell matrix (DSCM) could rejuvenate expanded MSCs in
proliferation and chondrogenic potential; this process may provide a large quantity of high quality
MSCs for cell-based cartilage regeneration. DSCM-expanded MSCs exhibiting an enhanced capacity
against oxidation and inflammation may represent a promising anti-inflammatory strategy in the near
future.
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Abstract
As a tissue-specific stem cell for chondrogenesis, synovium-derived stem cells (SDSCs) are a
promising cell source for cartilage repair. However, a small biopsy can only provide a limited number
of cells. Cell senescence from both in vitro expansion and donor age presents a big challenge for stem
cell based cartilage regeneration. Here we found that expansion on decellularized extracellular matrix
(dECM) full of three-dimensional nanostructured fibers provided SDSCs with unique surface profiles,
low elasticity but large volume as well as fibroblast-like shape. dECM expanded SDSCs yielded
larger pellets with intensive staining of type II collagen and sulfated glycosaminoglycans compared to
those grown on plastic flasks while SDSCs grown in ECM yielded 28-day pellets with minimal matrix
as evidenced by pellet size and chondrogenic marker staining, which was confirmed by both
biochemical data and real-time PCR data. Our results also found lower levels of inflammatory genes
in dECM expanded SDSCs that might be responsible for enhanced chondrogenic differentiation.
Despite an increase in type X collagen in chondrogenically induced cells, dECM expanded cells had
significantly lower potential for endochondral bone formation. Wnt and MAPK signals were actively
involved in both expansion and chondrogenic induction of dECM expanded cells. Since young and
healthy people can be potential donors for this matrix expansion system and decellularization can
minimize immune concerns, human SDSCs expanded on this future commercially available dECM
could be a potential cell source for autologous cartilage repair.
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Introduction
Articular cartilage has a limited capacity for self-repair. Once damaged, the injured cartilage will
develop defects. Despite promising results from autologous chondrocyte implantation [1], donor
tissue availability is a challenge. Recent advances make adult stem cells an attractive cell source for
cartilage regeneration, especially tissue-specific stem cells such as synovium-derived stem cells
(SDSCs) [2,3]. Since in vitro expansion is a necessary step before in vivo application, accompanying
cell senescence and dedifferentiation represents a formidable challenge for stem cell-based cartilage
repair [4].
We found that decellularized extracellular matrix (dECM) deposited by mesenchymal stem cells could
rejuvenate stem cells [5-11] and primary cells [12-14] in both proliferation and differentiation
capacity. For instance, dECM deposited by SDSCs significantly promoted expanded porcine SDSCs
(pSDSCs) in both proliferation and chondrogenic potential [5]. In vivo transplantation of dECM
expanded pSDSCs demonstrated efficacy in promoting cartilage regeneration in a partial thickness
cartilage defect porcine model [15].
Our recent reports suggested that this in vitro cell expansion system also benefits human SDSC
(hSDSC) expansion and rejuvenation of chondrogenic potential [16,17], which brings hope for the
potential use of this approach in clinical treatment [18,19]. However, a concomitant up-regulation of
type X collagen (COL10A1) was also observed in chondrogenically differentiated hSDSCs that have
undergone dECM expansion, indicating a tendency toward chondrogenic hypertrophy.
In this study, we fully characterized cell morphology, volume, elasticity, and surface phenotypes in
hSDSCs following dECM expansion. We not only defined proliferation and chondrogenic potential in
dECM expanded hSDSCs but also examined whether increased expression of COL10A1 could be a
sign of endochondral bone formation. Since both the mitogen-activated protein kinase (MAPK) and
Wnt signals are critical pathways for chondrogenesis and have crosstalk in stem cell mediated
cartilage regeneration [20], these two signals were evaluated for their changes in both cell expansion
and chondrogenic induction of hSDSCs after preconditioning using dECM and conventional plastic
flasks, which might provide evidence for further investigation of potential mechanisms underlying the
rejuvenation of hSDSCs by dECM expansion.
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Materials and Methods
SDSC culture
Adult human synovial fibroblasts (4 donors, two male and two female, average 43 years old, all had
no known joint disease), referred to as hSDSCs [16,17], were obtained from Asterand (North America
Laboratories, Detroit, MI). Human SDSCs were plated and cultured in a growth medium [alpha
minimum essential medium (αMEM) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin,
100 µg/mL streptomycin, and 0.25 μg/mL fungizone (Invitrogen, Carlsbad, CA)] at 37C in a
humidified 5% CO2 and 21% O2 incubator. The medium was changed every three days.

dECM preparation
The preparation of dECM was described in our previous study [16,17]. Briefly, plastic flasks (Plastic)
were precoated with 0.2% gelatin (Sigma-Aldrich, St. Louis, MO) at 37C for 1 h and seeded with
passage 3 (P3) hSDSCs at 6,000 cells/cm2. After the cells reached 90% confluence, 50 μM L-ascorbic
acid phosphate (Wako Chemicals USA, Inc., Richmond, VA) was added for 8 days. The medium was
changed every other day. The deposited matrix was incubated with 0.5% Triton X-100 containing 20
mM ammonium hydroxide at 37C for 5 min and stored at 4C in phosphate-buffered saline (PBS)
containing 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL fungizone.

SDSC expansion
P3 hSDSCs were cultured at 3000 cells/cm2 for one passage on two substrates: dECM or Plastic. The
cell number was counted using a hemocytometer. Expanded cells were also evaluated for cell
morphology using scanning electronic microscopy (SEM), and atomic force microscopy (AFM), cell
number using a hemocytometer, and proliferation index and surface markers using flow cytometry.

Morphological observation using the SEM and AFM
Representative samples (n=2) were primarily fixed in 2.5% glutaraldehyde (Sigma-Aldrich) for 2 h,
followed by secondary fixation in 2% osmium tetroxide (Sigma-Aldrich) for another 2 h. The samples
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were then dehydrated in a gradient ethanol series, in hexamethyldisilazane (HMDS, Sigma-Aldrich) at
a ratio of 1:1 with ethanol twice for 1 h each time, in HMDS at a ratio of 1:2 with ethanol overnight,
and in HMDS three times for 4 h each time. The samples were air-dried for 24 h and gold sputter was
added. The images were recorded by an SEM (Hitachi, Model S 2400).
Morphology of culture substrates (dECM and Plastic) and both morphology and elasticity of
expanded hSDSCs were performed using an MFP-3D-BIO AFM (Asylum Research, TE2000-U,
Santa Barbara, CA) integrated with an inverted fluorescence microscope (Nikon Eclipse, Ti-U, Nikon
Instruments Inc., Melville, NY) and Olympus TR400-PB cantilevers with manufacturer spring
constant of 0.09 N/m. The samples were imaged in Petri dishes after they were fixed with 1%
glutaraldehyde and washed once with PBS. The location of the cantilever on the sample was
confirmed using a 10× microscopy objective. For the morphology imaging, each sample was mapped
in PBS buffer using contact mode. An area of 90 µm by 90 µm was imaged with the pixel resolutions
of 512 and scan rate at 0.2 Hz. For the quantitative nanomechanical analysis, a Sneddon’s
modification of the Hertz model developed for a four-sided pyramid was employed. The fixed cell
sample elasticity (Young’s modulus, E) was corrected with the indentation of the tip, , through the
following equation: E 

 1 2 F
, where E is the elastic modulus, v is Poisson’s ratio with a value
2 tan  2

of 0.5 for ECM and cells, F is the force given by the cantilever deflection multiplied with the
cantilever spring constant,  is the open angle used in this study which had a value of 36º, and lastly 
is the indentation depth [21]. The average height, projected cell area and the volume of the fixed cells
were calculated using the MFP-3D Bio dedicated Igor Pro software (Asylum Research). The diameter
of matrix fibers were determined by the measurement of full width of half maximum (FWHM) using
ImageJ software.

Measurement of expanded cell proliferation index using flow cytometry
Before cell expansion, passage 3 hSDSCs were labeled with CellVue® Claret (Sigma-Aldrich) at
2×10-6 M for 5 min according to the manufacturer’s protocol. Expanded cells were collected and
measured using a BD FACS (fluorescence activated cell sorting) Calibur flow cytometer (dual laser)
(BD Biosciences, San Jose, CA). Twenty thousand events of each sample were collected using
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CellQuest Pro software (BD Biosciences) and cell proliferation index was analyzed by ModFit LT
version 3.1 (Verity Software House, Topsham, ME).

Evaluation of cell surface phenotypes using flow cytometry
The following primary antibodies were used in flow cytometry to detect hSDSC surface phenotypes:
integrin β1 (CD29) was purchased from Abcam (Abcam, Cambridge, MA); CD105 and the stagespecific embryonic antigen-4 (SSEA-4) were from Santa Cruz Biotechnology (Santa Cruz, CA); and
CD90 was from BD Pharmingen (BD Biosciences). IgG1 and IgG2a (Beckman Coulter, Fullerton,
CA) were used as the isotype controls. Samples (n=3) of each 0.2  106 expanded cells were
incubated on ice in cold PBS containing 0.1% ChromPure Human IgG whole molecule (Jackson
ImmunoResearch Laboratories, West Grove, PA) and 1% NaN3 (Sigma-Aldrich) for 30 min. Then, the
cells were sequentially incubated in the dark in the primary antibodies for 30 min. The fluorescence
was analyzed by a FACS Calibur (BD Biosciences) using FCS Express software package (De Novo
Software, Glendale, CA).

Chondrogenic induction and evaluation of expanded hSDSCs
After in vitro expansion, 0.25×106 of hSDSCs from each group were centrifuged at 500 g for 5 min in
a 15-mL polypropylene tube to form a pellet. After overnight incubation (day 0), the pellets were
cultured for 35 days in a serum-free chondrogenic medium consisting of high-glucose Dulbecco’s
Modified Eagle’s Medium (DMEM), 40 μg/mL proline, 100 nM dexamethasone, 100 U/mL penicillin,
100 μg/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate, and 1×ITSTM Premix [6.25 μg/mL
insulin, 6.25 μg/mL transferrin, 6.25 μg/mL selenous acid, 5.35 μg/mL linoleic acid, and 1.25 μg/mL
bovine serum albumin (BSA), from BD Biosciences] with supplementation of 10 ng/mL transforming
growth factor beta 3 (TGF-β3, PeproTech Inc., Rocky Hill, NJ). Chondrogenic differentiation was
evaluated using histology, immunostaining, biochemical analysis, microarray, and real-time
polymerase chain reaction (PCR).
Representative pellets (n=3) were fixed in 4% paraformaldehyde at 4C overnight, followed by
dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks. Five
μm-thick sections from the center of representative pellets were histochemically stained with Alcian
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blue (Sigma-Aldrich; counterstained with fast red) for sulfated glycosaminoglycans (GAGs). For
immunohistochemical analysis, the consecutive sections were immunolabeled with primary antibodies
against type II collagen (II-II6B3; Developmental Studies Hybridoma Bank, Iowa City, IA) and type
X collagen (Sigma-Aldrich) followed by the secondary antibody of biotinylated horse anti-mouse IgG
and IgM, respectively (Vector, Burlingame, CA). Immunoactivity was detected using Vectastain ABC
reagent (Vector) with 3,3’-diaminobenzidine as a substrate.
Representative pellets (n=4) were digested for 4 h at 60C with 125 μg/mL papain in PBE buffer (100
mM phosphate and 10 mM ethylenediaminetetraacetic acid, pH 6.5) containing 10 mM cysteine, by
using 200 μL enzyme per sample. To quantify cell density, the amount of DNA in the papain digestion
was measured using the QuantiTTM PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor®
Series 4000 (Applied Biosystems, Foster City, CA). GAG was measured using dimethylmethylene
blue dye and a Spectronic BioMate 3 Spectrophotometer (Thermo Scientific, Milford, MA) with
bovine chondroitin sulfate as a standard.
Global gene expression was evaluated in hSDSCs after expanded cell chondrogenic induction. The
pellets from dECM expanded cells were referred to as Ep while those from Plastic expanded cells
were referred to as Pp. Total RNAs were isolated from the pellets using Trizol (Invitrogen) followed
by additional purification using an RNeasy Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. The required amount of cDNA (5.5 µg) was processed for fragmentation
and biotin labeling using the GeneChip® WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA).
The entire reaction of fragmented and biotin-labeled cDNA (50 µL) with added hybridization controls
was hybridized to the human GeneChip® 1.0 ST Exon Arrays (Affymetrix) at 45C for 17 h in the
GeneChip® Hybridization Oven 640 (Affymetrix). The raw data was uploaded into Partek (St. Louis,
MO) software for initial analysis and Ingenuity Pathway Analysis (IPA, Redwood City, CA) for
pathway and functional analysis. Briefly, raw intensity was background-subtracted, robust multi-array
analysis (RMA) normalized, log-transformed, and fold changes determined. The batch effects (scan
date) were removed before fold change calculation. Cluster analysis was used to compare the genes
(the dECM group versus the Plastic group) annotated in IPA as affecting chondrodysplasia or bone
ossification. For bone ossification, genes were filtered to 60 with the greatest differential expression.
Clustering was done using heatmap.2 in R (Euclidean distance, complete linkage).
After extraction and purification of total RNA from samples (n=4), about 1 µg of mRNA was used for
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reverse transcriptase with a High-Capacity cDNA Archive Kit (Applied Biosystems) at 37C for 120
min. Chondrogenic marker genes [type II collagen (COL2A1; assay ID: Hs00156568_m1), aggrecan
(ACAN; assay ID: Hs00153935_m1), and SRY (sex determining region Y)-box 9 (SOX9; assay ID:
Hs00165814_m1)], hypertrophic marker genes [COL10A1 (assay ID: H200166657_m1) and alkaline
phosphatase (ALPL; assay ID: Hs01029144_m1)], Wnt signal genes [WNT3A (assay ID:
Hs00263977_m1), WNT5A (assay ID: Hs00998537_m1), and WNT11 (assay ID: Hs00182986_m1)],
and inflammation related genes [interleukin 1 beta (IL1B; assay ID: Hs01555410_m1), and a
disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5; assay ID:
Hs00199841_m1)] were customized by Applied Biosystems as part of the Custom TaqMan® Gene
Expression Assays. Eukaryotic 18S RNA (assay ID: Hs99999901_s1) was carried out as the
endogenous control gene. Real-time PCR was performed with the iCycler iQTM Multi-Color Real
Time PCR Detection (Perkin-Elmer, Waltham, MA). Relative transcript levels were calculated as χ=2ΔΔCt

, in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s.

Characterization of both MAPK and Wnt signals using Western blot
Adult hSDSCs from cell expansion (day 1, 3, and 5) and pellets before (day 0) and after (day 1 and 7)
chondrogenic induction were dissolved in the lysis buffer (Cell Signaling, Boston, MA) with protease
inhibitors. Total protein was quantified using the BCA Protein Assay Kit (Thermo Fisher Scientific).
Thirty micrograms of protein from each sample were denatured and separated using NuPAGE®
Novex® Bis-Tris Mini Gels in the XCell SureLock Mini-Cell (Life Technologies) at 120 V at 4°C
for 3 h. Bands were transferred onto a nitrocellulose membrane using an XCell II™ Blot module (Life
Technologies) at 15 V at 4°C overnight. The membrane was incubated with primary monoclonal
antibodies in 5% bovine serum albumin (BSA) in TBST buffer (10 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.05% Tween-20) for 1 h (β-actin served as an internal control), followed by the secondary
antibody of horseradish peroxidase–conjugated goat anti-mouse (Thermo Fisher Scientific) for 1 h.
SuperSignal West Femto Maximum Sensitivity Substrate and CL-XPosure Film (Thermo Fisher
Scientific) were used for exposure. The primary antibodies used in immunoblotting included the
MAPK family antibody sampler kit [extracellular signal-regulated protein kinases 1 and 2 (Erk1/2),
Jun N-terminal kinase (Jnk), and p38], phosphorylated (p-) MAPK family antibody sampler kit, and
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the Wnt signaling antibody sampler kit (Cell Signaling). Wnt11 polyclonal antibody was obtained
from Thermo Fisher Scientific. ImageJ software was used to quantify immunoblotting bands.

Statistics
Numerical data are presented as the mean and the standard error of the mean. The Mann-Whitney U
test was used for pair-wise comparison in biochemistry and real-time PCR data analysis. All statistical
analyses were performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). A p value less
than 0.05 was considered statistically significant. For microarray data analysis, a regulation z-score
statistic was calculated to predict if the observed numbers of genes changed in the direction to
produce the functional effect would occur by chance. A z-score > 2 or < -2 was considered significant.

Results
Expansion on dECM changed cell morphology and increased cell proliferation
Before plating cells, SEM data showed that, compared with a flat surface on Plastic substrate, dECM
coated flasks exhibited a three-dimensional structure with interconnected nanofibers (Fig. 1A) that
was corroborated by morphological data from AFM (Fig. 1B), in which the diameter of matrix fibers
was 109.5 ± 39.6 nm (n=82). SEM data also showed that hSDSCs displayed a well-organized
fibroblast-like cell shape when expanded on dECM rather than a broad and flat cell shape when
grown on Plastic substrate (Fig. 1C). This finding was also in line with cell morphology shown by
AFM (Fig. 1D), in which several parameters were measured for fixed cells with glutaraldehyde after
expansion on Plastic and dECM substrates, including average height (1.33 ± 0.57 µm versus 2.34 ±
0.44 µm), projected cell area (713.7 ± 154.4 µm2 versus 916.0 ± 190.9 µm2), and volume (962.3 ±
502.7 µm3 versus 2101.3 ± 354.1 µm3). Young’s moduli of the fixed cells were 91.22 ± 64.15 kPa
after expansion on Plastic and 53.33 ± 53.47 kPa when expanded on dECM (Fig. 1E).
To determine whether dECM expansion also affected cell proliferation rate, 3000 cells per cm2 were
incubated on both substrates for seven days. The data from cell counting showed that the cells grown
on Plastic flasks increased 6.95-fold compared with 8.57-fold on dECM (Fig. 2A), which was
confirmed by proliferation index data (8.46 versus 22.28) measured in expanded cells (Fig. 2B). To
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further characterize molecular phenotype changes following dECM expansion, flow cytometry was
used to quantify both percentage and median fluorescence intensity of typical mesenchymal stem cell
markers in expanded cells (Fig. 2C). Notably, despite almost 100% expression in the cells after
expansion on both substrates, the median fluorescence intensity of CD29, CD90, and CD105
dramatically decreased in dECM expanded cells. In contrast, the percentage of SSEA4 doubled in
dECM expanded cells concomitantly with a slight increase in median fluorescence intensity.

Expansion on dECM enhanced cell chondrogenic potential
To determine whether dECM expansion could enhance hSDSC chondrogenic potential, a pellet
culture system was used for chondrogenic induction. Histology data showed that dECM expanded
cells yielded 35-day-pellets with a larger size despite starting with the same initial cell density as
those from Plastic expanded cells. The increased pellet size was accompanied by similarly increased
staining intensity of both sulfated GAG and type II collagen, two cartilage markers, in the pellets from
dECM expanded cells (Fig. 3A). The staining data were further confirmed by the quantification data
at both the protein and mRNA levels. Our biochemical analysis data showed that, after a 35-daychondrogenic induction, expansion on dECM enhanced DNA ratio (167.35 ± 4.01 %, adjusted by day
0) while expansion on Plastic decreased this ratio (82.03 ± 4.06 %); despite the lower amounts at day
0, after chondrogenic induction, both GAG amount per pellet and ratio of GAG to DNA from the
dECM group dramatically increased and were higher than those from the Plastic group (Fig. 3B).
Real-time PCR data showed that all chondrogenic marker genes (SOX9, COL2A1 and ACAN) were
up-regulated during chondrogenic induction, especially in cells from the dECM group (Fig. 3C).
Interestingly, despite a dramatic increase 24 h after chondrogenic induction, SOX9 expression in
dECM expanded cells reached a comparable level at day 7 and decreased afterwards compared with
that from the Plastic group (Fig. 3C). Our data also showed that both IL1B and ADAMTS5, two typical
inflammatory genes, were significantly down-regulated in chondrogenically induced hSDSCs from
the dECM group (Fig. 3D).

Expansion on dECM promoted cell hypertrophy but not toward an osteogenic lineage
To determine whether expansion on dECM would enhance hSDSCs’ hypertrophy during
chondrogenic induction, we examined markers of hypertrophy. Immunostaining data showed that the
33

35-day-pellets from dECM expanded hSDSCs were intensely stained with type X collagen compared
with those from Plastic expanded cells (Fig. 4A). These data were further confirmed by our real-time
PCR data in which both COL10A1 (Fig. 4B) and ALPL (Fig. 4C) were dramatically up-regulated in
chondrogenically induced hSDSCs following dECM expansion.
Next, we wanted to determine whether expansion on dECM would promote hSDSCs toward bone
ossification and/or chondrodysplasia. Pathway analysis of microarray data showed expression of 63
genes related to chondrodysplasia (Fig. 4D) and 377 genes related to bone ossification (the 60 genes
most differentially expressed are shown in Fig. 4E). Compared with the pellets from Plastic expanded
hSDSCs, chondrogenically induced hSDSCs from the dECM group exhibited an up-regulation in
fibroblast growth factor receptor 2 (FGFR2) and noggin (NOG) and a down-regulation in FGF18,
forkhead box O1 (FOXO1), bone morphogenetic protein 4 (BMP4), and caspase 3 (CASP3),
suggesting that, after dECM expansion, ossification of bone is decreased (prediction z-score: -2.43)
(Fig. 4F). An up-regulation of indian hedgehog (IHH), COL2A1, chondroitin sulfate synthase 1
(CHSY1), and solute carrier family 35 (UDP-GlcA/UDP-GalNAc transporter) member D1 (SLC35D1)
indicated that, after dECM expansion, dysplasia of the skeleton (including chondrodysplasia) is
decreased (prediction z-score: -2.00) (Fig. 4F).

Growth in ECM dramatically decreased expanded cell chondrogenic capacity
To determine whether expansion on dECM (“ON”, deposited by other SDSCs) was superior to SDSCs
that were grown in ECM (“IN”, deposited by expanded SDSCs) in chondrogenic capacity, expanded
cells were incubated in a pellet culture system supplemented with chondrogenic induction medium for
28 days. Both groups exhibited a similar pellet size at day 2 but, at day 28, SDSCs expanded on
dECM yielded pellets with dramatically increased size whereas SDSCs grown in ECM yielded pellets
that had no change in size visible to the naked eye, which was accompanied by less staining intensity
of both sulfated GAG and type II collagen compared to those expanded on dECM (Fig. 5A). Based on
the DNA ratio adjusted by day 0, cell viability at day 28 in the IN ECM group was about 90% while
in the ON dECM group, it was about 168%. Despite the higher GAG amount (2.73-fold) and ratio of
GAG to DNA (1.99-fold) at the initial time point (day 0), 28-day chondrogenic induction yielded
pellets from the IN ECM group with a lower GAG amount (0.13-fold) and ratio of GAG to DNA
(0.18-fold) compared to those from the ON dECM group (Fig. 5B). Real-time PCR data showed that,
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after 28-day chondrogenic induction, all chondrogenic marker genes (SOX9, COL2A1 and ACAN)
showed a similar trend in the pellets with lower mRNA levels from the IN ECM group compared to
the ON dECM group (Fig. 5C).

Both Wnt and MAPK pathways were actively involved in dECM mediated chondrogenesis
To determine whether Wnt signals were involved in dECM mediated cell expansion, real-time PCR
was used to measure WNT3A (a canonical signal) and WNT5A and WNT11 (noncanonical signals) in
hSDSCs following cell expansion. We found that WNT3A was undetectable but, compared to the
Plastic group, both WNT5A and WNT11 were up-regulated in dECM expanded cells, particularly
WNT11 (Fig. 6A). The above data were confirmed by Western blot data in which both Wnt5a and
Wnt11 exhibited a higher level of expression in dECM expanded hSDSCs (Fig. 6B). Intriguingly, we
also found that wnt3a protein was detectable and exhibited a higher level in dECM expanded hSDSCs
compared to those grown on Plastic (Fig. 6B).
Similar to cell expansion, WNT3A mRNA was undetectable while Wnt3a protein exhibited a higher
level in dECM expanded hSDSCs during the early stage of chondrogenic induction. Wnt5a and
Wnt11 exhibited comparable expression profiles in both mRNA (Fig. 6C) and protein (Fig. 6D).
Compared to an up-regulation of Wnt5a in the beginning followed by a decrease afterwards, a
continuing increase of Wnt11 at both mRNA and protein levels was found in the pellets from both
expanded cells, with dECM expanded hSDSCs exhibiting a significant advantage over those
expanded on Plastic.
To determine whether MAPK signals were involved in dECM mediated cell expansion, Western blot
was used to measure phosphor (p)-Erk, Erk, p-p38, p38, p-Jnk, and Jnk in hSDSCs after a five-day
expansion. We found that p-Erk, p-p38, p-Jnk, p38, and Jnk exhibited higher levels in dECM
expanded cells than those grown on Plastic (Fig. 7A). However, during chondrogenic induction, most
MAPK signals increased at day 1 but decreased afterwards (Fig. 7B).

Discussion
Our previous work found that dECM could rejuvenate pSDSCs for both proliferation and
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chondrogenic potential. We recently found this in vitro cell expansion system also applied to hSDSCs.
In order to make this approach applicable to future clinical treatment, in this study, we characterized
dECM and expanded cells using both SEM and AFM and compared them to the Plastic control; we
also characterized proliferation and chondrogenic capacity of adult hSDSCs after expansion on dECM
and determined whether dECM expanded cells exhibited a differentiation trend toward bone
formation as well as potential involvement of Wnt and MAPK signals. We found that dECM
expanded hSDSCs exhibited a fibroblast shape, a low level of elasticity, enhanced proliferation,
unique changes in stem cell surface markers, and enhanced chondrogenic capacity and hypertrophy,
which are consistent with our previous findings [16,17]. We also found, for the first time, that dECM
expansion could dramatically decrease the potential differentiation toward bone and dysplasia in the
skeleton. Additionally, we discovered that both Wnt and MAPK signals are actively involved in
dECM expanded hSDSC chondrogenesis.
It is known that microenvironments play important roles in stem cell lineage specifications. Cell
proliferation leads to an increase of cell volume while one of the hallmarks of apoptosis is cell
shrinkage [22]. In this study, cells expanded on dECM showed more than a two-fold increase in cell
volume, suggesting strong mitotic activity; comparatively, the low volume value for those cells grown
on Plastic substrate indicated low mitotic activity of cells that might experience senescence and
apoptosis. This observation was supported by expanded cell proliferation index data (Plastic versus
dECM: 8.46 versus 22.28). We also found that dECM was a nanostructured three-dimensional matrix,
on which expanded cells possessed low elasticity and high chondrogenic potential compared to those
grown on Plastic substrate, which might be explained by lower elasticity favoring expanded stem cells
chondrogenic differentiation [16,23,24]. In this study, dECM expansion lowered cell elasticity, about
0.58-fold compared to those cells grown on Plastic substrate. This finding is consistent with our
previous report, in which dECM expansion yielded cells with elasticity about 0.40-fold compared to
those grown on Plastic substrate [16], despite the fact that the absolute values were much higher than
previous ones due to the fixation of expanded cells using glutaraldehyde before measurement.
Evidence has more recently emerged that fixation is considered the preferred method for reliable data
analysis (reproducible) of both cell elasticity and cell morphology [25,26] since this method not only
allows for longer scanning time but further limits changes associated with the inherent dynamics of
living cells within the extended observation time of at least one hour per cell.
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In this study, the increase in cell number from passage 4 to 5 in the dECM group was 1.23-fold that in
the Plastic group while our previous study showed about an increase of 14.57-fold that in the Plastic
group [5]. The chondrogenic index from chondrogenically induced pSDSCs in the dECM group was
1.36-fold that in the Plastic group while our previous study showed an increase of about 18.71-fold
that in the Plastic group [5]. The discrepancy of nanofiber size is probably responsible for expanded
SDSC proliferation rate and chondrogenic potential. Our data suggested that the diameter of dECM
fibers measured by AFM was 109.5 ± 39.6 nm, which was about double the size of dECM fibers
measured by SEM (45.1 ± 8.8 nm) from our previous study [5]. As described by Oh and colleagues,
small (around 30-nm diameter) nanotubes promoted adhesion without noticeable differentiation,
whereas larger (70- to100-nm diameter) nanotubes elicited a dramatic stem cell elongation (10-fold
increase), which induced cytoskeletal stress and differentiation [27]. Another report by Park et al.
indicates that a 15-20 nm spacing was better for integrin activation, while tube diameter larger than 50
nm severely impaired cell spreading, adhesion, and spacing of 100 nm resulting in dramatically
reduced cell proliferation, migration, and differentiation [28]. Further investigation needs to determine
whether donor age affects the diameter of dECM fibers.
For cell proliferation, we found that hSDSCs grown on dECM became fibroblast-like in shape and
exhibited enhanced proliferation; CD29, CD90, and CD105 exhibited a decreased expression while
SSEA4 was up-regulated, which is consistent with our recent report using hSDSCs [16]. Interestingly,
despite a similar trend in cell morphology and proliferation capacity, our early report found that
dECM expanded pSDSCs displayed an enhanced expression of CD90 [5] rather than a decreased level
in this study, which is probably due to the source of SDSCs from different species (porcine versus
human) and/or donor age (3-month-old versus 43-year-old). This discrepancy remains to be
elucidated.
As we observed in a previous report [5], dECM expanded hSDSCs had a lower level of GAG and
ACAN before chondrogenic induction (at day 0) which may be indicative of “stemness” because these
pretreated SDSCs exhibited an enhanced chondrogenesis when incubated in a chondrogenic medium,
as evidenced by an improved cell survival capacity (DNA amount adjusted by day 0) and enhanced
chondrogenic differentiation. In contrast, SDSCs grown in ECM yielded pellets with the lowest levels
in GAG/pellet, GAG/DNA, ACAN, and COL2A1, indicating the minimum chondrogenic matrix
deposition.
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The aim of using dECM for cell expansion is to provide a large quantity of high-quality stem cells for
cartilage regeneration. In line with a recent report [17], an up-regulation of COL10A1 was observed in
chondrogenically induced adult hSDSCs after expansion on dECM, but this outcome differed from
the decreased level of hypertrophy in dECM expanded pSDSCs [5]. We expect the expanded cells to
have high chondrogenic potential but less tendency to differentiate into bone. Our microarray data for
pellets suggested that FGFR2 [29] and NOG [30] were up-regulated and FGF18 [31], FOXO1 [32],
BMP4 [33], and CASP3 [34] were down-regulated during chondrogenic induction of dECM expanded
hSDSCs. BMP signaling is critical for osteogenesis; as a potent BMP antagonist, reduction of noggin
enhanced BMP signaling and in vitro osteoblast bone formation [30]; activating mutations of FGFR2
decreased the expression of NOG [35]. In addition, mice lacking FGF18 display delayed ossification
and decreased expression of osteogenic markers [31]; as an early molecular regulator in the
differentiation of mesenchymal cells into osteoblasts, silencing FOXO1 in a tibia organ culture model
was demonstrated to decrease the expression of RUNX2 and impair bone formation [32]. Human
BMP4 protein was reported to increase (in a dose dependent manner) ossification of endochondral
bone [33]. Delayed ossification and decreased bone mineral density in caspase-3-deficient (Casp3-/and Casp3+/-) mice suggested that caspase-3 is crucial for the differentiation of bone marrow stromal
cells by influencing the TGF-beta/Smad2 pathway and cell cycle progression [34]. Our findings
suggest that dECM expansion decreased the tendency of hSDSCs toward ossification of bone. We
also found that IHH [36], COL2A1 [37], CHSY1 [38], and SLC35D1 [39] were up-regulated in dECM
expanded hSDSCs, indicative of a down-regulation of dysplasia of the skeleton, including
chondrodysplasia.
Wnt signaling molecules are involved in a multitude of developmental processes including
chondrogenesis [40]. In this report, both canonical and noncanonical Wnt signals were activated in
dECM expanded hSDSCs, indicating that Wnt signals are probably associated with enhanced cell
proliferation. For example, Wnt3a promoted the proliferation of undifferentiated mesenchymal stem
cells (MSCs) [41,42]. Wnt5a induced endothelial cell proliferation and enhanced cell survival under
serum-deprived conditions [43]. Despite a continuing increase in both groups, especially in the dECM
group, there is not sufficient evidence to support the role of Wnt11 in MSC proliferation. Intriguingly,
overexpression of Wnt11 was recently demonstrated in suppressing MSC proliferation and arresting
the cell cycle at the G0/G1 phase [44].
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During chondrogenic induction, both WNT3A and WNT5A in dECM expanded hSDSCs exhibited a
comparable trend, with an initial increase followed by a decrease; in contrast, Wnt11 expression
exhibited a time-dependent increase in both groups, particularly for dECM expanded cells. This
finding might indicate that the signals of both Wnt3a and Wnt5a are most related to cell expansion
with a minor effect on the early stage of chondrogenic differentiation. Noncanonical Wnt signaling
pathways such as Wnt5a and Wnt11 are known to promote chondrogenesis in vitro by increasing
cartilage nodule formation [40,45]. Our data showed that Wnt5a and Wnt11 were up-regulated at both
the mRNA and protein levels in dECM expanded hSDSCs except that Wnt5a exhibited a decrease at
the later stage of chondrogenic induction. This outcome could possibly be explained by a previous
report that Wnt5a specifically promotes entry into the prehypertrophic phase, whereas it conversely
blocks chondrocyte hypertrophy, acting in a stage-specific context [46].
Wnt5a has been shown to have stage-dependent regulation of chondrocyte differentiation by
promoting chondroprogenitor proliferation and inhibiting chondrocyte hypertrophy [47]; in addition,
Wnt5a-infected limbs reveal a delay in the onset of type X collagen expression, a marker for
hypertrophic chondrocytes [48]. It is possible that, in the early stage, the Wnt5a was highly activated
in dECM expanded hSDSCs in order to boost chondrogenesis while the decreased expression of
Wnt5a in the late stage contributes to enhanced hypertrophy. Interestingly, we also witnessed
increased expression of Wnt11, which has been reported to greatly enhance chondrogenesis [44].
Although overexpression of Wnt11 did not appear to delay chondrocyte differentiation including type
X collagen [40], more investigation is needed to confirm the correlation between Wnt11 expression
and chondrogenic hypertrophy.
Similar to Wnt signals, all MAPK signals were up-regulated in dECM expanded hSDSCs, likely
indicating a potential crosstalk between Wnt and MAPK signals during chondrogenesis. The MAPK
pathway is one of the conserved signal transduction systems in cartilage, where it plays a crucial role
in chondrogenic differentiation. Erk and p38 MAPK have central roles in mediating chondrocyte
proliferation and related gene expression [49]. During the proliferation stage, dECM expanded cells
showed enhanced expression of p-Erk and Erk; interestingly, Wnt3a can also promote Erk1/2
phosphorylation, and this signal was proposed to mediate proliferation of NIH3T3 cells [50]. Wnt5a
also promotes Erk1/2 phosphorylation in endothelial cells and Wnt5a protects cells from apoptosis via
Erk signaling [51].
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During chondrogenic induction, the MAPK signals were observed to tentatively increase followed by
a drop at day 7, indicating that the role of MAPK signals is mainly at the early stage of chondrogenic
differentiation. This finding is in line with previous reports which maintain that the Erk pathway
might be predominantly involved during early cartilage developmental stages in relaying signals
down-steam of FGF actions [52,53] and Erk1/2 activities are observed to decrease as chondrogenesis
proceeds and inhibition of Erk1/2 with PD98059 enhances chondrogenesis [54]. Jnk has been reported
to have a minor role in chondrogenesis [55,56]. However, in this study, we did find Jnk signals to be
increased during cell expansion and at the early stage of chondrogenic induction; the potential
mechanisms are still under investigation.

Conclusion and Perspectives
Our study demonstrated that dECM deposited by hSDSCs formed a three-dimensional nanostructured
matrix; expansion on dECM yielded a large-quantity of hSDSCs with enhanced chondrogenic
potential; despite an increase of type X collagen in chondrogenically induced cells, dECM expanded
cells had significantly lower potential for endochondral bone formation. Even though the composition
of dECM has been characterized in a recent report [16], research on the crosstalk between expanded
SDSCs and dECMs is still in its infancy. dECM expansion of hSDSCs and subsequent chondrogenic
induction were accompanied by a significant change in both Wnt and MAPK signals, indicating
potential mechanisms underlying dECM mediated hSDSC rejuvenation, which needs further in-depth
investigation. Progress in understanding environment-oriented epigenetic regulatory mechanisms
could benefit cartilage regeneration and engineering on a larger scale and provide more promising
therapeutic applications [57]. For future clinical application, young and healthy donors can be selected
for deposition of this ECM [16]; a decellularized process can minimize concerns about immune
issues; and this dECM can be commercialized to make one-step in vitro expansion possible.
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Figure 2. 1 Morphological characterization of culture substrates and expanded cells.
Surface topography of both substrates, Plastic and dECM, was characterized using SEM (A) and AFM
(B). Scale bar for SEM (A): 5 µm. Expanded cells on either Plastic (three cells) or dECM (four cells)
after fixation in glutaraldehyde were characterized using SEM (C) and AFM (D) for morphology and
using AFM (E) for elasticity. Scale bar for SEM (C): 50 µm.
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Figure 2. 2 dECM promoted expanded human SDSCs’ proliferation and changed expression of
stem cell surface markers.
(A) Fold change of cell number by day 0 was used to indicate cell proliferation after 7-day-expansion
on 175 cm2 flasks (n=6). (B) Flow cytometry was used to measure the proliferation index (PI) of
expanded human SDSCs. (C) Flow cytometry was used to measure both percentage and median of
stem cell surface markers (CD29, CD90, CD105, and SSEA4) of expanded ASDSCs.
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Figure 2. 3 dECM promoted expanded human SDSCs’ chondrogenic differentiation.
(A) Before histological staining, pellet size was measured with a scale bar as mm; Alcian blue (AB)
was used to stain sulfated GAGs and immunohistochemistry staining (IHC) was used to detect type II
collagen (Col II). (B) Biochemical analysis was used for DNA and GAG contents of pellets; cell
viability in chondrogenic medium was evaluated using DNA ratio adjusted by day 0; a ratio of GAG
to DNA indicated chondrogenic index. Real-time polymerase chain reaction (PCR) was used to
evaluate (C) chondrogenic marker gene expression (SOX9, ACAN, and COL2A1) and (D)
inflammation related genes (IL1B and ADAMTS5). Data are shown as average ± standard deviation
(SD) for n = 4. *p < 0.05 indicated a statistically significant difference.
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Figure 2. 4 dECM promoted expanded human SDSCs’ chondrogenic differentiation.
Human SDSCs were grown on either Plastic or dECM for one passage followed by chondrogenic
induction in a pellet culture system for 35 days. (A) Immunohistochemistry staining (IHC) was used
to detect type X collagen. (B) Real-time PCR was used to evaluate hypertrophic marker gene
expression (COL10A1 and ALPL). Data are shown as average ± standard deviation (SD) for n = 4. *p
< 0.05 indicated a statistically significant difference. (C) Microarray data were used to predict the
effect of dECM expansion on subsequent chondrogenic induction, especially on ossification of bone
and chondrodysplasia. Ossification of bone and chondrodysplasia were predicted to be decreased in
the pellets from dECM expanded cells, relative to those from Plastic expanded cells. Expression
results for the genes are shown as FC (log2). The orange line denotes predicted activation of the target
molecule (NOG) by the observed state of the upstream molecule (FGF18). Blue lines denote predicted
inhibition of the molecule or function by the observed state (up-regulation or down-regulation) of the
upstream molecule. Gray lines indicate that an effect on function predicted or interaction between
molecules noted to occur, but existing data do not support prediction of direction of change. Gold
indicates the effect on the downstream molecule is inconsistent with that predicted by direct
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interaction of the molecules.
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Figure 2. 5 hSDSCs grown in ECM (“IN”) exhibited a decline in chondrogenic potential
compared with those expanded on dECM (“ON”).
(A) Before histological staining, pellet size was measured with a scale bar as mm; Alcian blue (AB)
was used to stain sulfated GAGs and immunohistochemistry staining (IHC) was used to detect type II
collagen (Col II). (B) Biochemical analysis was used for DNA and GAG contents of pellets; cell
viability in chondrogenic medium was evaluated using DNA ratio adjusted by day 0; a ratio of GAG
to DNA indicated chondrogenic index. (C) Real-time PCR was used to evaluate chondrogenic marker
gene expression (SOX9, ACAN, and COL2A1. Data are shown as average ± SD for n=4. *p < 0.05
indicated a statistically significant difference.
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Figure 2. 6 Wnt signals were actively involved in chondrogenesis of dECM expanded human
SDSCs.
Both real-time PCR (A, C) and Western blot (B, D) were used to evaluate canonical Wnt signal
(Wnt3a) and noncanonical Wnt signals (Wnt5a and Wnt11) in human SDSCs during cell expansion
(A, B) and chondrogenic induction (C, D) at both mRNA and protein levels. β-actin was used as an
internal control. Data are shown as average ± standard deviation (SD) for n = 4. *p < 0.05 indicated a
statistically significant difference. ImageJ software was used to quantify immunoblotting bands.
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Figure 2. 7 MAPK signals were actively involved in chondrogenesis of dECM expanded human
SDSCs.
Western blot were used to evaluate Erk1/2, p38, and Jnk signals in both phosphorylated and
nonphosphorylated formats in human SDSCs during cell expansion (A) and chondrogenic induction
(B). β-actin was used as an internal control. ImageJ software was used to quantify immunoblotting
bands.
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Abstract
Autologous stem cells are a promising cell source for cartilage regeneration; however, cell replicative
senescence and joint posttraumatic inflammation provide challenges to bring this treatment modality
to fruition. In this study, we hypothesized that preconditioning with p38 MAPK inhibitor (sb203580)
would recharge decellularized extracellular matrix (dECM) expanded human synovium-derived stem
cell (hSDSC) chondrogenesis in an inflammatory environment. We found that preconditioning with
sb203580 greatly enhanced dECM expanded hSDSC proliferation and chondrogenic potential while
supplementation with sb203580 in an induction medium dramatically retarded hSDSC chondrogenic
differentiation, even for dECM expanded cells. We also found that sb203580 preconditioning
enhanced matrix-expanded hSDSC chondrogenic capacity even in an interleukin-1 (IL-1) induced
inflammatory environment. Non-detectable expression of HLA-DR in the hSDSCs grown on
allogeneic dECM indicates the feasibility of commercial preparation of these dECMs from healthy,
young donors for patients who need autologous transplantation. Our study indicated that p38 MAPK
inhibitor has a distinctive priming effect on dECM mediated stem cell cartilage regeneration.
Combined rejuvenation with sb203580 and dECM expansion can precondition hSDSCs’ resurfacing
capacity for osteoarthritic patients with cartilage defects.
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Introduction
Cartilage defects do not heal themselves due to a shortage of blood supply. Recently, adult stem cells
have become a promising cell source for autologous cartilage regeneration. Adipose-derived stem
cells (ASCs) have limited chondrogenic ability and bone marrow stromal cells (BMSCs) tend to
undergo endochondral ossification upon chondrogenic induction [1]. By comparison, synoviumderived stem cells (SDSCs) are a tissue-specific stem cell for cartilage regeneration [2] and have been
successfully used in cartilage regeneration studies [3-5]. In vitro expansion is a necessary step before
in vivo application and represents a formidable challenge since stem cells are thought to exist in
“niches” where extrinsic signals modulate the intrinsic signals that drive self-renewal and cell fate
determination [6]. Outside of their niche, adult stem cells lose their developmental potential quickly
and tend to either randomly differentiate or undergo apoptosis over time [7].
Decellularized extracellular matrix (dECM) could provide such an in vitro “niche”-like
nanostructured microenvironment in which porcine SDSCs (pSDSCs) were greatly expanded with
enhanced chondrogenic potential [8,9]. Despite success in using adult human SDSCs (hSDSCs) in this
system [10], the rejuvenation effect was not as robust as that using young pSDSCs [8]. Different
species and donor age might cause this discrepancy [7]. Furthermore, posttraumatic joint
inflammation, normally accompanying cartilage defects [11,12], could perhaps lead to reduced
efficiency of dECM on the rejuvenation of adult hSDSCs [13].
The p38 mitogen-activated protein kinase (MAPK) signaling cascade is known to be involved in
various biological responses such as cell proliferation and differentiation [14]. Recently, p38 MAPK
was also found to be activated by various pro-inflammatory and stressful stimuli [15]. There is
increasing evidence showing that in vivo application of p38 MAPK inhibitors can decrease
inflammation and related damage [16]; unfortunately, these inhibitors also arrest tissue regeneration
[17-19].
To maximize advantages and minimize disadvantages, in this study, a p38 MAPK inhibitor was used
to precondition hSDSCs during cell expansion on either plastic flasks (Plastic) or dECM followed by
chondrogenic induction in a pellet culture system. In comparison, p38 MAPK inhibitor was
supplemented in induction medium instead for the assessment of the direct effect on hSDSC
chondrogenesis. Expanded hSDSCs were also evaluated for chondrogenic capacity in an interleukin-1
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beta (IL-1β) induced inflammatory environment. Lastly, dECM deposited by allogeneic cells were
evaluated for eliciting potential immune issues in hSDSCs after expansion. We hypothesized that
preconditioning with p38 MAPK inhibitor would recharge dECM expanded hSDSC chondrogenesis
in an inflammatory environment.

Materials and Methods
SDSC culture
Adult human synovial fibroblasts (4 donors, two male and two female, average 43 years old, all had
no known joint disease), referred to as hSDSCs [10,20,21], were obtained from Asterand (North
America Laboratories, Detroit, MI). Human SDSCs were plated and cultured in a growth medium
[alpha minimum essential medium (αMEM) containing 10% fetal bovine serum (FBS), 100 U/mL
penicillin, 100 µg/mL streptomycin, and 0.25 μg/mL fungizone (Invitrogen, Carlsbad, CA)] at 37C in
a humidified 5% CO2 and 21% O2 incubator. The medium was changed every three days.

dECM preparation
The preparation of dECM was described in our previous study [10,21,22]. Briefly, plastic flasks
(Plastic) were precoated with 0.2% gelatin (Sigma-Aldrich, St. Louis, MO) at 37C for 1 h and seeded
with passage 3 (P3) SDSCs. After cells reached 90% confluence, 250 μM L-ascorbic acid phosphate
(Wako Chemicals USA, Inc., Richmond, VA) was added for 8 days. The deposited matrix was
incubated with 0.5% Triton X-100 containing 20 mM ammonium hydroxide at 37C for 5 min and
stored at 4C in phosphate-buffered saline (PBS) containing 100 U/mL penicillin, 100 µg/mL
streptomycin, and 0.25 µg/mL fungizone.

Morphological characterization of dECM with or without hSDSCs
Representative samples (n=3) were primarily fixed in 2.5% glutaraldehyde (Sigma-Aldrich) for 2 h,
followed by secondary fixation in 2% osmium tetroxide (Sigma-Aldrich) for another 2 h. The samples
were then dehydrated in a gradient ethanol series, in hexamethyldisilazane (HMDS, Sigma-Aldrich) at
a ratio of 1:1 with ethanol twice for 1 h each time, in HMDS at a ratio of 1:2 with ethanol overnight,
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and in HMDS three times for 4 h each time. The samples were air-dried for 24 h and gold sputter was
added. The images were recorded by a scanning electron microscope (SEM) (Hitachi, Model S 2400).

Preconditioning using p38 MAPK inhibitor during cell expansion
Passage 3 hSDSCs were cultured at 3000 cells/cm2 for one passage (8 days) on two substrates: dECM
or Plastic. Ten µM of sb203580 (p38 MAPK inhibitor, LC Laboratories, Woburn, MA) were added 48
h after cell seeding throughout the culture. The groups without sb203580 preconditioning served as a
control. There were four groups: Plastic expansion alone (Pcontrol), Plastic expansion plus sb203580
(Psb203580), dECM expansion alone (Econtrol), and dECM expansion plus sb203580 (Esb203580).
The cell number in T175 flasks (n=6) from each group was counted using a hemocytometer. For
proliferation index (PI), P3 hSDSCs (before expansion) were labeled with CellVue® Claret (SigmaAldrich) at 2×10-6 M for 5 min according to the manufacturer’s protocol. After passaging, expanded
cells were collected and measured using a BD FACS Calibur flow cytometer (dual laser) (BD
Biosciences, San Jose, CA). Twenty thousand events of each sample were collected using CellQuest
Pro software (BD Biosciences) and PI was analyzed by ModFit LT version 3.1 (Verity Software
House, Topsham, ME).
The following primary antibodies were used to detect expanded hSDSC surface immunophenotype
profiles: Alexa Fluor 488 anti-human CD29 antibody (BioLegend, San Diego, CA), FITC anti-human
CD90 antibody (Biolegend), FITC anti-human CD105 antibody (BioLegend), PE anti-human SSEA4
(the stage-specific embryonic antigen 4) antibody (BioLegend), and isotype-matched IgGs (Beckman
Coulter, Fullerton, CA). Samples (n=3) of each 2×105 expanded cells were incubated on ice in cold
PBS containing 0.1% Chrom-Pure Human IgG whole molecule (Jackson ImmunoResearch
Laboratories, West Grove, PA) and 1% NaN3 (Sigma-Aldrich) for 30 min. The cells were then
incubated in the dark in the primary antibody for 30 min. Fluorescence was analyzed by a FACS
Calibur (BD Biosciences) using FCS Express software package (De Novo Software, Los Angeles,
CA).

Chondrogenic induction of expanded hSDSCs with dECM and/or p38 MAPK inhibitor
preconditioning
After in vitro expansion, 0.3×106 of hSDSCs from each group (Pcontrol, Psb203580, Econtrol, and
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E203580) were centrifuged at 500 g for 5 min in a 15-mL polypropylene tube to form a pellet. After
overnight incubation, the pellets were cultured for 35 days in a serum-free chondrogenic medium
consisting of high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM), 40 μg/mL proline, 100
nM dexamethasone, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.1 mM ascorbic acid-2phosphate, and 1×ITSTM Premix [6.25 μg/mL insulin, 6.25 μg/mL transferrin, 6.25 μg/mL selenous
acid, 5.35 μg/mL linoleic acid, and 1.25 μg/mL bovine serum albumin (BSA), from BD Biosciences]
with supplementation of 10 ng/mL transforming growth factor beta 3 (TGFβ3, PeproTech Inc., Rocky
Hill, NJ). Chondrogenic differentiation was evaluated using histology, immunostaining, and
biochemical analysis.
Representative pellets (n=3) were fixed in 4% paraformaldehyde at 4C overnight, followed by
dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks. Fiveμm thick sections were histochemically stained with Alcian blue (Sigma-Aldrich; counterstained with
fast red) for sulfated glycosaminoglycans (GAGs). For immunohistochemical analysis, the sections
were immunolabeled with primary antibody against type II collagen (Col II; II-II6B3; Developmental
Studies Hybridoma Bank, Iowa City, IA) followed by the secondary antibody of biotinylated horse
anti-mouse IgG (Vector, Burlingame, CA). Immunoactivity was detected using Vectastain ABC
reagent (Vector) with 3,3’-diaminobenzidine as a substrate.
Representative pellets (n=4) were digested for 4 h at 60C with 125 μg/mL papain in PBE buffer (100
mM phosphate and 10 mM ethylenediaminetetraacetic acid, pH 6.5) containing 10 mM cysteine, by
using 200 μL of enzyme per sample. To quantify cell density, the amount of DNA in the papain
digestion was measured using the Quant-iTTM PicoGreen® dsDNA assay kit (Invitrogen) with a
CytoFluor® Series 4000 (Applied Biosystems, Foster City, CA). GAG was measured using
dimethylmethylene blue dye and a Spectronic BioMate 3 Spectrophotometer (Thermo Scientific,
Milford, MA) with bovine chondroitin sulfate as a standard.

Treatment using p38 MAPK inhibitor during chondrogenic induction
After in vitro expansion, the pellets from both the Plastic and dECM groups were cultured for 28 days
in a serum-free chondrogenic medium supplemented with 10 µM of sb203580 throughout the culture.
The groups without sb203580 treatment served as a control. Chondrogenic differentiation was
evaluated using Alcian blue staining for sulfated GAGs, immunostaining for type II collagen, and
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biochemical analysis for DNA and GAG amounts in pellets.

Preconditioning strategy for hSDSC-based chondrogenesis in an inflammatory environment
After in vitro expansion, the pellets from both the Plastic and dECM groups were cultured for 24 days
in a serum-free chondrogenic medium. Two dosages of IL-1β, 0.1 and 1 ng/mL, were applied either
throughout the culture (day 0-24), at the early (day 0-15), or late stage (day 15-24) of chondrogenic
induction. Chondrogenic differentiation was evaluated using Alcian blue staining for sulfated GAGs,
immunostaining for type II collagen, biochemical analysis for DNA and GAG amounts in pellets, and
TaqMan® real-time polymerase chain reaction (PCR) for chondrogenic markers including SOX9 [SRY
(sex determining region Y)-box 9], ACAN (aggrecan), and COL2A1 (type II collagen).
After in vitro expansion with or without 10 µM of sb203580, the pellets from both the Plastic and
dECM groups were cultured for 35 days in a serum-free chondrogenic medium with 1 ng/mL of IL1β. Chondrogenic differentiation was evaluated using Alcian blue staining for sulfated GAGs,
immunostaining for type II collagen, biochemical analysis for DNA and GAG amounts in pellets, and
real-time PCR for chondrogenic markers in terms of ACAN and COL2A1 and inflammatory factors
including PTGS2 (prostaglandin G/H synthase and cyclooxygenase), VEGFA (vascular endothelial
growth factor A), and MMP13 (matrix metallopeptidase 13).
Total RNA was extracted from pellets (n=4) using an RNase-free pestle in TRIzol® (Invitrogen).
About 1 µg of mRNA was used for reverse transcription with a High-Capacity cDNA Archive Kit
(Applied Biosystems) at 37C for 120 min. Chondrogenic marker genes [COL2A1 (assay ID:
Hs00156568_m1), ACAN (assay ID: Hs00153935_m1), and SOX9 (assay ID: Hs00165814_m1)] and
inflammatory genes [PTGS2 (assay ID: Hs00153133_m1), VEGFA (assay ID: Hs00900055_m1), and
MMP13 (assay ID: Hs00233992_m1)] were customized by Applied Biosystems as part of the Custom
TaqMan® Gene Expression Assays. Eukaryotic 18S RNA (assay ID: Hs99999901_s1) was carried out
as the endogenous control gene. Real-time PCR was performed with the iCycler iQTM Multi-Color
Real Time PCR Detection (Perkin-Elmer, Waltham, MA). Relative transcript levels were calculated as
χ=2-ΔΔCt, in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s.

Potential immune issues in hSDSCs after expansion on dECM deposited by either allogeneic or
xenogeneic cells
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Human SDSCs were expanded on either Plastic or dECM deposited by either hSDSCs (HECM) or
pSDSCs (PECM) followed by the evaluation of surface marker expression for CD45 using anti-CD45
APC (BD Biosciences) and HLA-DR [major histocompatibility complex (MHC), class II, DR] using
anti-human HLA-DR FITC (eBioscience, San Diego, CA), and isotype-matched IgGs (Beckman
Coulter). Samples (n=5) of each 3×105 expanded cells were incubated on ice in cold PBS containing
0.1% Chrom-Pure Human IgG whole molecule (Jackson ImmunoResearch Laboratories) and 1%
NaN3 (Sigma-Aldrich) for 30 min. The cells were then incubated in the dark in the primary antibodies
(both HLA-DR and CD45 simultaneously) for 30 min. The fluorescence data were analyzed by a BD
LSRFortessa™ (BD Biosciences), collected using BD FACSDiva 8.0 Software (BD Biosciences) at
10,000 events/sample. The results were analyzed using FCS Express 4 software (De Novo Software).

Statistics

Numerical data are presented as the mean and the standard error of the mean. A Mann-Whitney U test
and a linear model with contrast analysis were used for pairwise comparison in biochemistry and realtime PCR data analysis. All statistical analyses were performed with SPSS 13.0 statistical software
(SPSS Inc., Chicago, IL). A p value less than 0.05 was considered statistically significant.

Results
Preconditioning using sb203580 further promoted proliferation of dECM expanded cells
SEM data (Fig. 1A) showed that dECM deposited by hSDSCs was composed of randomly arranged
fine matrix fibers and expansion on dECM yielded hSDSCs with a tiny fibroblast-like shape
compared to a flattened and broad shape when grown on Plastic. Flow cytometry data (Fig. 1B)
indicated that, despite a slight increase of proliferation index in hSDSCs when grown on Plastic,
preconditioning using sb203580 presented a 2.62-fold increase in dECM expanded hSDSCs compared
to a 1.65-fold increase in dECM expansion alone. Proliferation index data were confirmed by cell
number change (Fig. 1C), in which preconditioning using sb203580 presented a 2.00-fold increase in
dECM expanded hSDSCs compared to a 1.41-fold increase in dECM expansion alone. Flow
cytometry data (Fig. 1D) also showed that mesenchymal stem cell (MSC) surface markers (CD29,
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CD90, and CD105) were down-regulated at the median in dECM expanded hSDSCs; when combined
with sb203580 preconditioning, the expression of the above markers presented a slight increase.
Interestingly, sb203580 preconditioning increased SSEA4 expression in both percentage and median
of Plastic expanded hSDSCs followed by dECM expansion with the co-preconditioning of sb203580
and dECM expansion having the largest.

sb203580 preconditioning enhanced dECM expanded hSDSC chondrogenic potential while use of
sb203580 in the induction phase arrested hSDSC chondrogenic differentiation
To determine whether p38 MAPK inhibitor preconditioning played a role in hSDSC expansion and
chondrogenic potential, 10 µM of sb203580 was added to culture medium for hSDSC expansion on
either Plastic or dECM. Both dECM expansion and sb203580 preconditioning alike led to
chondrogenically differentiated 35-day pellets of a larger size with more intense staining of sulfated
GAGs and type II collagen (Fig. 2A) and higher cell viability (DNA ratio adjusted by day 0) and GAG
amount (chondrogenic marker) (Fig. 2B) compared to the corresponding Plastic group. Copreconditioning with dECM and sb203580 yielded the largest hSDSC pellets (Fig. 2A) with the
highest cell viability and GAG amount followed by the dECM group with the Plastic group having the
lowest viability (Fig. 2B).
To determine whether p38 MAPK inhibitor played a role in hSDSC chondrogenic differentiation, 10
µM of sb203580 was supplemented in a serum-free chondrogenic medium. Due to a dramatic
decrease in pellet size from both the Plastic and dECM groups, chondrogenic induction was ended at
day 28. Despite enhanced chondrogenic staining in the pellets from the dECM group, the addition of
sb203580 in the induction medium significantly decreased both staining and size of pellets in both
groups, even as early as day 14 (Fig. 3A). The above findings were corroborated by biochemical
analysis data, in which sb203580 arrested cell viability and reduced both GAG amount per pellet and
ratio of GAG to DNA in both the Plastic and dECM groups (Fig. 3B).

dECM expansion protects chondrogenically induced hSDSCs from IL-1β induced inflammatory stress
To determine whether dECM expanded hSDSCs had the ability to resist inflammatory stress, two
doses of IL-1β, 0.1 and 1 ng/mL, were used to treat chondrogenically induced hSDSCs after
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expansion on either dECM or Plastic. Continuous treatment with IL-1β from day 0 to day 15 of
chondrogenic induction yielded small pellets with less intensive staining of sulfated GAGs and type II
collagen compared to the untreated control in both the dECM and Plastic groups, particularly for
treatment with 1 ng/mL of IL-1β (Fig. 4A). Without IL-1β treatment, dECM expanded hSDSCs
yielded pellets with higher GAG amount per pellet and ratio of GAG to DNA than those from Plastic
expansion. With IL-1β treatment, both GAG amount per pellet and ratio of GAG to DNA decreased in
a dose-dependent fashion; however, dECM expanded hSDSCs yielded pellets with a significantly
higher ratio of GAG to DNA than those from Plastic expansion (Fig. 5A).
Continuous treatment with IL-1β from day 0 to day 24 of chondrogenic induction yielded pellets with
a dramatic decrease in both size and chondrogenic staining when 1 ng/mL of IL-1β was applied; there
was no significant difference when 0.1 ng/mL of IL-1β was used, particularly for dECM expanded
cells (Fig. 4B). Interestingly, treatment with IL-1β from day 15 to day 24 of chondrogenic induction
yielded pellets with a significant improvement in both size and chondrogenic staining for both dECM
and Plastic expansion even in the presence of 1 ng/mL of IL-1β (Fig. 4C). The above histology result
was supported by quantification data. Biochemical analysis data showed that continuous treatment
with 1 ng/mL of IL-1β yielded pellets with a significant decrease in both DNA ratio and ratio of GAG
to DNA (Fig. 5B). However, treatment with 1 ng/mL of IL-1β from day 15 to day 24 of chondrogenic
induction yielded pellets with a significant increase in both DNA ratio and GAG amount compared to
the corresponding group with continuous IL-1β treatment (Fig. 5B). The above protein level data were
also consistent with the mRNA data using real-time PCR for chondrogenic marker genes including
SOX9, ACAN, and COL2A1 (Fig. 5C).

sb203580 preconditioning promotes dECM rejuvenated hSDSCs’ ability against inflammation during
chondrogenic induction
The above results indicated that continuous treatment with 1 ng/mL of IL-1β from day 0 to day 24 of
chondrogenic induction yielded pellets with diminished chondrogenic differentiation in hSDSCs from
dECM expansion compared with the corresponding control without IL-1β treatment. In this study, we
assumed that co-preconditioning using dECM and sb203580 would retard the diminished
chondrogenic differentiation of dECM expanded hSDSCs in the presence of a high concentration of
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IL-1β. Continuous treatment for 35 days with 1 ng/mL of IL-1β reduced the difference in
chondrogenic capacity in hSDSCs from dECM and Plastic expansion. Compared to the slight increase
in pellet size observed in Plastic expanded cells, preconditioning using sb203580 dramatically
increased both size and chondrogenic staining in the 35-day IL-1β treated pellets from dECM
expanded hSDSCs (Fig. 6A). This histology result was also supported by both biochemical analysis
and real-time PCR data. dECM expanded cells yielded pellets with a higher amount of GAG and a
higher ratio of GAG to DNA compared to those from Plastic expanded cells in the presence of 1
ng/mL of IL-1β (Fig. 6B) despite no difference in ACAN and COL2A1 (Fig. 6C). Preconditioning
using sb203580 dramatically increased both GAG amount and ratio of GAG to DNA (Fig. 6B) as well
as ACAN and COL2A1 (Fig. 6C) in hSDSC pellets from both dECM and Plastic expansion with the
co-preconditioning group being the highest.
To determine whether sb203580 preconditioning had any inhibitory effect on inflammation during
subsequent chondrogenic induction, real-time PCR data (Fig. 6D) showed that, without sb203580
preconditioning, dECM expanded hSDSCs yielded 35-day pellets with a significantly lower VEGFA
level compared to those from Plastic expanded cells. With sb203580 preconditioning, dECM
expanded hSDSCs yielded pellets with significantly lower levels of PTGS2, MMP13, and VEGFA; a
notable increase in these gene expressions occurred in pellets from Plastic expanded hSDSCs.

Allogeneic dECM expanded hSDSCs exhibited a non-detectable HLA-DR expression
Flow cytometry was also used to determine whether expansion of hSDSCs on Plastic, HECM
(allogeneic substrate), or PECM (xenogeneic substrate) increased HLA-DR expression. After
subtracting the respective unstained negative controls (Fig. 7A/B) from the percent HLA-DR-positive
values for both Plastic (Fig. 7C) and dECM substrates (Fig. 7D/E), the percent HLA-DR-positive cells
in each population were 1.08% for Plastic expanded hSDSCs (Fig. 7C), 0.81% for HECM expanded
hSDSCs (Fig. 7D), and 6.48% for PECM expanded hSDSCs (Fig. 7E). These cells also exhibited a
similar trend when comparing the mean fluorescence intensity (MFI) values: the Plastic group was
474.19, the HECM group was 357.23, and the PECM group was 583.29. Additionally, all hSDSC
samples were CD45 negative, ensuring there was no persisting contamination in the hSDSC
populations with HLA-DR+ immune cells following their isolation from synovial tissue.
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Discussion
Cartilage tissue engineering has emerged as a potential therapeutic option for cartilage repair;
however, once transplanted into the joints, cells or premature cartilage often face an inflammatory
environment, making cartilage resurfacing challenging [13]. Among the proinflammatory cytokines,
IL-1β acts as an important mediator of increased ECM degradation by stimulating a number of events,
such as an increase of MMPs and nitric oxide production [23] and by suppressing type II collagen and
proteoglycan synthesis [24]. In osteoarthritic joints, the IL-1β concentration was reported to range
from 1-10 pg/mL [25]. Xie et al. reported that the mean concentration of IL-1β in synovial fluid from
early osteoarthritis in dysplastic hips was 55 (SD 12), ranging from 24 to 74 pg/mL [26]. Attur et al.
reported that 5 ng/mL of IL-1β could significantly suppress proteoglycan synthesis from both human
and bovine chondrocytes [27]. Yudoh et al. reported a significant reduction in production of type II
collagen by rabbit chondrocytes incubated in the presence of 10 ng/mL of IL-1β [28]. Thus, in this
study, IL-1β was added into chondrogenic medium to simulate the inflammatory environment often
encountered in joint capsule; 0.1 ng/mL of IL-1β was chosen to represent a relatively low
concentration despite the fact that this dose is still higher than the reported pathological concentration
of IL-1β in osteoarthritis [25]. One ng/mL of IL-1β was chosen to represent a relatively high
concentration.
In this report, we found that dECM expansion could maintain an advantage over Plastic expansion in
chondrogenic capacity of hSDSCs in the presence of a low concentration (0.1 ng/mL) of IL-1β.
However, this advantage was diminished when a high concentration (1 ng/mL) of IL-1β was applied
during chondrogenic induction. Interestingly, premature tissue pellets from dECM expanded hSDSCs
could, to a certain degree, resist the decline of chondrogenic differentiation resulting from a high
concentration of IL-1β. This finding is consistent with a previous report in which more mature
cartilaginous tissue was more resistant to 1 ng/mL of IL-1β exposure [29]. Previous investigations
showed that inflammatory-related genes such as MMP13, PTGS2, and VEGF were upregulated in the
presence of IL-1β but were blocked by application of sb203580 [30-32]. In this study, despite a higher
expression in the preconditioning group by sb203580, these inflammatory genes were significantly
downregulated in chondrogenically induced hSDSCs when a co-preconditioning strategy with dECM
expansion was applied. This finding might be attributable to the anti-inflammatory function of
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sb203580 [16,33] and antioxidant characteristics of dECM during cell expansion [10].
Consistent with previous reports [34,35], we found that the use of sb203580 in the induction medium
significantly diminished TGFβ mediated hSDSC chondrogenic differentiation. It is well known that
TGFβ induces chondrogenic differentiation classically through the SMAD pathway and also via p38
MAPK signaling [36]. For instance, TGFβ induced rapid phosphorylation of SMAD2, extracellular
signal-activated kinase 1/2 (ERK1/2), and p38 MAPK in ATDC5 cells; however, incubation with
sb203580 repressed TGFβ-induced ACAN, suggesting an important role for transcriptional cross-talk
between the TGFβ and p38 MAPK pathways in expression of early chondrocyte differentiation [37].
A recent study suggested that, following activation by TGFβ, MAPKs (in particular the p38 MAPK
pathway) were involved in the control of post-translational modification of SMADs by a direct
phosphorylation or through their downstream effector molecules [38]. Another report indicated that
SOX9 is likely a downstream target of the p38 MAPK pathway because the increased activity of the
SOX9-dependent COL2A1 enhancer in primary chondrocytes was abolished by sb203580 [39].
Our recent study demonstrated that dECM deposited by young and healthy hSDSCs could rejuvenate
older hSDSCs in chondrogenic potential [22], indicating that allogeneic dECM can be a promising
approach to expand patient hSDSCs for autologous transplantation. To solve the immune concerns in
hSDSCs after expansion on allogeneic dECMs, expression of HLA-DR was used as an indicator since
HLA-DR is known to be involved in graft rejection and other adverse immune events [40,41]. The
flow cytometry data showed no increase in HLA-DR expression in the HECM (allogeneic control)
expanded cells compared to the Plastic group (negative control); however, there was a greater than 6fold increase in the percent HLA-DR-positive expression when hSDSCs were expanded on PECM
(xenogeneic control) versus Plastic or HECM substrates. Not only does the PECM-expansion of
hSDSCs seem to produce more HLA-DR+ cells than the Plastic or HECM-expansion, but the MFI
values also suggest that these PECM-expanded cells seem to express more HLA-DR per cell. These
increases in HLA-DR+ expression could be troubling for future clinical use of PECM substrates for
hSDSC expansion strategies, as studies have demonstrated the ability of MHC class II-positive
antigen-presenting cells, and more recently synovial fibroblasts, to cause T-cell activation [42,43]. In
order to verify that all hSDSC populations were void of immune cells whose presence could create
false positives for HLA-DR expression, CD45 expression was also examined. All hSDSCs, regardless
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of expansion condition, were comparatively negative for CD45 expression, leading us to conclude that
the hSDSCs were the cells expressing HLA-DR. Compared to potential immunogenicity from PECMexpanded hSDSCs, allogeneic HECM-expansion seems a potentially more attractive strategy for
future clinical use; however, further in vivo studies will be necessary to investigate this issue.

Conclusion
This study is the first to investigate p38 MAPK inhibitor for its preconditioning in hSDSC
proliferation and chondrogenic potential as well as its inhibitory effect on hSDSC chondrogenic
differentiation. The joint preconditioning effect of p38 MAPK inhibitor and dECM expansion on
hSDSC chondrogenesis in the presence of IL-1β was also explored. We found that preconditioning
with sb203580 favored hSDSC proliferation and chondrogenic capacity, which was enhanced in
combination with dECM expansion; however, the application of sb203580 in the induction medium
suppressed the growth of chondrogenic pellets in both the Plastic and dECM groups. The inhibitory
effect of IL-1β on chondrogenic differentiation of expanded hSDSCs was in a dose- and phasedependent manner. Despite the fact that pre-differentiated hSDSCs acquired an enhanced capacity
against inflammatory insult, expanded hSDSCs could only survive chondrogenic induction in the
presence of a low dose of IL-1β; interestingly, we found that sb203580 preconditioning could enhance
matrix expanded hSDSC chondrogenesis even under stimulation by a high dose of IL-1β. This
preconditioning strategy could enhance the successful rate of implantation of undifferentiated stem
cells or premature tissue constructs in treating cartilage defects in which a harsh inflammatory
environment exists. Non-detectable expression of HLA-DR in hSDSCs grown on allogeneic dECM
indicates the feasibility of commercial preparation of these dECMs from healthy, young donors for
patients who need autologous transplantation.
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Figure 3. 1 Preconditioning using sb203580 enhanced proliferation of dECM expanded hSDSCs.
(A) Scanning electron microscopy was used to characterize surface topography of both Plastic and
dECM (scale bar: 20 µm) and morphology of expanded hSDSCs (scale bar: 200 µm). (B) Human
SDSCs were expanded on either dECM or Plastic for one passage (8 days) with or without
preconditioning of sb203580. Flow cytometry was used to measure proliferation index of expanded
cells. (C) A hemocytometer was used to measure cell numbers in T175 flasks (n=6) from each group.
(D) Flow cytometry was used to measure both percentage and median fluorescence intensity of MSC
surface markers (CD29, CD90, and CD105) and SSEA4 of expanded cells.
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Figure 3. 2 Preconditioning using sb203580 enhanced chondrogenesis of dECM expanded
hSDSCs.
Human SDSCs expanded on either dECM or Plastic for one passage (8 days) with or without
preconditioning of sb203580 were followed by a 35-day chondrogenic induction in a pellet system.
(A) Pellets were photographed before histology; Alcian blue (Ab) was used to stain sulfated GAGs
and immunohistochemical staining (IHC) was for Col II. (B) Biochemical analysis was used for DNA
and GAG amounts in chondrogenic pellets. Cell proliferation and viability were evaluated using DNA
ratio (DNA amount at days 35 and 14 adjusted by that at day 0). Chondrogenic index was evaluated
using ratio of GAG to DNA. Data are shown as average ± SD for n = 4. * p < 0.05 suggests a
statistically significant difference. NS indicates no significant difference.
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Figure 3. 3 Human SDSCs expanded on either dECM or Plastic for one passage were followed
by a 28-day chondrogenic induction in a pellet system with or without preconditioning of
sb203580.
(A) Pellets were photographed before histology; Alcian blue (Ab) was used to stain sulfated GAGs
and immunohistochemical staining (IHC) was for Col II. (B) Biochemical analysis was used for DNA
and GAG amounts in chondrogenic pellets. Cell proliferation and viability was evaluated using DNA
ratio (DNA amount at days 28 and 14 adjusted by that at day 0). Chondrogenic index was evaluated
using ratio of GAG to DNA. Data are shown as average ± SD for n = 4. * p < 0.05 suggests a
statistically significant difference.
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Figure 3. 4 Chondrogenic induction of dECM-expanded hSDSCs in the presence of IL-1β.
Human SDSCs were expanded on either Plastic or dECM for one passage followed by a pellet culture
in a serum-free chondrogenic medium supplemented with either 0.1 or 1 ng/mL of IL-1β treatment for
15 days (A), 24 days (B), or the later stage between the 15th and 24th days (C). Chondrogenic
induction without IL-1β treatment served as a control. Alcian blue (Ab) was used to stain sulfated
GAGs. Immunohistochemistry staining (IHC) was used to detect collagen II (Col II).
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Figure 3. 5 Chondrogenic induction of dECM-expanded hSDSCs in the presence of IL-1β.
Human SDSCs were expanded on either Plastic or dECM for one passage followed by a pellet culture
in a serum-free chondrogenic medium supplemented with either 0.1 or 1 ng/mL of IL-1β treatment for
15 days (A), 24 days, or the later stage between the 15th and 24th days (B). Biochemical analysis was
used for DNA and GAG amounts in the chondrogenically-induced pellets. Cell proliferation and
viability was evaluated using DNA ratio (DNA amount adjusted by that at day 0). Chondrogenic index
was evaluated using a ratio of GAG to DNA. (C) Real-time PCR was used to evaluate chondrogenic
marker gene expression (SOX9, ACAN, and COL2A1) in day 24 pellets. Data are shown as average ±
SD for n = 4. * p < 0.05 compared with the corresponding Plastic group. # p < 0.05 compared with the
corresponding group with the same dose treatment of IL-1β.
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Figure 3. 6 35-day-chondrogenic induction of dECM-expanded hSDSCs preconditioned with
sb203580 in the presence of 1 ng/mL IL-1β.
Human SDSCs were expanded on either Plastic or dECM for one passage with or without
preconditioning using sb203580 followed by a 35-day pellet culture in a serum-free chondrogenic
medium supplemented with continuous treatment of IL-1β at 1 ng/mL. (A) Alcian blue (Ab) was used
to stain sulfated GAGs. Immunohistochemistry staining (IHC) was used to detect collagen II (Col II).
(B) Biochemical analysis was used for DNA and GAG amounts in the 35-day chondrogenicallyinduced pellets. Chondrogenic index was evaluated using a ratio of GAG to DNA. (C) Real-time PCR
was used to evaluate chondrogenic marker gene expression (ACAN and COL2A1) in day 35 pellets.
(D) Real-time PCR was used to evaluate inflammatory marker gene expression (PTGS2, MMP13, and
VEGFA) in day 35 pellets. Data are shown as average ± SD for n = 4. * p < 0.05 compared with the
corresponding Plastic group. # p < 0.05 compared with the corresponding group without sb203580
treatment.

72

Figure 3. 7 Flow cytometry analysis of CD45 and HLA-DR surface marker expression following
cell expansion.
Unstained Plastic-expanded (A) and dECM-expanded (B) hSDSCs were used as negative controls.
CD45 and HLA-DR surface marker expression was analyzed for each sample of hSDSCs expanded
on Plastic (C), HECM (D), and PECM substrates (E). Additionally, a separate macrophage/monocyte
population was analyzed for CD45 expression (F) as a positive control.

73

Chapter 4. Biomechanical signals guiding stem cell cartilage
engineering: from molecular adaption to tissue functionality

As submitted to Eur Cell Mater

1,2,#

Ying Zhang, MS, 3,#Song Chen, MS, and 1,2,4,*Ming Pei, MD, PhD

1

Stem Cell and Tissue Engineering

Laboratory, Department of Orthopaedics, West Virginia

University, Morgantown, West Virginia 26506, USA; 2Mechanical and Aerospace Engineering, West
Virginia University, Morgantown, West Virginia 26506, USA; 3Department of Arthroplasty Surgery,
Changzheng Hospital, Second Military Medical University, Shanghai 200003, China; 4Exercise
Physiology, West Virginia University, Morgantown, West Virginia 26506, USA

Running head: Biomechanical Signals & Stem Cell Chondrogenic Differentiation

Key words: Biomechanics; Cartilage Regeneration; Extracellular Matrix; Stiffness; Stem Cell

*Corresponding author: Ming Pei MD, PhD, Stem Cell and Tissue Engineering Laboratory,
Department of Orthopaedics, West Virginia University, PO Box 9196, One Medical Center Drive,
Morgantown, WV 26506-9196, USA, Telephone: 304-293-1072; Fax: 304-293-7070; Email:
mpei@hsc.wvu.edu

74

Abstract
In vivo Cartilage is in a state of constant mechanical stimulation. It is therefore reasonable to deduce
that mechanical forces play an important role in cartilage formation. Mechanical forces, such as
compression, tension, and shear force, have been widely applied for cartilage engineering; however,
relatively few review papers have summarized the influences of biomechanical signals on stem cellbased neo-cartilage formation and cartilage engineering in both molecular adaption and tissue
functionality. In this review, we will discuss recent progress related to the influences of substrate
elasticity on stem cell chondrogenic differentiation and elucidate the potential underlying mechanisms.
Aside from active sensing and responding to the extracellular environment, stem cells also could
respond to various external mechanical forces, which also influence their chondrogenic capacity; this
topic will be discussed along with associated signaling pathways. We expect that these different
regimens of biomechanical signals can be utilized to boost stem cell-based cartilage engineering and
regeneration.
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Introduction
Damage to cartilage represents one of the biggest challenges in musculoskeletal therapeutics due to its
limited aptitude for healing and regenerative capabilities [1]. Lack of treatments to restore cartilage
tissue function has prompted research on functional cartilage tissue substitutes in this rapidly
emerging field [2]. Engineered tissue implants are attractive and offer a promising approach to
cartilage restoration. Many tissue engineering techniques have been attempted such as developing
alternate cell sources, optimizing scaffolds, and applying novel exogenous agents and mechanical
stimulation regimens to produce cartilage constructs that could match native cartilage in biochemical
and biomechanical properties [3].
Although stem cell biologists have long appreciated the regulatory roles of soluble stem cell niche
signals (e.g., growth factors and cytokines) in regulating stem cell fate, recent evidence demonstrated
that biophysical information such as mechanical cues that exist in the extracellular microenvironment
can also be sensed by cells. This information can be transduced into intracellular biochemical and
functional responses, a process known as mechanotransduction [4, 5], which plays a critical role in
determining stem cell fate. There are two different regimens of mechanotransduction: “inside-out” or
“outside-in” sensing. For the active “inside-out” sensing, changes in extracellular matrix (ECM)
stiffness and surface topography can be felt and responded to by cells through generating traction
forces. For the passive “outside-in” sensing, the cell responds to a force imparted upon itself such as
shear stress, compression, or pressure [6].
The report from Evans and colleagues suggests a fundamental role for mechanosensing in mammalian
development and illustrates that the mechanical environment should be taken into consideration when
engineering implantable scaffolds or when producing therapeutically relevant cell populations in vitro
[7]. While biomechanics-driven approaches have been thoroughly investigated for their potential
influence on mesenchymal stem cell (MSC) differentiation [8], relatively few review papers have
summarized the influences of biomechanical signals on stem cell based neo-cartilage formation and
cartilage engineering in both molecular adaption and tissue functionality. In this review, we will
discuss recent progress related to the influences of substrate elasticity on stem cell chondrogenic
differentiation and elucidate the potential underlying mechanisms. Aside from the active sensing and
responding to the extracellular environment, stem cells also could respond to various external
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mechanical forces, which also influence their chondrogenic capacity; this topics will be discussed
along with associated signaling pathways.

Substrate elasticity influences stem cell/chondrocyte fate
Landmark work by Engler and coworkers (2006) [9] suggests that soft (elastic modulus, E, 0.1-1 kPa),
medium (E, 8-17 kPa), and hard (E, 25-40 kPa) matrices can induce MSC lineage specification
toward neurons, muscles, and osteoblasts, respectively. A recent report using a three-dimensional (3D)
numerical model showed that matrix stiffness plays a significant role in controlling the fate of MSCs
[10]. Substrate rigidity was also found to exert long-term effects on modulation of cell proliferation
[11]. Studies from different elasticity evaluation systems have provided a lot of evidence suggesting
that chondrocytes and stem cells grown on soft substrates tend to chondrogenic differentiation
compared to stiffer substrates. (Table 1)

Cells grown on less stiff hydrogels showed enhanced chondrogenic potential
The development of hydrogels tailored for cartilage engineering has been a research and clinical goal
for over a decade. Coaxing stem cells toward a chondrogenic phenotype and promoting new matrix
formation are a significant challenge that must be overcome for the successful application of
hydrogels in cartilage repair. A previous report indicates that stiffer hydrogels affect ligand
presentation and gel porosity, which influence cell proliferation, clustering, migration, and ECM
deposition patterns [12]. In designing hydrogels for cartilage engineering, their elasticity is an
important factor determining stem cell/chondrocyte chondrogenic differentiation.

Polyacrylamide (PAM) hydrogels
Xue and colleagues (2013) [13] found that, using polyacrylamide (PAM) hydrogels with different
stiffnesses as culture substrates, human bone marrow MSC (BMSC) aggregation was more
predominant when cultured on soft matrix (E, 1.6 ± 0.3 kPa) rather than on hard matrix (E, 40 ± 3.6
kPa); expanded on soft matrix BMSCs exhibited a dramatic upregulation of chondrogenic marker
genes, SOX9 [SRY (sex determining region Y)-box 9], ACAN (aggrecan), and COL2A1 (type II
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collagen). In contrast, the promotion of osteogenic marker expression by hard gel was overridden by a
high seeding density. Interestingly, Allen and coworkers (2012) [14] reported that primary murine
chondrocytes and ATDC5 cells grown on 0.5 MPa PAM hydrogel substrates deposited more
proteoglycan and expressed more SOX9, ACAN, and COL2A1 mRNA relative to cells exposed to
substrates of other stiffnesses (E, 0.2 MPa and 1.1 MPa). This finding suggests that the
chondroinductive effect of this discrete stiffness (E, 0.5 MPa), which falls within the range reported
for articular cartilage [15], requires the stiffness-sensitive induction of transforming growth factor
beta1 (TGFβ1).
Less stiff substrates favoring a chondrogenic lineage also apply to hybrid hydrogels. Kwon and
Yasuda (2013) [16] found that mouse BMSCs cultured on the high stiffness sulfonate-coated PAM (SPAM) hydrogels (E, ~150 kPa) spread out with strong expression of stress fibers, while BMSCs
cultured on the low stiffness S-PAM hydrogels (E, ~1 kPa) had round shapes with fewer stress fibers
but more cortical actins. Importantly, even in the absence of chondrogenic induction, the lower
stiffness S-PAM hydrogels led to higher mRNA levels of chondrogenic markers COL2A1, ACAN, and
SOX9 and lower mRNA levels of an undifferentiation marker SCA1 (stem cell antigen-1), indicating
that the mechanical properties of S-PAM hydrogels strongly influence chondrogenesis. Similarly, Park
and colleagues found that human BMSCs on stiff substrates (type I collagen-coated PAM hydrogels)
had higher expression of smooth muscle cell (SMC) markers ACTA1 (α-actin) and CNN1 (calponin 1);
in contrast, BMSCs on soft substrates had a higher expression of chondrogenic marker COL2A1 and
adipogenic marker LPL (lipoprotein lipase). TGFβ increased SMC marker expression on stiff
substrates; however, TGFβ increased chondrogenic marker expression and suppressed adipogenic
marker expression on soft substrates, while adipogenic medium and soft substrates induced
adipogenic differentiation effectively [17]. Using a two-dimensional (2D) culturing system in which
PAM gels with different concentrations of bis-acrylamide were coated with type I collagen, Schuh and
coworkers found that, after porcine chondrocytes were cultivated on these hybrid hydrogels with a
Young’s modulus of 4, 10, 40, and 100 kPa for 7 days, cellular proliferation and actin organization
were decreased on matrices of 4 kPa compared with stiffer substrates. The differentiated phenotype of
the chondrocytes grown on matrices of 4 kPa was stabilized, evidenced by higher levels of COL2A1
and ACAN and a lower level of COL1A1, indicating that chondrocytes sense the elasticity of the
matrix and might be used for the design of scaffolds with mechanical properties specifically tailored
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to support the chondrogenic phenotype in tissue engineering applications [18].

Polyethylene glycol (PEG) hydrogels
Results from Liu and coworkers have shown that human BMSCs expanded on PEG10-CMP (collagen
mimetic peptide) hybrid hydrogel (E, 3.730 kPa) had significantly more staining intensity of aggrecan
and type II collagen immunostaining than the cells grown on PEG10 hydrogels (E, 4.231 kPa), which
was confirmed at mRNA levels by real-time PCR data, indicating that soft matrix induced a greater
degree of chondrogenic differentiation [19]. This finding in PEG hydrogel also applies to bovine
articular chondrocytes. Nicodemus and coworkers found that the deposition of aggrecan and type II
collagen was the highest at both protein and mRNA levels when chondrocytes were encapsulated in
hydrogels with the lowest crosslinking 60 kPa compressive modulus while the catabolic gene
expression of MMP1 (matrix metalloproteinase 1) and MMP13 was elevated about 25-fold in
hydrogels with 590 kPa compressive modulus [20]. This finding indicates that the ECM synthesis,
degradation, and remodeling might be correlated with chondrocyte responses to hydrogel elasticity
differences.

Defined matrix hydrogels
Wang and colleagues synthesized 3D hydrogels with varied matrix stiffnesses (3, 30, and 90 kPa) by
using hydrogels with different concentrations of matrix compositions such as chondroitin sulfate (CS),
hyaluronic acid (HA), and heparin sulfate (HS). Results showed that, in softer hydrogels (~ 3 kPa),
increasing HA concentrations resulted in substantial upregulation of ACAN and COL2A1 expression
in a dose-dependent manner in human adipose-derived stem cells (ADSCs), which was reversed in
HA-containing hydrogels with higher stiffness (~ 90 kPa). This finding suggested that matrix stiffness
and biochemical cues interact in a nonlinear manner to regulate chondrogenesis of ADSCs in a 3D
environment [21].

Cells grown on less stiff scaffolds showed enhanced chondrogenic potential
In cartilage regeneration, it is important that the implants to be transplanted to the defect sites not only
maintain their mechanical integrity, but also deliver mechanical signals to adherent cells in the body.
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Synthetic scaffolds
Nam and coworkers reported that pure poly(ε-caprolactone) (PCL) fibers with a lower modulus (7.1
MPa) provided a more appropriate microenvironment for chondrogenesis, evidenced by a marked
upregulation of chondrocytic SOX9, ACAN, and COL2A1 genes and chondrocyte-specific ECM
glycosaminoglycan (GAG) production in embryonic mesenchymal progenitor cells. In contrast, the
stiffer core-shell poly (ether sulfone)-poly (ɛ-caprolactone) (PES-PCL) fibers (30.6 MPa) supported
enhanced osteogenesis by promoting osteogenic RUNX2 (runt-related transcription factor 2), ALP
(alkaline phosphatase), and OCN (osteocalcin) gene expression as well as ALP activity. The findings
demonstrate that the microstructure stiffness/modules of a scaffold and the pliability of individual
fibers may play a critical role in controlling stem cell differentiation [22]. By taking advantage of a
synthetic tetrafunctional ethylene oxide/propylene oxide block copolymer (Tetronic®1307), two
different shear storage moduli (G’) of 1 kPa or 2 kPa were fabricated and synthesized. Nucleus
pulposus-derived stem cells (NP-SCs) expanded on matrices with a low shear storage modulus (G’= 1
kPa) significantly promoted more proliferation and chondrogenic differentiation, which was
evidenced by higher expression of SOX9 and ACAN genes and sulfated GAG (sGAG), whereas
matrices with a high modulus (G’= 2 kPa) promoted osteogenic differentiation, which was proven by
enhanced expression of osteogenesis related markers such as OCN and OPN (osteopontin) genes and
higher ALP activity [23].

Natural scaffolds
Murphy and coworkers investigated the influence of ECM elasticity on stem cell differentiation. They
found that, in homogeneous collagen-GAG (CG) natural scaffolds with the same composition but
different stiffnesses (0.5, 1.0, and 1.5 kPa), scaffolds with the lowest stiffness facilitated a significant
upregulation of SOX9 expression and that Wistar rat BMSCs were directed toward a chondrogenic
lineage in more compliant scaffolds. In contrast, the highest level of RUNX2 expression was found in
the stiffest scaffolds and BMSCs were directed toward an osteogenic lineage in stiffer scaffolds [24].
The results from the work of Fernández-Muiños and colleagues (2014) [25] suggested that mouse
embryonic fibroblasts (MEFs) which were cultured in RAD16-I (PuraMatrix, self-assembling peptide
nanofiber scaffolds) at a low elastic modulus value (~ 0.1 kPa) expressed the chondrogenic inductor
bone morphogenetic protein 4 (BMP4) and its antagonist Noggin. On the other hand, at a higher
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elastic modulus value (~ 5 kPa), the cells expressed Noggin but not BMP4, and did not engage in
chondrogenesis, which suggested that the balance between BMP/Noggin could be implicated in the
chondrogenic process.

Cells grown on less stiff dECMs showed enhanced chondrogenic potential
The development of decellularized ECM (dECM) maintains the stemness and specific cell
morphology desired for chondrogenesis [26] and allows dECM produced by the patient’s own cells to
be used thereby overcoming the issues of possible exogenous pathogen transfer [27].

Cartilage-derived dECMs
During the past decade, there has been increasing interest in creating biological scaffolds composed of
ECM derived from the decellularization of tissues or organs for tissue engineering applications.
Schwarz and colleagues found decellularization and sterilization process (DP) treatment made the
linear modulus of the scaffolds decrease significantly from 6.5 ± 2.3 MPa in native porcine nasal
septal cartilage (pNSC) to 1.92 ± 0.85 MPa in processed cartilage. Processed pNSC scaffolds seeded
with human primary chondrocytes were cultured for 42 days in chondrogenic induction medium. Due
to the decreased linear modulus in processed pNSC, scaffolds seem to provide adequate substrate
stiffness to support redifferentiation and maintenance of the chondrogenic phenotype [28]. Garrigues
and coworkers (2014) [29] found that the predominant effects on human ADSCs of incorporation of
cartilage-derived matrix (CDM) into electrospun PCL scaffolds were to stimulate sGAG synthesis and
COL10A1 gene expression. Compared with single-layer scaffolds, multilayer scaffolds enhanced cell
infiltration and ACAN gene expression. Interestingly, compared with single-layer constructs,
multilayer PCL constructs had a much lower elastic modulus; PCL-CDM constructs had an elastic
modulus approximately 1% that of PCL constructs. These findings suggest the role of lower elastic
modulus particularly from CDM in promoting chondrogenesis. Thus decellularized cartilage
(tissue/organ) scaffolds with controlled elasticity hold great potential in regulating the chondrogenesis
of therapeutic cells and cartilage regeneration in vivo.

Cell-derived dECMs
Recent reports demonstrate the influence of cell-derived matrix stiffness on chondrogenic
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differentiation of adult stem cells. Zhang and coworkers (2015) [30] reported that human synoviumderived stem cells (SDSCs) expanded on stem cell-derived dECM greatly enhanced their proliferation
and chondrogenic differentiation capacity. To determine the effect of mechanical properties of culture
substrates on cultured cells, atomic force microscopy (AFM) was used to measure the elasticity of
both substrates and expanded cells. They found that Young’s moduli of the fixed cells using
glutaraldehyde were 91.22 ± 64.15 kPa after expansion on plastic flasks and 53.33 ± 53.47 kPa when
expanded on dECM. The finding indicates that a lower stiffness substrate might be related to
enhanced chondrogenic potential. Furthermore, an AFM study showed that dECM (AECM) deposited
by adult SDSCs (ASDSCs) exhibited a higher elasticity than that deposited by fetal SDSCs (FECM)
(61.82 ± 35.86 versus 58.26 ± 13.37 kPa, p = 0.000); the elasticity of plastic flasks could be
considered as infinite. Interestingly, Li and colleagues (2014) [31] found that the elasticity of
expanded ASDSCs was parallel to their substrate; the comparison between plastic flasks and AECM
was 9.07 ± 4.56 versus 3.60 ± 1.79 (kPa) (p = 0.000) while the comparison between AECM and
FECM was 3.60 ± 1.79 versus 3.45 ± 2.29 (kPa) (p = 0.024). They also found that expanded ASDSCs
on FECM yielded 21-day pellets with the highest chondrogenic markers including aggrecan and type
II collagen at the both mRNA and protein levels followed by those grown on AECM; cells grown on
plastic flasks had the lowest amount of chondrogenic markers. The fact that stem cells maintained
better chondrogenic potentials on dECM with lower elasticity suggested that, during in vitro
expansion, dECM could be designed with an appropriate elasticity in order to better maintain its
chondrogenic potential. However, the study of influences of mechanical properties of the in vitro
microenvironment on chondrogenesis of stem cells is still in its infancy and many potential
mechanisms need to be explored.

Potential mechanisms of substrate elasticity underlying chondrogenic
differentiation
The stronger mechanical feedback on stiff substrates was believed to lead to the conformational
changes of tension-sensitive proteins or protein-protein topographic changes [32].
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Integrin-mediated focal adhesion signaling
Integrins and other cell surface receptors provide external links to the ECM, but their functions at the
cell–ECM interface require the participation of a multiprotein complex of adhesome components.
Cytoskeleton includes microfilament, microtubule, and intermediate filament. The main components
of actin cytoskeleton are stress fibers and focal adhesion (FA), which have been reported to influence
MSC shape, mechanical properties, and differentiation down osteogenic, adipogenic, and
chondrogenic pathways [36]. Focal adhesion is the attachment point of ECM and the actin
cytoskeleton that could transmit the extracellular signals into cytoplasm [33]. The aggregation of FA
kinase (FAK) with integrins and other cytoskeletal proteins in focal contacts has been proposed to be
responsible for FAK activation, whose phosphorylation is associated with Src activation. The
activation of the FAK/Src complex serves as a potential substrate for tensin, vinculin, paxilin, p130cas
[34], and talin [35]. Impaired functioning of vinculin in primary chondrocytes resulted in the reduced
expression of chondrocyte-specific genes [37]. The round chondrocyte cytoskeletal structure was
found to reduce vinculin expression compared with the fibroblastic chondrocyte cytoskeletal structure
[38]. (Fig. 1A)
Rho, Rac, and Cdc42 GTPase were reported to regulate the assembly of multimolecular focal
complexes associated with actin stress fibers, lamellipodia, and filopodia [39]. Small GTPases
impacted chondrogenic differentiation through regulating nanomechanics of human ADSCs [40];
specifically, inhibition of Rac1 led to an increase of COL2A1 gene expression [40] while Rac1
activation inhibited chondrogenesis [41]. In mouse limb-bud MSCs, treatment with Y27632 to inhibit
Rho-associated protein kinase (ROCK) increased GAG production of the cells and caused cortical
actin organization. This treatment also reduced the number of actin fibers and caused cell rounding.
Conversely, RhoA overexpression inhibited GAG synthesis and SOX9 [42]. Therefore, the
RhoA/ROCK pathway plays a role in regulating the markers of chondrogenic differentiation.
Cytochalasin also has been shown to increase SOX9 [43], strongly indicating that the mechanism for
this regulation is likely related to the actin cytoskeleton. Therefore, decreased actin cytoskeletal
organization appears to increase chondrogenesis in MSCs. A soft substrate can only withstand low
levels of force exerted by cells. When cells generate traction forces higher than what the substrate can
withstand, the matrix may yield and cells could adapt by decreasing the traction force, integrin
binding, and their own stiffness [44, 45], which modulate cell spreading and thus differentiation [46,
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47]. Limits of cell adhesion strength on a soft substrate can provide feedback to cells to decrease
stress fiber formation, which also explains why Rho activation fails to induce stress fibers on soft
substrates [17] despite the fact that Rho GTPase plays an important role in actin assembly and focal
adhesion formation. (Fig. 1A)
Non-muscle myosin II (NM II)-mediated contraction sensed and transmitted through substrate
elasticity by cells played a critical role in chondrogenesis. For instance, the co-culture of mouse
BMSCs with blebbistatin, a potent NM II inhibitor, blocked NM II-mediated mechanical sensing and
suppressed chondrogenesis induced by the low stiffness of S-PAM gels, suggesting the central roles of
NM II-mediated mechanical sensing in inducing chondrogenic genes [16]. Similarly, Murphy and
coworker found that the treatment of Wistar rat BMSCs with blebbistatin hindered the ability of cells
to sense the elasticity of the matrix and abolished the upregulation of transcription factor SOX9 as a
result of cells sensing the elasticity of the scaffold [24]. In addition, the actin structure also plays a
critical role in chondrogenic differentiation; disruption of the actin cytoskeleton by cytochalasin D
induced chondrogenic differentiation of limb bud mesenchymal cells [48]. Thus, the dependence of
chondrogenic differentiation on substrate stiffness seems to be related to the changes of cytoskeletal
structures in stem cells. (Fig. 1A)

The tension-sensitive protein pathway
The traction force generated by substrate elasticity difference might induce certain protein unfolding,
which serves as ‘molecular strain gauges’ that expose binding domains of some proteins and signaling
molecules. For example, stretch forces can unfold talin, which binds to integrins and actins, exposing
its binding sites for vinculin, and the exposed sites on vinculin can activate mitogen-activated protein
kinase (MAPK) leading to a series of cell signaling chain reactions [6]. The nuclear translocation of
MAPK involves β-like importins [162]. Yang et al. [163] find that p38 MAPK directly phosphorylates
Drosha, which reduces its interaction with DGCR8, promotes its nuclear export and degradation by
calpain, and increases cell death under stress. On the other hand, the nuclear export of MAPK requires
its dephosphorylation, and it is exported in a MAPKK-dependent manner [164, 165] After
phosphorylating MAPKK, nuclear localized MAPK is dephosphorylated by MKPs. Inactivated
MAPK returns to the cytosol, partly through phosphorylated MAPKK acting as a carrier, to receive
the next stimulation. Tension forces may also influence the assembly, stability, and turnover of
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receptor-ligand complexes and functional module components. For example, the cell membrane
tension and possible membrane fluidity might affect conformational dynamics of G protein-coupled
receptor (GPCR); the activated GPCR might lead to cytoskeleton re-arrangement through regulating
the RhoGEF protein and its downstream RhoA/ROCK activities [49]. (Fig. 1B)

The stretch-activated channel pathway
The stronger mechanical feedback on stiff substrates may also lead to the activation of stress-sensitive
ion channels [50]. Recently, it has been shown that cells on substrates of differing stiffness exhibit
changes in the amplitude of calcium ion oscillations, proving that stretch activated channel
permeability is related to active sensing of the substrate elasticity changes of the cell [51]. Substrate
rigidity sensing was induced by intrinsic mechanical stimuli such as generation of traction forces onto
the substrate via stress fiber/FA system. Endothelial cells cultured on stiffer substrate showed
spontaneous Ca2+ oscillations with larger amplitude than those on soft substrate [51]. Intracellular
Ca2+ plays a crucial role in the reorganization of the actin cytoskeleton through modulating actinassociating protein activities. Increases in cytosol Ca2+ induces stress fiber contractility through
phosphorylation of myosin light chain kinase (MLCK) and/or activation of proteases [52].
Ca2+/Calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 and mediates Rasstimulated Raf activation, which might lead to activation of downstream signals [53]. Constitutive
CaMKII signaling in premature maturation of chondrocytes was a cell-autonomous effect associated
with downregulation of cell-cycle regulators and upregulation of chondrocyte maturation markers [54]
(Fig. 1C).

TWIST1 signaling
In the TWIST1-G3BP2 mechanotransduction pathway, increasing substrate stiffness was reported to
induce integrin-dependent phosphorylation events and release of TWIST1 from its cytoplasmic
anchor G3BP2 to enter the nucleus; TWIST1 is an essential mechano-mediator that promotes
epithelial-mesenchymal transition (EMT) in response to increasing matrix stiffness [55]. (Fig. 1D)

YAP/TAZ signaling
Dupont and coworkers (2011) [56] reported the identification of the Yorkie-homologues YAP (Yes85

associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) as nuclear relays of
mechanical signals exerted by ECM rigidity and cell shape. This regulation requires Rho GTPase
activity and tension of the actomyosin cytoskeleton, but is independent of the Hippo/LATS cascade.
Crucially, YAP/TAZ proteins are functionally required for differentiation of MSCs induced by ECM
stiffness. This finding was mirrored by a recent report that YAP negatively regulated chondrogenic
differentiation of MSCs [58]. Finally, as Moore et al. put forward, how the short-term substrate
rigidity sensing is translated into the long-term sensing involved in cell differentiation remains
unknown [59]; although much is shared between the two processes, they may have radically different
time constants and frequencies. It is still a key challenge to link the early rigidity mechanisms to the
long-term processes involved in cellular differentiation (Fig. 1E).

Nuclear deformation and gene expression
Substrate elasticity variations induce integrin-mediated cell activities leading to actomyosin
contraction which is followed by transferring through nesprins to the nucleus. In addition, the
chromosome is linked to the nuclear membrane through lamins, whose activities may lead to
chromatin reorganization, DNA replication, and chondrogenesis-related gene changes. The plasma
membrane is physically linked with the nuclear membrane [57]; it is possible that physical factors and
nuclear deformation could regulate gene expressions through an as-yet-unknown mechanism.
Molecular connections between integrins, cytoskeletal filaments, and nuclear scaffolds were supposed
to provide a discrete path for mechanical signal transfer through cells and to produce integrated
changes in cell and nuclear structure changes [60]. Many related proteins are involved in this process,
such as F-actins, intermediate filaments, Nesprin1/2, Nesprin3, SUN1/2 as well as lamins. For
example, nesprin-1 and nesprin-2 dimerise with nesprin-3 forms a meshwork composed of perinuclear cytoskeletal filaments around the nuclear periphery. The existence of the linker of the
nucleoskeleton and cytoskeleton complex provides more evidence that the traction forces arising due
to matrix rigidity can physically affect the structural organization of the nucleus. (Fig. 1F)
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External forces on stem cell/chondrocyte chondrogenic differentiation
Biomechanical forces are key factors that keep mature cartilage healthy. During normal activity, in
vivo articular cartilage undergoes cyclic compression (at a frequency of approximately 1 Hz during
locomotion) and chondrocytes are exposed to a uniform compressive force within the range of 3 to 10
MPa [61]. With the emergence of tissue engineering as an independent research field and the
understanding that chondrocytes are mechanically sensitive cells [62, 77], great effort has been made
to determine how external mechanical stimuli, such as compression and hydrostatic pressure (HP),
may improve the development of cartilage tissue in vitro [63]. (Table 2)

Compression
Direct compression has been used to modulate matrix composition and concomitantly influence
neocartilage properties. Mauck and coworkers reported that dynamic loading yielded 28-day bovine
chondrocyte-seeded agarose disks with a six-fold increase in the equilibrium aggregate modulus over
free swelling controls; sGAG content and hydroxyproline content were also found to be greater in
dynamically loaded disks after 21 days of loading [64]. After human BMSCs were subjected to
chondrogenic differentiation in either chitosan-coated poly L-lactide-co-3-caprolactone scaffolds [66]
or HA hydrogel [65], dynamic compression enhanced cartilage formation and suppressed chondrocyte
hypertrophy. Using a custom built loading device, compression, shear, or a combination of both
stimuli were applied onto fibrin/polyurethane composites in which human BMSCs were embedded.
While no exogenous growth factors were added to the culture medium, Schätti and colleagues (2011)
[67] found that either compression or shear alone was insufficient for the chondrogenic induction of
human BMSCs. However, the application of shear superimposed upon dynamic compression led to
significant increases in chondrogenic gene expression. Histological analysis detected sGAG and type
II collagen only in the compression and shear group.
Despite a positive effect on matrix deposition, compressive loading at the early stage of chondrogenic
induction is not constructive. For instance, Mouw and colleagues (2007) [68] found that the response
to TGFβ1 treatment of bovine BMSCs seeded in agarose gel was determined by the timing of
dynamic loading; application at the early stage (day 8 after chondrogenic induction) decreased the
ACAN gene level while loading at the later stage (day 16 after chondrogenic induction) increased
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chondrogenic gene expression. Thorpe and coworkers (2010) [69] also found that the application of
dynamic compression from day 0 inhibited chondrogenesis of porcine BMSCs, indicating that MSC
seeded constructs should first be allowed to undergo chondrogenesis in vitro prior to implantation in a
load bearing environment. The influences of mechanical loading on stem cells’ chondrogenic
differentiation also depend on stem cell type. For example, dynamic mechanical compression
significantly increased chondrogenic differentiation of goat BMSCs encapsulated in a hydrogel but
decreased cartilage-specific gene expression in human embryonic stem cell-derived cells in the
absence of TGFβ1 [70].

Hydrostatic pressure
As one component of the mechanical stresses present within diarthrodial joints [76], HP is the
prevailing mechanical signal governing normal articular cartilage homeostasis [77], and thus has the
potential to be applied in cartilage tissue engineering [78].
To date, many studies have focused on the effects of HP stimuli on chondrocyte-mediated synthesis
and degradation of cartilage matrix macromolecules [79, 80, 81]. Articular chondrocytes, usually from
an animal source, respond positively to pulsatile (0.0125–1 Hz) HP loadings ranging 0.3–5 MPa, by
increasing GAG synthesis and deposition, as well as expression of healthy articular cartilage markers
[79, 80, 82]. However, when high HP magnitudes were applied, on the order of 20 MPa, incorporation
rates of

35

SO4 and [3H] proline into adult bovine articular cartilage slices decreased but were

reversible [83]; on the order of 30 MPa, stress response related genes such as heat shock protein 70
(HSP70), HSP45, growth arrest and DNA damage-inducible 45 (GADD45), and GADD153 were
significantly increased in immortalized human chondrocyte cell lines [84]. At 50 MPa, inflammatory
factors such as interleukin 6 (IL6) and tumor necrosis factor alpha (TNFA) mRNAs were significantly
increased in a human chondrosarcoma cell line [71] and apoptosis was observed in rabbit
chondrocytes cultured in alginate beads [85]. The same outcome was observed when culturing human
osteoarthritic chondrocytes under physiologically normal pressure magnitudes (5 MPa) [86]. Duration
and magnitude of applied intermittent HP were also reported to differentially alter human chondrocyte
matrix protein expression [87]. Continuous high HP could cause structural alterations in normal
human chondrocytes, which obtained similar, if not identical, characteristics to those typical of
osteoarthritic chondrocytes [88].
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Recently, more attention has focused on the influence of HP on stem cell chondrogenic differentiation.
In the absence of chondrogenic factors, such as TGFβ, Miyanishi and coworkers (2006) [78] found
that treatment with intermittent HP alone upregulated SOX9, COL2A1, and ACAN in human BMSC
pellets, and co-treatment with intermittent HP and TGFβ greatly enhanced chondrogenic
differentiation. Puetzer and associates (2013) [89] found that cyclic HP initiated human ADSCs’
chondrogenic differentiation but will not last long in the absence of chondrogenic factors. In the
presence of chondrogenic factors, HP was found to increase chondrogenic differentiation in human
ADSCs [90, 91] and porcine SDSCs and infrapatellar fat pad derived stem cells (FPSCs) [92]. Using
porcine BMSCs and FPSCs embedded in agarose gel, Caroll and coworkers (2014) [93] found that
cyclic HP not only increased the ratio of GAG to DNA and both dynamic and equilibrium moduli but
also suppressed calcification of BMSC constructs.

Osmotic pressure
Cartilage matrix contains a large amount of negatively charged aggrecans entangled within the
collagen matrix, which can attract a high concentration of cations relative to other physiologic fluids,
leading to increased interstitial osmolarity. The interstitial osmolarity range of healthy articular
cartilage lies within 350 to 450 mOsm depending on the zone [94]. The loss and gain of water exposes
the chondrocytes to dynamic changes in osmotic pressure, thereby exposing chondrocytes to both
hyper- and hypo-osmotic stresses [95]. The production of ECM of articular chondrocytes is also
greatly influenced by the osmolarity of the culturing medium. For instance, chondrocyte alginate
beads cultured in 550 moSm medium for 48 h increased sGAG synthesis compared to culture in 380
mOsm medium, while culture in 270 mOsm medium decreased sGAG synthesis [96]. The effects of
osmolarity on ECM production may be due in part to regulation of the chondrocyte transcription
factor Sox9. Treatment of freshly isolated chondrocytes from osteoarthritic human articular cartilage
with hyperosmotic medium led to an increase in the levels of Sox9 mRNA and protein, an effect
mediated in part by an increase in the half-life of SOX9 mRNA with hyperosmotic exposure [97]. A
similar study in equine articular chondrocytes showed that hyperosmotic treatment had varying effects
on SOX9 mRNA levels depending on chondrocyte sources and whether treatment was applied in a
static or cyclic manner [98].
Growth and chondrogenic differentiation of MSCs are also influenced by culture medium osmolarity.
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High-osmolarity medium (485 mOsm) reduced proliferation of human ADSCs [99]. Caron and
colleagues (2013) [100] found that increasing the osmolarity of chondrogenic induction medium by
100 mOsm resulted in significantly enhanced chondrogenic marker expression such as COL2A1 and
ACAN in two chondroprogenitors, ATDC5 and human BMSCs. Sampat and coworkers (2013) [101]
found that the application of hypertonic media (400 mOsM) to constructs comprised of SDSCs or
chondrocytes led to increased mechanical properties as compared to hypotonic (300 mOsM) or
isotonic (330 mOsM) media. Constant exposure of SDSC-seeded constructs to 400 mOsM media
from day 0 to day 49 yielded a Young's modulus of 513 ± 89 kPa and GAG content of 7.39 ±
0.52 %ww on day 49, well within the range of values of native, immature bovine cartilage. Primary
chondrocyte-seeded constructs achieved a Young's modulus almost as high, reaching 487 ± 187 kPa
and 6.77 ± 0.54 %ww (GAG) for the 400 mOsM condition (day 42). These findings suggest
hypertonic loading as a straightforward strategy for 3D cultivation with significant benefits for
cartilage engineering strategies.

Shear force
Chondrocytes in articular cartilage are subjected to synovial fluid flow-induced shear force. Shear
force is known to affect chondrocyte homeostasis and induce catabolic and anabolic pathways. Fluid
flow-induced shear force (1.6 Pa) caused individual chondrocytes to elongate and align tangential to
the direction of cone rotation, stimulated GAG synthesis by two-fold, and increased the length of
newly synthesized chains in human and bovine chondrocytes; however, it also increased prostaglandin
E2 and nitric oxide synthesis and caused higher rates of apoptosis and downregulation of COL2A1
and ACAN mRNA [102]. These results are consistent with reports from Mohtai et al., showing that
high shear stress (1 Pa) elicits the release of pro-inflammatory cytokines such as IL-6 and mediates
matrix degradation and chondrocyte cell death [103]. Goodwin and associates have shown that shear
force level as low as 0.092 Pa could have an adverse effect on cells [104].
Not only for chondrocytes, caution should also be taken when applying flow-perfusion in stem cell
chondrogenic induction. Alves da Silva and coworkers (2011) [105] found that 28-day flow-perfusion
dramatically enhanced ECM deposition and type II collagen production in human BMSCs seeded
onto fiber mesh scaffolds in chondrogenic induction medium. This finding is inconsistent with a
recent report. After 18-day chondrogenic induction of human BMSCs in pellets mounted into 3D90

printed porous scaffolds followed by a continuous flow for 10 days, Kock and associates (2014) [106]
found that decreased GAG release, in combination with diminished type II collagen staining,
indicated reduced chondrogenesis in response to flow-perfusion. Although flow-perfusion could
possibly influence the differentiation of chondrogenic differentiated MSCs, effects are inconsistent
and strongly donor-dependent.
In the context of cartilage engineering, high or even moderate levels of shear are still undesirable in
the formation of hyaline cartilage; the fluid flow-induced convective transport and low shear force
have been exploited using a rotating-wall bioreactor. Many experiments have been proven effective at
producing better cartilage constructs in rotating-wall bioreactors [107, 108,109, 110]. Although
successfully applied in cartilage engineering, the effects seen in studies applying fluid shear force
might be due to more than the physical stimuli of the fluid-induced shear, because fluid flow through
engineered cartilage constructs also undoubtedly increases nutrient transport and oxygen diffusion.

Potential mechanisms of external forces underlying chondrogenic
differentiation
Previous attempts to decipher signaling pathways that may be involved in chondrocyte
mechanotransduction were primarily focused at plasma membrane proteins with putative
mechanosensor functions (i.e. receptors and ion channels that are primarily exposed to mechanical
stimuli), including purinergic P2 receptors [111], α5β1 integrins [112], transient receptor potential
channel vanilloid-4 [113], N-methyl-D-aspartate type glutamate receptors (NMDAR) [114], annexin
V [115], and stretch-activated Ca2+ channels [116, 117]. As far as signaling events downstream of
plasma membrane receptors are concerned, the involvement of the Src and FAK, the extracellular
signal-regulated kinase (ERK), and the phosphatidylinositol 3-kinase (PI3K)/Akt pathways have been
reported in various models [118]. Of note, the majority of the above studies were performed on
mature articular chondrocytes. This section will focus on potential mechanisms of external forces
underlying stem cell chondrogenic differentiation.

The PKA/PP2A-CREB-SOX9 pathway
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Since the Sox transcription factors, Sox9 in particular, are pivotal elements of chondrogenesis, many
signaling events regulate their expression and/or function in chondrogenic cells. Among other factors,
the Sox9 promoter is known to be regulated by the cyclic adenosine monophosphate (cAMP) response
element binding protein (CREB) that binds to a CRE site upstream of Sox9 [119]. The cAMPdependent Ser/Thr protein kinase A (PKA) is known to phosphorylate the Sox9 protein (at Ser 211),
which induces its translocation into the nucleus and enhances its transcriptional activity [120]. Indeed,
there is a complex synergism between Sox9 function and the cAMP–PKA–CREB pathway in both
mature and differentiating chondrocytes [155]. Juhász and colleagues (2014) [121] applied a uniaxial
intermittent cyclic load (0.05 Hz, 600 Pa; for 30 min) which provided HP and fluid shear on
chondroprogenitor cells isolated from limb buds of four-day-old chicken embryos. They found that
the applied mechanical load significantly augmented cartilage matrix production and elevated mRNA
expression of several cartilage matrix constituents, including COL2A1 and ACAN, as well as matrixproducing hyaluronan synthases through enhanced expression, phosphorylation, and nuclear signals
of the main chondrogenic transcription factor Sox9. Along with increased cAMP levels, a
significantly enhanced PKA activity was also detected and CREB, the archetypal downstream
transcription factor of PKA signaling, exhibited elevated phosphorylation levels and stronger nuclear
signals in response to mechanical stimuli. The involvement of PKA in the regulation of in vitro
chondrogenesis was also confirmed in earlier reports [122, 123]. All of the above effects were
diminished by the PKA-inhibitor H89. Meanwhile, protein phosphatase 2A (PP2A) activity was
reduced following mechanical loading and treatments with the PP2A-inhibitor okadaic acid were able
to mimic the effects of the intervention, which confirm an earlier report in that PP2A could
counterbalance the chondrogenesis promoting effect of PKA via Sox9 and CREB phosphorylation
[123]. These findings indicate that proper mechanical stimuli augment in vitro cartilage formation by
promoting both differentiation and matrix production of chondrogenic cells; the opposing regulation
of the PKA/CREB-Sox9 and the PP2A signaling pathways is crucial in this phenomenon. (Fig. 2A)

Calcium signaling
Mechanotransduction of HP has been proposed to differ from other mechanical loads due to the fact
that HP generates a state of stress with little deformation [61], which might be partially explained by a
proposed element of HP mechanotransduction with fluctuations in intracellular ion concentrations
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[124, 125, 126]. Stretch activated calcium channels (SACCs) have been demonstrated to be required
for mechanotransduction of a variety of loading types in chondrocytes and MSCs [116, 117, 126, 127].
Voltage gated calcium channels (VGCCs) are activated by membrane depolarization and mediate Ca2+
influx [128]. Ca2+ influx via SACCs and/or VGCCs increases Ca2+ concentrations directly and also
indirectly through calcium-induced calcium release via calcium-sensitive receptors in the
sarcoendoplasmic reticulum calcium stores (SERCS) [128]. VGCCs and SERCS were both found to
be required for chondrogenesis in high-density chicken MSC culture [129] and they have both been
implicated in mechanotransductive pathways [130, 131, 132]. (Fig. 2B)
In an in vitro study using porcine BMSCs seeded into agarose hydrogels, Steward and colleagues
(2014) [133] found that chelating free Ca2+, inhibiting VGCCs, and depleting intracellular calcium
stores suppressed the beneficial effect of HP on chondrogenesis, indicating that Ca2+ mobility may
play an important role in the mechanotransduction of HP. However, inhibition of SACCs in the
current experiment yielded similar results to the control group, suggesting that mechanotransduction
of HP is distinct from loads that generate cell deformation. Inhibition of the downstream targets
calmodulin, CaMKII, and calcineurin all knocked down the effect of HP on chondrogenesis,
implicating these targets in MSC response to HP. All of the pharmacological inhibitors that abolished
the chondrogenic response to HP also maintained a punctate vimentin organization in the presence of
HP, as opposed to the mechanoresponsive groups where the vimentin structure became more diffuse.
These results suggest that Ca2+ signaling may transduce HP via vimentin adaptation to loading.
Calmodulin, CaMKII, and calcineurin also have been implicated in mechanotransduction of fluid flow
and compression in MSCs as well as chondrocytes [130, 132]. Moreover, transient receptor potential
channels (TRP channels) have received the most attention because of their calcium ion permeability
[134] and ability to permit transient calcium influx in stretched cells [135]. Functional gene screening
has identified that TRPV4, a mechanically and osmotically sensitive ion channel [136], is a regulator
of the chondrogenic differentiation of C3H10T1/2 MSCs [137].

The RhoA/Rac1-ROCK pathway
Rho GTPases not only function as key regulators of stress fiber assembly and FA formation [138] but
also play a central role in the regulation of actin cytoskeleton [139]. Rho GTPases are involved in
integrin-mediated mechanotransduction [140, 141] and regulate stress fiber formation in adult stem
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cells under mechanical stimulation [142]. By the activation of Rho GTPase, the MAPK/ERK cascade
is connected with the regulation of integrin β signaling [143]. Chondrocytes have been found to
predominantly express β1 subunits [144]. Along with binding a subunits, the β1 subunits serve as
receptors for collagen which further facilitate cellular cytoskeletal interaction with ECM components
[145]. Formation of stress fibers, along with activation of integrin β1, FAK, and ERK, was involved in
tension stretch-mediated inhibition of chondrogenesis [146], highlighting the role of the
integrin/FAK/ERK signaling axis in mediating external physical stimulation. (Fig. 2C2)
Connective tissue growth factor (CTGF), a mechanosensitive gene which provides unique binding
domains for growth factors (i.e. TGFβ) and integrins, is involved in cytoskeletal tension modulated by
the RhoA/ROCK signaling pathway [147] (Fig. 2C1). CTGF gene expression is known to be induced
through mechanical stimulation and, in particular, through mechanical stretch [148, 149]. Since CTGF
does not work independently, other growth factors, integrin family proteins and possible regulatory
mechanisms linking this signaling cascade remain to be investigated. Moreover, after glycocalyx is
damaged, the response of cytoskeleton to shear stress is suppressed; however, the FA is almost
unaffected [150]. (Fig. 2C3)
Rac1 plays an important regulatory role in cytoskeletal assembly during lamellipodia formation in
cells under mechanical stimulation [151, 152, 153]. The activation of Rac1 has also been shown to
promote the expression of N-cadherin and ultimately enhance the transcription of SOX5, SOX6,
SOX9, COL2A1, and ACAN mRNAs [154]. Zhao and coworkers (2015) found that RhoA played a
positive and Rac1 had a negative role in the HP-induced F-actin stress fiber assembly; RhoA and
Rac1 play central roles in the pressure-inhibited ERK phosphorylation, and Rac1, but not RhoA, was
involved in the pressure-promoted c-Jun N-terminal kinase (JNK) phosphorylation. Pressure
promoted the expression of osteogenic marker genes in BMSCs at an early stage of osteogenic
differentiation through the upregulation of RhoA activity while pressure enhanced the expression of
chondrogenic marker genes in BMSCs during chondrogenic differentiation via the upregulation of
Rac1 activity. This finding is corroborated by other studies that showed that the inhibition of RhoAROCK activity induced rounded cell morphologies and promoted the expression of chondrogenic
marker genes in BMSCs [42, 156]. (Fig. 2C)

Other related pathways
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Another possible mechanism by which mechanical stimuli may exert their positive role during in vitro
chondrogenesis is via the primary cilium. Ultrastructural studies have confirmed that mature
chondrocytes possess an immotile primary cilium that has a microtubule axoneme core made up of a
ring of nine microtubule doublets, but devoid of the central pair of microtubules (thus designated as 9
+ 0) that motile cilia always have (called a 9 + 2 axoneme) [118]. Interestingly, Wann and Knight
(2012) [157] found that primary chondrocytes treated with IL-1 exhibited a 50% increase in cilia
length after 3 h exposure and this elongation occurred via a PKA-dependent mechanism; inhibition of
IL-1-induced cilia elongation by PKA inhibition also attenuated the chemokine response. Primary
cilia have been well documented to serve as a nexus that integrates chemical and mechanical signals.
In particular, they are considered as mechanosensors of fluid flow in many cell types including human
MSCs, arthritic chondroprogenitor cells [118], and chondrocytes where they are unique sensory
organelles that project into the pericellular matrix and interact with their close environment (i.e. types
II and IV collagen) via integrins, G proteins, and various Ca2+ channels, many of which have been
implicated as mechanoreceptors [158]. Studies show that the canonical Wnt/β-catenin signaling
pathway is closely related to the primary cilia. Glycogen synthase kinase 3 (GSK3) regulates the
assembly and maintenance of flagella in Chlamydomonas reinhardtii [159]. Corbit and coworkers
[160] demonstrated that the primary cilium restricts the activity of the canonical Wnt pathway in
mouse embryos, primary fibroblasts, and embryonic stem cells. Meanwhile, the primary cilium may
act as a detour to the nucleus, thereby segregating cytosolic components to keep the Wnt pathway in
check [161]. (Fig. 2D)

Concluding remarks
The prevalence and severity of articular cartilage degeneration have stimulated potential methods of
cartilage regeneration inspired by biomechanical approaches. Although multiple mechanical factors
such as compression, hydrostatic pressure, and shear force have been introduced in cartilage
engineering, the traditional method often produces fibrocartilage rather than hyaline cartilage. At the
single cell or subcellular level, the way in which biomechanical factors in cell environments and
external forces influence cell behaviors and fates remains elusive. While it is still important to unravel
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these mechanisms, future prospects for cartilage engineering should focus more on optimization of
cell niche such as changing ECM matrix stiffness. By doing so, stem cells could respond to a
changing environment in a desirable mechanotransductive way, together with many other potent
growth factors to regulate stem cell chondrogenic fate. A major goal of this review is to offer a
perspective on this new trend in designing stem cell microenvironment and its promise for stem cell
research and to enable novel, clinically relevant strategies for cartilage regeneration. Biomechanics
research from tissue to molecular levels has driven recent developments in musculoskeletal medicine
and will continue to be at the frontier of cartilage biology and regeneration.
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Table 4. 1 The influence of substrate stiffness on chondrogenic differentiation
Substrate

Cell
Human BMSCs

Human BMSCs

Human BMSCs

Hydrogels

Mouse BMSCs

Porcine
chondrocytes

dECM

Synthetized scaffold

Primary murine
chondrocytes and
ATDC5 cells
Bovine articular
chondrocytes
Human ADSCs

C3H10T1/2
murine
embryonic MPCs
Porcine NP-SCs

Substrate stiffness
PEG10 hydrogel (E, 4.231 kPa) vs PEG-CMP
hybrid hydrogel (E, 3.730 kPa)
Type I collagen-coated PAM hydrogels with
varied stiffnesses,
“1 kPa” vs “3 kPa” vs “15 kPa”
PAM hydrogels with varied Young’s modulus,
“1.6 ± 0.3 kPa” vs “40 ± 3.6 kPa”
S-PAM hydrogels with varied elastic moduli,
“1 kPa” vs “15 kPa” vs “150 kPa”
Type I collagen-coated PAM hydrogel
with varied Young’s moduli,
“4 kPa” vs “10 kPa” vs “40 kPa” vs “100 kPa”
PAM hydrogels with varied stiffnesses,
“0.2 MPa” vs “0.5 MPa” vs “1.1 MPa”
PEG hydrogels with different compressive
moduli, “60 kPa” vs “320 kPa” vs “590 kPa”
Defined matrix hydrogels (CS/HA/HS)
with varied stiffnesses,
“3 kPa” vs “30 kPa” vs “90 kPa”
PCL fibers (7.1 MPa) vs core-shell PES-PCL
fibers (30.6 MPa)
Tetronic®1307 with two different shear storage
moduli (G’) of “1 kPa” vs “2 kPa”

Wistar rat
BMSCs
MEFs

CG scaffolds with varied stiffnesses,
“0.5 kPa” vs “1 kPa” vs “1.5 kPa”
RAD16-I with varied elastic moduli,
low (~ 0.1 kPa) vs high (~ 5 kPa)

Human primary
chondrocytes

DP treatment decreasing the linear modulus of
pNSC (6.5 ± 2.3 MPa) to processed cartilage
(1.92 ± 0.85 MPa)
Elastic modulus of PCL-CDM scaffolds
approximately 1% that of PCL scaffolds
FECM (58.26 ± 13.37 kPa) vs AECM (64.82 ±
35.86 kPa) vs Plastic flasks (infinite)

Human ADSCs
Human SDSCs

Human SDSCs

Chondrogenic effects
More staining intensity of aggrecan and type II collagen as
well as higher levels of ACAN and COL2A1 when grown on
softer hybrid hydrogel
Upregulation of COL2A1 when expanded on soft hydrogels

References
Liu et al.,
2010

Upregulation of SOX9, ACAN, and COL2A1 when expanded
on soft PAM hydrogel
The highest mRNA levels of SOX9, ACAN, and COL2A1 and
the lowest mRNA level of SCA1 when grown on the lowest
stiffness hydrogels
The highest mRNA levels of COL2A1 and ACAN and lowest
levels of COL1A1 when grown on the softest hydrogel

Xue et al.,
2013
Kwon and
Yasuda,
2013
Schuh et
al., 2010

The most proteoglycan deposition and mRNA levels of SOX9,
ACAN, and COL2A1 when expanded on 0.5 MPa PAM
hydrogel
The highest level of aggrecan and type II collagen when
expanded on 60 kPa PEG hydrogel
Increasing HA resulting in upregulation of ACAN and
COL2A1 in softer hydrogels, which was reversed in HAcontaining hydrogels with higher stiffness
Upregulation of chondrocytic SOX9, ACAN, and COL2A1
genes and GAG production when grown on PCL fiber scaffold

Allen et
al.,2012

Promoted cell proliferation and increased expression of SOX9
and ACAN genes and sulfated GAGs when grown on scaffolds
with a low shear storage modulus
Upregulation of SOX9 genes when grown on soft scaffold
A spontaneous process of cartilage-like formation when
grown on scaffolds with a low elastic modulus

dECM vs Plastic flasks

Increased aggrecan and type II collagen at both mRNA and
protein levels in pNSC constructs during chondrogenic
induction
Enhanced expression of sulfated GAG synthesis and
COL10A1 gene when grown on PCL-CDM compared to PCL
Expanded ASDSCs on FECM yielded 21-day pellets with the
highest chondrogenic markers followed by on AECM with
grown on plastic flasks being the least
Expanded ASDSCs on dECM yielded 35-day pellets with the
higher chondrogenic markers compared to plastic flasks

Abbreviation: ADSCs: adipose-derived stem cells; AECM: decellularized ECM deposited by adult
SDSCs; ASDSCs: adult SDSCs; BMSCs: bone marrow stromal cells; CG: collagenglycosaminoglycan; CDM: cartilage-derived matrix; CMP: collagen mimetic peptide; CS; chondroitin
sulfate; dECM: decellularized ECM; DP: decellularization and sterilization process; ECM:
extracellular matrix; FECM: decellularized ECM deposited by fetal SDSCs; HS: heparin sulfate; HA:
hyaluronic acid; MPCs: mesenchymal progenitor cells; MEFs: mouse embryonic fibroblasts; NP-SCs:
nucleus pulposus-derived stem cells; pNSC: porcine nasal septal cartilage; PAM: polyacrylamide;
PES: poly(ether sulfone); PEG: poly(ethylene glycol); PCL: poly(ε-caprolactone); RAD16-I:
PuraMatrix, self-assembling peptide nanofiber scaffolds; S-PAM: sulfonate-coated PAM; SCA1: stem
cell antigen-1; SDSCs: synovium-derived stem cells; Tetronic®1307: synthetic tetrafunctional
ethylene oxide/propylene oxide block copolymer
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Park et al.,
2011

Nicodemus
et al., 2011
Wang et al.,
2014
Nam et al.,
2011
Navaro et
al., 2015
Murphy et
al., 2012
FernándezMuiños et
al. 2014
Schwarz et
al., 2012
Garrigues
et al., 2014
Li et al.,
2014
Zhang et
al., 2015

Table 4. 2 Influences of external mechanical forces on stem cell chondrogenic differentiation
Forces

Compression

Hydrostatic
pressure

Osmotic
pressure

Shear forces

Cell type and culture conditions
Mouse limb bud mesenchymal cells
in 3D type I collagen gel

Force conditions
20%-30% strain

Effects
Increased type II collagen and aggrecan expression,
enhanced SOX9 mRNA, down-regulation of IL-1β

Rabbit BMSCs in 2%
agarose gel (107 cells/ml)
Porcine BMSCs embedded in 2%
agarose gel and grown in CIM
Porcine BMSCs seeded in 2%
agarose gel
Human BMSCs encapsulated in
HA hydrogels in CIM
Human BMSCs in 3% alginate

Subjected to a cyclic,
unconfined compression test
1 h/day, 1 Hz, 10% strain

Increased aggrecan and type II collagen over non-loaded
controls
Increased ACAN, COL1A1, and COL2A1 mRNA in a
temporal and spatial-dependent manner
The application of dynamic compression from day 0
inhibited chondrogenesis of MSCs
Increased mechanical properties as well as the GAG and
collagen contents but reduced hypertrophic markers
Increased SOX9, COL2A1, COL10A1, and ACAN
mRNA
Higher load frequency and higher amplitude induced
higher GAG synthesis, higher chondrocytic gene
expressions
Combined forces led to significant increases in
chondrogenic gene expression and sGAG and type II
collagen staining
Enhanced cartilage formation and suppressed
hypertrophy
Increased ratio of GAG to DNA and both dynamic and
equilibrium moduli but suppressed calcification of
BMSC constructs

Human BMSCs embedded in
fibrin/polyurethane gels and grown
in CIM with 1ng/mL TGFβ1
Human BMSCs embedded in
fibrin/polyurethane composites in
defined medium w/o GFs
Human BMSCs seeded onto the
PLCL/chitosan scaffolds in CIM
Porcine BMSCs and FPSCs
embedded in agarose gel and
cultured in CIM with 10 ng/mL
TGFβ3
Porcine SDSCs and FPSCs formed
in pellets and cultured in CIM with
1/10 ng/mL TGFβ3
Human ADSCs encapsulated in GG
hydrogel and cultured in CIM with
10 ng/mL TGFβ3
Human ADSCs embedded in
collagen gel and cultured in CIM
with 10 ng/mL TGFβ1
Human BMSCs formed in pellets
and cultured in CIM containing 10
ng/mL TGFβ3
Human SDSCs embedded in
agarose gel and cultured in a
growth medium with 10% FBS
Bovine SDSCs and chondrocytes
encapsulated in 2% w/v agarose in
10% FBS + GF cocktail
ATDC5 and human BMSCs in a
monolayer culture in CIM
Human BMSCs seeded onto
CPBTA and grown in CIM (1
ng/mL TGFβ3)
Human BMSCs in a pellet culture
system with CIM

1 Hz, 10% strain, 1 h/day
10% strain, 1 Hz, 4 h/day, 5
days/wk
1.5 h on/4.5 h off, 8 day, 1
Hz, 15% strain
1 h/day, 7 days, 0.1 or 1 Hz,
10-15, 20 or 30% strain
1 Hz 0.4 mm strain and/or
shear force (ball oscillation
of ±25oC at 1 Hz)
5% of strain, 1 Hz, 2 h/day,
7 days/week for 3 weeks
CHP at 10 MPa, 1 Hz, 4
h/day, 5 days/week, for 5
weeks
CHP at 10 MPa, 1 Hz, 4
h/day, for 14 days
HP at 0.4 and 5 MPa, 0.5
Hz, 4 h/day, 5 days/week for
4 weeks
CHP at 0-0.5 MPa (4.93
atm), 0.5 Hz for one week
IHP at 10 MPa, 1 Hz, 4
h/day for 14 days

CHP at 7.5 MPa, 1 Hz, 4
h/day, for 21 days
300 mOsM vs 330 mOsM vs
400 mOsM for 7 weeks
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BMSCs: 285 ± 5 mOsM
A continuous flow of 100
µL/min/fiber mesh for 28
days
A continuous flow of 1.22
mL/min for 10 days
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Fig 4. 1 Potential mechanisms of substrate stiffness on stem cell chondrogenic fate.
A) Integrin-mediated focal adhesion signaling; B) The tension-sensitive protein pathway; C) The
stretch-activated channel pathway; D) TWIST1 signaling; E) YAP/TAZ signaling; and F) Nuclear
deformation and gene expression. [Abbreviation: CaMK: Calcium/calmodulin-dependent protein
kinase; CDC42: Cell division cycle 42; FA: Focal adhesion; FAK: Focal adhesion kinase; G3BP2: Ras
GTPase-activating protein-binding protein 2; MEK: MAPK kinase; MLCK: Myosin light chain
kinase; SAM: stretch activated channels; Src: Proto-oncogene tyrosine-protein kinase; TAZ:
transcriptional coactivator with PDZ-binding motif; TF: Transcriptional factor; TWIST1: Twistrelated protein 1; YAP: Yes-associated protein.]
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Fig 4. 2 Potential mechanisms of external forces on stem cell chondrogenic fate.
A) The PKA/PP2A-CREB-SOX9 pathway; B) Calcium signaling; C) The RhoA/Rac1-ROCK
pathway; and D) Other related pathways. [Abbreviation: AKT: Protein Kinase B (PKB); CaMK:
Calcium/calmoduin-dependent protein kinase; FAK: Focal Adhesion Kinase; GATA4: Transcription
factor GATA-4; GR: Growth Factors; IP3: Inositol 1,4,5-triphosphate; Mechano-sensitive genes: Egrl,
lex1, Fos, Jun, Cox2; MLCK: Myosin Light Chain Kinase; NFAT: Nuclear Factor of Activated T
cells; PI3K: Phosphatidylinositol 3-Kinase; PKC: Protein Kinase C (PKC); PLC: Phospholipase C;
STATs: Signal transducers and activators of transcription.]
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Chapter 5. Optimization of decellularized extracellular matrix to
reprogram infrapatellar fat pad-derived stem cells for cartilage tissue
engineering
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Abstract
Adult stem cells gradually lose their stemness and become senescent when plated in monolayer
culture in vitro. This obstacle could be overcome by developing a decellularized extracellular matrix
(dECM) for stem cell expansion. Stem cells expanded on in vitro dECM produce a large amount of
high quality therapeutic cells and have proved to be successful in cartilage tissue engineering. To
obtain a maximal stem cell numbers with optimal chondrogenic potential, optimization of the in vitro
dECM niche is urgently needed. Driven by biomechanics research on stem cells, in this study, we
hypothesized that the elasticity of dECMs could be designed by controlling the culture days or
changing L-ascorbic acid concentration in the normal growth medium. Stem cells expanded on
dECMs of varied elasticity were compared for their responses to expanded substrates, cell surface
phenotypes, proliferation and chondrogenic differentiation. Stem cells expanded on the substrates in
the 1-10 kPa substrate elasticity range have demonstrated enhanced chondrogenesis compared to their
counterparts on other substrate elasticities. Furthermore, stem cells on passage senescent stem cellderived dECMs had decreased chondrogenesis but did not show significant differences with respect to
their elasticity compared to early passage stem cell dECM. Future work about proteomics is desirable
to further determine the potential biochemical and molecular mechanisms contributing to
chondrogenic differentiation differences.
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Introduction
Two challenges need to be overcome for the advancement of regenerative cartilage medicine. One
challenge is to generate articular cartilage-like chondrocytes that do not undergo hypertrophy as a
terminal differentiation stage. Infrapatellar fat pad (IPFP) cells have advantages over synoviumderived stem cells (SDSCs) and bone marrow-derived stem cells (BMSCs) because they are less
likely to become hypertrophic when incubated in a chondrogenic induction medium. Even under
chondrogenc induction, BMSCs have showed a 5- to 10-fold increase in osteocalcin and Alkaline
phosphatase (ALP) compared to SDSCs [1]. Another challenge is to prevent stem cell
dedifferentiation and enhance proliferation and chondrogenic capacity during in vitro cell expansion.
Previously, series of studies were conducted in our lab, indicating that decellularized extracellular
matrix (dECM) deposited by stem cells is a promising and novel cell expansion system for cartilage
tissue engineering, not only enhancing cell proliferation but also promoting expanded cell
chondrogenic potential instead of (or even against) hypertrophy. Our lab has pioneered the
investigations of cartilage engineering and regeneration based on the use of SDSCs and dECM
rejuvenation.
To optimize the application of adult stem cells, an efficient expansion system that can rejuvenate or at
least maintain the self-renewal and differentiation potentials of adult stem cells is urgently needed.
Work has been done in our laboratory to maximize its rejuvenation effect by combining dECM with
fibroblast growth fact (FGF-2) and low oxygen [2]. However, few studies have been reported to focus
on improving the dECM system itself.
dECM is a complex mixture of molecules comprised of collagen, elastic fibers, heparinand
proteoglycans, as well as associated non-matrix molecules such as growth factors [3, 4]. It not only
provides a natural reservoir of growth factors and other signaling molecules, it also serves as a
physical support for cells [5]. While collagen fibers, the most abundant ECM molecules, provide
tissues with mechanical strength, elastic fibers provide extensibility, elastic recoil and resiliency.
In recent years, the importance of substrate mechanics has been increasingly appreciated. The
mechanical properties of substrates have been shown to significantly influence cell functions such as
morphogenesis, proliferation and differentiation. Many synthetic three-dimensional (3D) gels of
fibrin, collagen I and Matrigel have been studied with a variety of compressive and tensile techniques
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and the findings vary widely, ranging from 175 to 112,000 Pa [6]. It is believed that in this range,
substrates can clearly affect cell growth and differentiation [7].
Ascorbic acid (AA) was proven to promote mesenchymal stem cell (MSC) proliferation with
extended culture times [8]; different AA concentrations have been used to stimulate the secretion of
decellularized ECM in our previous studies [9, 10]. AA has been widely applied in cell sheet
technology, the use of cell sheets is advantageous because an entirely natural neo-tissue assembled by
the cells, with mature extracellular matrix (ECM), can be engineered [11, 12].
By application of AA, dECMs with varied elasticity were produced and manipulated by controlling
culture days or different AA concentrations. The elasticity of cell-derived decellularized ECMs has
demonstrated influence on the chondrogenic differentiation of stem cells. Previous work in our lab
showed that Adult SDSC-derived ECM (AE) exhibited a higher elasticity than fetal SDSC-derived
ECM (FE) [61.82 ± 35.86 versus 58.26 ± 13.37 (kPa)]. Interestingly, the elasticity of expanded
ASDSCs (Adult SDSCs) was mirrored by their substrates; living cells expanded on plastic and AE
were 9.07 ± 4.56 versus 3.60 ± 1.79 (kPa) while the comparison between AE4 and FE4 was 3.60 ±
1.79 versus 3.45 ± 2.29 (kPa) [9]. The lower elasticity in FE4 is likely to be associated with
enhancement of ASDSC chondrogenic potentials. A recent study by Zhang and coworkers confirmed
that human SDSCs expanded on dECM exhibited a fibroblast shape, a low level of elasticity,
enhanced proliferation, unique changes in stem cell surface markers and enhanced chondrogenic
capacity and hypertrophy [10].
Many papers have been published on the effects of ascorbic acid on ECM production, cell
proliferation and differentiation [13]. However, few studies reported on the effects of various
concentrations of ascorbic acid on the in vitro behaviors of stem cells including proliferation and
differentiation [8]. Studies from Choi and coworkers showed that cell growth was significantly
enhanced in proportion to the increasing AA concentration; MSCs cultured in 250 μM AA showed
the highest cell proliferation activity. Cell proliferation was demonstrated to be the highest in 250 μM
AA containing culture medium.
Some studies have shown that ascorbic acid induces various cellular responses in a variety of cells
and that the dose- and environmental parameter-dependent ascorbic acid effects also modulate various
cellular responses such as ECM synthesis, proliferation and differentiation. Generally, a low
concentration of ascorbic acid increases cell proliferation while a higher concentration of ascorbic
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acid will slow down cell growth or even be cytotoxic to cultured cells. AA concentration during
culture can modulate MSC proliferation and differentiation and specific levels of ascorbic acid serve
as potent positive modulators of MSC proliferation without causing a loss in the differentiation
capacity of the cells [8]. While the biochemical and molecular mechanisms of ascorbic acid on
cellular responses and which concentration of ascorbic acid induces a selective response are not clear,
studies from a biophysical perspective might provide a new mechanism of dECMs on cell response.
Previously in our lab, we conducted a series of studies by changing culturing days or using different
concentrations of AA; however, the optimum culture days and ascorbic acid concentration have never
been determined. We hypothesized that dECMs of different culture days and different concentrations
of AA during cell culture will also produce dECM with varied elasticity which can influence
expanded stem cells’ chondrogenic fates. Our ultimate goal is to optimize dECM synthesis by
controlling the ascorbic acid concentration and choosing appropriate culture days. By optimizing the
dECM (for example, a well-fitted elasticity range) which will influences the expanded stem cells,
chondrogenic differentiation could be maximized to better facilitate cartilage tissue engineering.

Materials and methods
dECM preparation
The preparation method for human IPFP stem cell-derived dECM was described in our previous study
[10]. Briefly, plastic flasks (P-Flask) were precoated with 0.2% gelatin (Sigma-Aldrich, St. Louis,
MO) at 37ºC for 1 h and seeded with passage 2 IPFPs at 6000 cells/cm2. In experiment 1, dECMs
were prepared by controlling the culture days with a fixed concentration of L-ascorbic acid (AA) in
10% fetal bovine serum (FBS)-containing complete medium. D0 (Cells reaching confluence without
addition of AA), D10 (AA stimulation for 10 days) and D20 (AA stimulation for 20 days) dECMs
were decellularized and stored in phosphate buffered saline (Invitrogen, Thermo Fisher Scientific,
Inc., Grand Island, NY). In experiment 2, dECMs were prepared by changing the concentration of Lascorbic acid and culture for 12 days. Different working concentrations of AA (50 uM, 250 uM, and
500 uM) were used to make decellularized ECM which was stored in PBS solution (Fig. 1). After all
dECMs were prepared, Passage 2 human IPFPs were seeded at 3000 cells/cm2 for growth with plastic
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flasks as a control.

Cell counting and proliferation index determination
Passage 2 human infrapatellar fat pad (hIPFP) stem cells were expanded on T175 plastic flasks with
growth medium containing alpha-minimum essential medium (αMEM), 10% fetal bovine serum
(FBS), 100 U/ml penicillin, 100 μg/mL streptomycin and 0.25 μg/mL fungizone for 12 days. After
detaching human IPFP cells, Passage 3 hIPFP cells were seeded into Plastic and dECM-coated flasks.
For the proliferation index (PI) test, before cell expansion, passage 3 hIPFPs were labeled with
CellVue® Claret (Sigma-Aldrich) at 2 × 10-6 M for 5 min according to the manufacturer’s protocol
(containing negative control and pre-stained group) at a seeding density is 3000 cells/cm2. After five
days, expanded cells were collected and measured using a BD FACS CaliburTM flow cytometer (dual
laser) (BD Biosciences, San Jose, CA). Twenty thousand events of each sample were collected using
CellQuest Pro software (BD Biosciences) and cell proliferation index was analyzed by ModFit LTTM
version 3.1 (Verity Software House, Topsham, ME).

Measurement of expanded cell proliferation index using flow cytometry
On day 6 after Passage 3 hIPFP expansion, cells from each group were detached. The following
primary antibodies were used in flow cytometry to detect hIPFP surface phenotypes: integrin b1
(CD29) (Abcam, Cambridge, MA); CD105 and the stage-specific embryonic antigen-4 (SSEA-4)
(Santa Cruz Biotechnology;Santa Cruz, CA) and CD90 (BD Pharmingen; BD Biosciences). Samples
(n = 3) of each 0.2 × 106 expanded cells were incubated in ice cold PBS containing 0.1% ChromPure
Human IgG whole molecule (Jackson ImmunoResearch Laboratories, West Grove, PA) and 1% NaN3
(Sigma–Aldrich) for 30 min. The cells were incubated in the dark in the primary antibodies for 30
min. Fluorescence was analyzed by a FACS Calibur (BD Biosciences) using FCS Express software
package (De Novo Software, Glendale, CA).

Chondrogenic induction and evaluation of expanded stem cells
HIPFP stem cells from each group (0.25×106) were centrifuged at 500 g for 5 min in a 15-mL
polypropylene tube to form a pellet. After overnight incubation (day 0), the pellets were cultured for
35 days in a serum-free chondrogenic medium consisting of high-glucose Dulbecco’s Modified
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Eagle’s Medium (DMEM), 40 µg/mL proline, 100 nM dexamethasone, 100 U/mL penicillin, 100
μg/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate and 1 × ITSTM Premix [6.25 μg/mL insulin,
6.25 μg/mL transferrin, 6.25 μg/mL selenousacid, 5.35 μg/mL linoleic acid and 1.25 μg/mL bovine
serum albumin (BSA), from BD Biosciences] with supplementation of 10 ng/mL transforming growth
factor beta 3 (TGF-β3, PeproTech Inc., Rocky Hill, NJ). In order to evaluate the passage-senescent
hIPFPs’ chondrogenic changes, P5 hIPFP cells were seeded at 1038 cells/cm2; after 12 days of
expansion, 4.5×106 were used to make pellets. Chondrogenic differentiation was evaluated using
histology, immunostaining, biochemical analysis and real-time polymerase chain reaction (RT-PCR).
Representative pellets (n=3) were fixed in 4% paraformaldehyde at 4C overnight, followed by
dehydrating in a gradient ethanol series, clearing with xylene and embedding in paraffin blocks. Five-μm
thick sections were histochemically stained with Alcian blue (Sigma-Aldrich; counterstained with fast red)
for sulfated glycosaminoglycans (GAGs). For immunohistochemical analysis, the sections were
immunolabeled with a primary antibody against type II collagen (Col II; II-II6B3; Developmental Studies
Hybridoma Bank, Iowa City, IA) followed by the secondary antibody of biotinylated horse anti-mouse IgG
(Vector, Burlingame, CA). Immunoactivity was detected using Vectastain ABC reagent (Vector) with 3,3’diaminobenzidine as a substrate.

Representative pellets (n = 4) were digested for 4 h at 60 ℃ with 125 μg/mL papain in PBE buffer
(100 mM phosphate and 10 mM ethylenediaminetetraacetic acid, pH 6.5) containing 10 mM cysteine,
by using 150 μL enzyme per sample. To quantify cell density, the amount of DNA in the papain
digestion was measured using the QuantiT™ PicoGreen_ dsDNA assay kit (Invitrogen) with a
CytoFluor_Series 4000 (Applied Biosystems, Foster City, CA). GAG was measured using
dimethylmethylene blue dye and a Spectronic BioMate 3 Spectrophotometer (Thermo Scientific,
Milford, MA) with bovine chondroitin sulfate as a standard.

TaqMan® real-time polymerase chain reaction (PCR)
After extraction and purification of total RNA from samples (n = 4), about 1 μg of mRNA was used
for reverse transcriptase with a High-Capacity cDNA Archive Kit (Applied Biosystems) at 37℃ for
120 min. Chondrogenic marker genes [type II collagen (COL2A1; assay ID: Hs00156568_m1),
aggrecan (ACAN; assay ID: Hs00153935_m1), [type I collagen (COL1A1; assay ID:
Hs00164004_ml)] and SRY (sex determining region Y)-box 9 (SOX9; assay ID: Hs00165814_m1)]
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and hypertrophic marker genes [type X (COL10A1 (assay ID: H200166657_m1)), were customized
by Applied Biosystems as part of the Custom TaqMan_Gene Expression Assays. Eukaryotic 18S RNA
(assay ID: Hs99999901_s1) was carried out as the endogenous control gene. Real-time PCR was
performed with the iCycler iQ™ Multi-Color Real Time PCR Detection (Perkin-Elmer, Waltham,
MA). Relative transcript levels were calculated as v = 2-ΔΔCt, in which ΔΔCt = ΔE-ΔC, ΔE = CtexpCt18s, and ΔC = Ctct1 - Ct18s.

Atomic force microscopy (AFM)
Elasticity of culture substrates (dECM and Plastic) and expanded hIPFP stem cells was determined
using an MFP-3D-BIO AFM (Asylum Research, TE2000-U, Santa Barbara, CA) integrating with an
inverted fluorescence microscope (Nikon Eclipse, Ti-U, Nikon Instruments Inc., Melville, NY) and
Olympus TR400-PB cantilevers with manufacturer spring constant of 0.09 N/m. For the human IPFP
stem cell elasticity measurement, Passage 2 hIPFP cells were seeded on Petri dishes with and without
dECM coated substrates at 20,000 cells/cm2 for overnight, then the cells were washed with phosphate
buffered saline (Invitrogen) two times for 5 min each and then ﬁxed with 4% glutaraldehyde solution
(Sigma=Aldrich) for 30 min, washed again and further analyzed in PBS. The location of the cantilever
above the sample was confirmed using a 10× microscopy objective. For the quantitative
nanomechanical analysis, a Sneddon’s modification of the Hertz model developed for a four-sided
pyramid was employed. The fixed cell samples elasticity (Young’s modulus, E) were corrected with

 1  2 F
the indentation of the tip, , through the following equation: E 
, where E is the elastic
2 tan   2
modulus, v is Poisson’s ratio with a value of 0.5 for dECM and cells, F is the force given by the
cantilever deflection multiplied with the cantilever spring constant,  is the open angle used in this
study which has a value of 36º and lastly,  is the indentation depth (A-Hassan et al., 1998).

Statistics

Numerical data are presented as the mean and the standard error of the mean. A Mann-Whitney U test
and a linear model with contrast analysis were used for pairwise comparison in biochemistry and realtime PCR data analysis. AFM data analysis was performed by Krukal Wallis nonparametric tests;
different letters represent the statistical significance (p<0.05) between groups. All statistical analyses
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were performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). A p value less than 0.05
was considered statistically significant.

Results
Expansion on dECM increased cell proliferation and changed cell surface phenotypes
Flow cytometry data indicated that, despite a comparable proliferation index of hIPFP stem cells
between the D20 and Plastic groups, D0, D10, P5 dECM expanded cells presented increases in
proliferation index, D0 dECM expanded cells demonstrated the highest proliferation index, while the
D20 dECM group was minimal in proliferatio index value (Fig. 2 A&B). Similarly, hIPFP cells
expanded on 50 uM, 250 uM and 500 uM AA prepared dECM demonstrated enhanced proliferation
index compared to Plastic, 50 uM and 250 uM dECM-expanded hIPFP cells showed much higher
proliferation index than their couterparts in 500 uM (4.78 vs 3.96) (Fig. 6A&B).
Flow cytometry data also showed that mesenchymal stem cell (MSC) surface markers (CD29, CD90
and CD105) were down-regulated at the median in dECM expanded hIPFP stem cells (Fig. 2 C&D;
Fig. 6 C&D). Not surprisingly, the SSEA-4 expression in both percentage and median of dECMs
expanded stem cells were enhanced compared to those on Plastic (Fig. 2 C&D; Fig. 6 C&D).

dECMs of varied elasticty due to different culture days distinctly enhanced expanded stem cells’
chondrogenic potential
To determine whether dECM (from different culture days with a fixed L-ascorbic acid concentration)
expanded hIPFP stem cells played distinct roles in chondrogenic potential, cells expanded on either
Plastic or dECM (D0, D10, D20, P5ECM) for one passage were induced for chondrogenic
differentiation. dECM expansion led to chondrogenically differentiated 35-day pellets of a larger size
with more intense staining of sulfated GAGs and type II collagen (Fig. 3A), higher cell viability
(DNA ratio adjusted by day 0) and GAG amount (chondrogenic marker) as well increased GAG/DNA
(chondrogenic index) (Fig. 3C) compared to the corresponding Plastic group. Stem cells expanded on
D20 dECM had the highest GAG amount and GAG/DNA ratio (chondrogenic index), followed by the
D10 dECM and D0 dECM groups. Although expanded cells from P5 dECM had a higher GAG
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amount and chondrogenic index than their counterparts on plastic, they had a decreased GAG amount
and chondrogenic index compared to P2 dECM with the same number of culture days (Fig. 3C). The
above protein level data were also consistent with mRNA data using real-time PCR for chondrogenic
marker genes including SOX9, ACAN, COL2A1, COL1A1 and COL10A1 (Fig. 4).

dECMs from different culture days showed distinct elasticity which was mirrored by expanded cells
To determine the effects of elasticity of culture substrates on grown cells, AFM was used to measure
the Young’s modulus of both substrate and expanded cells. The elasticity (Young’s modulus) of PL
could be considered as infinite (Bhana et al., 2010). D10 dECM exhibited a higher Young’s modulus
median value when compared with D0 dECM [6.12 (kPa) versus 3.33 (kPa)] (p<0.05), although there
is no statistical significance with P5 dECM (Fig. 5A). Interestingly, the elasticity of expanded stem
cells was parallel to their substrate; the median value of Young’s modulus between PL and D0
(p<0.05) was [193.1 (kPa) versus 36.78 (kPa)] while the median value between D0 and D10 (p<0.05)
was [36.78 (kPa) versus 64.05 (kPa)]. However, cells on D10 and P5 ECM showed no statistical
significance (Fig. 5B).

dECMs prepared by different L-ascorbic acid concentrations had different influences on expanded
hIPFP stem cells’ chondrogenesis
To determine whether dECMs (due to different concentrations of L-ascorbic acid stimulation) had
different influences on preconditioned hIPFP stem cells in chondrogenic potential, cells expanded on
either Plastic or dECM (50 uM, 250 uM and 500 uM dECM) for one passage were induced for
chondrogenic differentiation. Similarly, cells expanded on dECMs had enhanced chondrogenesis
capabilities compared to Plastic; cells on 250 uM dECM produced chondrogenically differentiated 35day pellets with the biggest size. Alcian blue and immunohistochemistry staining results showed more
intense staining of sulfated GAGs and type II collagen than 50 uM and 500 uM groups (Fig. 7A). The
quantative data further confirmed that 250 uM group had higher cell viability (DNA ratio adjusted by
day 0) and GAG amount (chondrogenic marker) as well as increased GAG/DNA (chondrogenic
index) (Fig. 7B) compared to the other dECM groups and the plastic group.
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dECMs prepared by different concentrations of L-ascorbic acid showed distinct elasticity which
reflected by expanded cells
To determine the effect of elasticity of culture substrates on grown cells, AFM was used to measure
the Young’s modulus of both substrate and expanded cells. The elasticity (Young’s modulus) of PL
could be considered as infinite (Bhana et al., 2010); 250 uM dECM exhibited a higher median
Young’s modulus value than 50 uM dECM [0.64 (kPa) versus 0.31 (kPa)] (p<0.05) (Fig. 8A).
Similarly, the Young’s modulus of expanded cells was parallel to their substrate. The median value of
Young’s modulus between PL and 250 uM dECM was [193.14 (kPa) versus 9.97 (kPa)] (p<0.05); the
comparison of hIPFP stem cells between 250 uM dECM and 50 uM dECM was [9.97 (kPa) versus
8.85 (kPa)] (p<0.05) (Fig. 8B).

Discussion
Ascorbic acid is necessary to biosynthesize ECM as well as to mimic the in vivo physiological
environment of mesenchymal stem cells (MSCs) and regulate their proliferation and differentiation.
Ascorbic acid alone was predicted to induce cell sheet formation to benefit cell-based tissue
engineering. Furthermore, ascorbic acid improved the DNA synthesis and proliferation ability of cells
without causing premature differentiation of the cells, which indicates that ascorbic acid delays
premature cell aging and inactivity. In addition, more collagen and other ECM constitutents were
produced and preserved during AA-induced cell sheet construction, including Col I, integrin β1 and
fibronectin, which were reported by previous studies [14, 15].
Cells sense their surroundings not through sight or sound but through the “touch” or “feel” of
insoluble mechanical cues and “smell” or “taste” of various soluble factors [16]. ECM is comprised of
a scaffold of collagens and other structural proteins that are interlaced with proteoglycans which,
together, control the local mechanical environment. The interlaced proteoglycans, glycoproteins and
adhesion molecules of dECM also contribute to the “stem cell niche” microenvironment through their
own signaling moieties and their ability to bind growth factors, cytokines, enzymes and other
diffusible molecules [17]. While various biochemical factors attracted stem cell biologists to elucidate
the potential mechanisms of dECM’s promoting effects on stem cells, few studies focus on the
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mechanical cues of dECM on stem cell differentiation. Understanding the mechanical properties of
cell-derived matrices is critical to design tissue engineering scaffolds in order to mimic the in vivo
environment and to optimize stem cell growth and differentiation. Conventionally used polystyrene
plastic culture system has a Young’s modulus in the GPa range [18], whereas a Young’ modulus that is
five orders of magnitude smaller has been demonstrated to have profound effects upon cell growth
and differentiation [7]. Reconstituted basement membrane has been reported to have a Young’s
modulus of 175 Pa while 2 mg/ml collagen gel has a Young’s modulus of 328 Pa [19]. Cells are
thought to differentiate optimally on tissue level elasticity; landmark work by Engler and coworkers
(2006) suggests that soft (elastic modulus, E, 0.1-1 kPa), medium (E, 8-17 kPa) and hard (E, 25-40
kPa) matrices can induce MSC lineage specification toward neurons, muscles and osteoblasts,
respectively. However, little is known about the effect of elasticity on chondrocyte behaviors and
chondrogenic differentiation fate. Compared to a substrate with higher elasticity, stem cells expanded
on a substrate with an appropriate elasticity range are generally regarded to prefer chondrogenesis.
In this study, elasticity differences of various expanded substrates were compared. Not surprisingly,
hIPFP stem cells expanded on Plastic, which is assumed to have GPa elasticity range [6] had the
highest cell elasticity, which might significantly influence cell morphology, cell proliferation and
chondrogenic differentiation, as evidenced by its minimal cell proliferation index and chondrogenic
differentiation compared to cells expanded on other dECM groups. dECMs from D0 showed the
lowest elasticity (~ 3kPa), lower than that from D10 and Passage 5 derived dECM (~10 kPa); P2 and
P5 dECMs showed no statistical significance of their elasticity. Cell types grown on soft substrates
usually display in vivo-like morphological and functional properties of compliance similar to that of
particular tissue from which they are derived. It has been reported that chondrocytes exhibit increased
growth and proliferation markers on gels with compliance similar to hard cartilage (~10 kPa) [20].
D10 dECM had ~10 kPa substrate elasticity value, indicating their tendency toward chodrogenesis.
Engler et al. reported that, in the 0.1~1 kPa substrate elasticity range, stem cells tend toward
neurogenic differentiation. In preparing dECM, an elasticity value that is matched with in vivo
chondrocyte tissue is critical to guide stem cell chondrogenesis. Therefore, an elasticity range value
should be established. Intermediate elasticity value (1-10 kPa) was regarded as benefiting
chondrogenesis. We assume that 3 kPa D0 dECM, while having the capability to promote
chondrogenic differentiation of stem cells, might also promote stem cells toward myogenic
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differentiation. Similarly, expanded on substrate with an elasticity lower than 1 kPa, stem cells might
tend more towards to neurogenic differentiation; therefore, a higher elasticity value of dECM (250 uM
dECM) and expanded stem cells in chondrogenic induction medium had better performace than its
counterpart (50 uM) with a lower Young’s modulus value, as evidenced by bigger pellet size, more
intense staining of chondrogenic marker and higher chondrogenic index (Fig. 7).
We noticed the significant value changes between substrate elasticity and cell elasticity values. In
measuring the elasticity of expanded cells, 4% glutaraldehyde solution was used to fix expanded cells
for 30 min, which led to increased cell elasticity values. The glutaraldehyde fixation method has been
used in our previous study [10], and it has been proven to be the preferred method for reliable data
analysis (reproducible) of both cell elasticity and cell morphology [21, 22]. There is still an ongoing
discussion about whether cell elasticity measurements performed on fixed cells could be used for
determination of the relative elasticity changes of unfixed cells. A recent publication made a case, for
the legitimacy of cell fixation for cell elasticity measurements;the trend of elasticity alternations of
endothelial cells exposed to TNF-α has been preserved by glutaraldehyde fixation [23].
Other possible influential factors, such as biochemical and molecular factors, might also exert
influences on chondrogenic differences. For example, compared to D0 dECM, D10 and D20 dECM
contain more ECM components such as collagen, fibronectin and laminin, which might serve as a
better reservoir for various growth factors, cytokines and other stimuli for stem cell chondrogenic
differentiation. However, one limitation of this study is that the dECM elasticity is not a fully
independent variable, as differences in crosslinking density can also alter ECM protein anchoring and
substrate porosity [24]. Undoubtedly the elasticity of dECM is a significant contributing factor
influencing chondrogenic differentiation.
Some investigators have used cell-derived extracellular matrix without ascorbic acid stimulation for
the application of tissue engineering (chondrogenesis or osteogenesis) and these experiments have
demonstrated good effects [25, 26, 27]. Unlike our conventional dECM preparation method, they
removed the cellular components either physically or chemically when cells reached to confluence
instead of allowing confluent cells grow under stimulation of ascorbic acid. In this experiment, we set
up such a parallel group, named the D0 group, in order to evaluate whether it is a better idea to use
pure decellularized extracellular matrix without ascorbic acid stimulation. The AFM data showed that
expanding substrate of the D0 group did have lower elasticity than the D10 group and expanded cells
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also mirrored their expanding substrate: on D0 substrate, hIPFP cells demonstrated lower elasticity
than their counterparts on D10. However, in regard to their chondrogenic differentiation capabilities,
hIPFP cells expanded on the D0 substrate had decreased chondrogenesis compared to those on D10
and D20 dECM. Biophysically, D0 dECM have an advantage over D10 and D20 groups with respect
to their lower elasticity, which theoretically will be beneficial for expanded cells’ chondrogenesis;
however, our observed results suggested that D20 and D10 dECM might have an edge over D0 dECM
with respect to their biochemical and molecular mechanisms, which is not yet elucidated.
Aging is another important factor that might affect the cell cytoskeletal organization and focal
adhesion. The loss of tissue elasticity has a close relationship with aging, as observed in human
epithelial tissue. It has been suggested that the loss of tissue elasticity results from increased
crosslinking of extracellular matrix proteins; however, Berdyyeva and coworkers demonstrated that
the increased rigidity of aging cells could also be attributed to a higher density of cytoskeletal fibers
[28]. Our previous study indicated that decellularized ECM, especially from young donors,
rejuvenated ASDSCs in expansion, as evidenced by increased cell proliferation and resistance to
apoptosis; chondrogenic differentiation also improved. In the characterization of cell and matrix
interaction, some unique proteins such as collagen and elastin in fetal ECM favored ASDSC
rejuvenation [9]. In this study, passage senescent stem cell derived dECM was used to compare its
rejuvenating effects on chondrogenesis of expanded stem cells. P5 dECM decreased the expanding
stem cells’ proliferation and chondrogenic differentiation compared to stem cells expanded on P2
dECM. The elasticity difference between P2 and P5 dECM was compared for both expanded
substrates and expanded stem cells. Our results sugested that there is no statistical significance
between P2 and P5 dECM substrates, which led us to conclude that other biochemical and molecular
factors contribute to this process. A wide variety of soluble growth factors, such as basic fibroblast
growth factor (FGF-2), TGF-β, vascular endothelial growth factor and hepatocyte growth factor binds
to components of dECM (such as heparin sulfate), which greatly slows their diffusion and serves to
fine-tune their local concentrations and gradients [17].
Since its inception, dECM has demonstrated great potential for application in cartilage tissue
engineering [29, 30]. Acquisition of a large amount of high-quality cells from dECM has been a great
advantage for cell-based cartilage regeneration. In this paper, we explored the possible optimized
methods for dECM by changing its elasticity, which proved to be useful for stem cell-based cartilage
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repair. However, the underlying mechanisms of promoting effects of dECMs on chondrogenesis are
still in their infancy, much work needs to be done in order to optimize dECM for this application.
Furthermore, future work will focus on elucidating other possible factors that might influence
chondrogenesis from a biochemical perspective; for example, by applying proteomics methods,
specific protein components will be screened and their roles in promoting chondrogenesis will be
determined. Eventually they can be integrated to optimize dECM system.
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Fig 5. 1 Schematics of preparation of dECM with different elasticities.
In experiment 1, dECMs were prepared by controlling the culture days with fixed 250 uM L-ascorbic
acid (AA) in 10% FBS-containing complete medium. D0 (HIPFP stem cells reach to confluence
without addition of AA), D10 (AA stimulation for 10 days), and D20 (AA stimulation for 20 days)
were harvested and decellularized. In experiment 2, dECMs were prepared by changing the
concentration of L-ascorbic acid but culture for fixed days. 50 uM, 250 uM, and 500 uM AA working
concentration were chosen to make decellularized ECM. After all dECMs were ready, Passage 2
hIPFPs were seeded at 3000 cells/cm2 for growth with Plastic as control.
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Fig 5. 2 dECMs (different culture days) enhanced expanded hIPFP stem cells’ proliferation and
changed stem cell markers’ expression.
(A&B) Human IPFPs were expanded on either dECM or Plastic for one passage (5 days). Flow
cytometry was used to measure proliferation index of expanded cells. (C) Flow cytometry was used to
measure both percentage and median fluorescence intensity of MSC surface markers (CD29, CD90,
and CD105) and SSEA4 of expanded cells.
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Fig 5. 3 dECM from different culture days expanded hIPFP stem cells showed varied
chondrogenic differentiation.
Human IPFP stem cells expanded on either dECM of different culture days (D0, D10, D20 and P6) or
Plastic for one passage (9 days) were followed by a 35-day chondrogenic induction in a pellet system.
(A) Pellets were photographed before histology; Alcian blue (Ab) was used to stain sulfated GAGs
and immunohistochemical staining (IHC) was for Col II. (B) Biochemical analysis was used for DNA
and GAG amounts in chondrogenic pellets. Cell proliferation and viability were evaluated using DNA
ratio (DNA amount at days 35 and 14 adjusted by that at day 0). Chondrogenic index was evaluated
using ratio of GAG to DNA. Data are shown as average ± SD for n = 4. *p < 0.05 suggests a
statistically significant difference.
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Fig 5. 4 Real-time PCR was used to evaluate chondrogenic induction of expanded hIPFP stem
cells on either Plastic or dECMs prepared by different culture days.
Human IPFP stem cells were expanded on either Plastic or dECM for one passage followed by a
pellet culture in a serum-free chondrogenic medium for 35 days. Real-time PCR was used to evaluate
chondrogenic marker gene expression (SOX9, COL2A1, ACAN, COL1A1 and COL10A1) in day 35
pellets. Data are shown as average ± SD for n = 4. * p < 0.05 compared with the corresponding Plastic
group.
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Fig 5. 5 Plastic and dECMs prepared by different culture days showed varied elasticity changes,
which was mirrored by elasticity changes of corresponding expanded cells.
AFM was used to measure Young’s modulus of both expanded substrate (A) and expanded hIPFP
cells (B). Different letters represent statistical significance (p<0.05) between different groups by
applying Krukal Wallis nonparametric tests.
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Fig 5. 6 dECMs (different culture days) promoted expanded hIPFP stem cells’ proliferation and
changed expression of stem cell surface markers.
(A&B) Human IPFP stem cells were expanded on either dECMs or Plastic for one passage (5 days).
Flow cytometry was used to measure proliferation index of expanded cells. (C&D) Flow cytometry
was used to measure both percentage and median fluorescence intensity of MSC surface markers
(CD29, CD90, and CD105) and SSEA4 of expanded cells.
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Fig 5. 7 Plastic and L-ascorbic acid phosphate-dependent dECMs expanded hIPFP stem cells
showed varied chondrogenic differentiation.
Human IPFP stem cells expanded on either dECM prepared by different concentration of L-ascorbic
acid phosphate (50μM, 250μM, 500μM) or Plastic for one passage (9 days) were followed by a 35day chondrogenic induction in a pellet system. (A) Pellets were photographed before histology;
Alcian blue (Ab) was used to stain sulfated GAGs and immunohistochemical staining (IHC) was for
Col II. (B) Biochemical analysis was used for DNA and GAG amounts in chondrogenic pellets. Cell
proliferation and viability were evaluated using DNA ratio (DNA amount at days 35 and 14 adjusted
by that at day 0). Chondrogenic index was evaluated using ratio of GAG to DNA. Data are shown as
average ± SD for n = 4. * p < 0.05 suggests a statistically significant difference.
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Fig 5. 8 Plastic and dECMs prepared by different concentration of L-ascorbic acid
demonstrated changed substrate and cells’ elasticity.
AFM was used to measure Young’s modulus of both expanded substrate (A) and expanded hIPFP
cells (B). Different letters represent statistical significance (p<0.05) between different groups by
applying Krukal Wallis nonparametric tests.
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Chapter 6. Antioxidation of decellularized stem cell matrix promotes
human synovium-derived stem cell-based chondrogenesis
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Abstract
Clinical treatment of cartilage defects is challenging due to concomitant posttraumatic joint
inflammation. This study was to demonstrate that the antioxidant ability of human adult synoviumderived stem cells (SDSCs) could be enhanced by ex vivo expansion on decellularized stem cell
matrix (DSCM). Microarray was used to evaluate oxidative, antioxidative, and chondrogenic status in
SDSCs after expansion on DSCM and induction in chondrogenic medium. Hydrogen peroxide (H2O2)
was added to create oxidative stress in either expanded SDSCs or chondrogenically induced
premature pellets. The effect of H2O2 on SDSC proliferation was evaluated using flow cytometry.
Chondrogenic differentiation of expanded SDSCs was evaluated using histology, immunostaining,
biochemical analysis, and real-time PCR. MAPK signaling pathways and p21 were compared in
DSCM and plastic flask expanded SDSCs with or without H2O2 treatment. We found that expansion
on DSCM upregulated antioxidative gene levels and chondrogenic potential in human SDSCs,
retarded the decrease in cell number and the increase in apoptosis, and rendered SDSCs resistant to
cell-cycle G1 arrest resulting from H2O2 treatment. Treatment with 0.05 mM H2O2 during cell
expansion yielded pellets with increased chondrogenic differentiation; treatment in premature SDSC
pellets showed that DSCM expanded cells have a robust resistance to H2O2-induced oxidative stress.
Erk1/2 and p38 were positively involved in antioxidative and chondrogenic potential in SDSCs
expanded on DSCM in which p21 was downregulated. DSCM could be a promising cell expansion
system to provide a large number of high-quality human SDSCs for cartilage regeneration in a harsh
joint environment.
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Introduction
Cartilage defects, especially from trauma-induced cartilage injuries, do not heal or self regenerate well
due to the absence of blood supply. Current treatment options include microfracture, osteochondral
transplantation, and autologous chondrocyte implantation (ACI) [1]. Compared to other treatments,
ACI has been shown to work in older, active populations with larger defects. Some limitations of ACI,
however, prevent its ultimate success. For example, trauma-induced cartilage injuries may lead to
early posttraumatic osteoarthritis [2]. A major source of the destructive power of inflammation is the
direct and indirect generation of reactive oxygen species (ROS) and free radicals after the
inflammatory cytokine response [3]. Despite studies investigating the inflammatory environment in
cartilage repair [4,5], there are few reports focusing on the effect of oxidative stress on stem cellbased chondrogenesis. Oxidative stress induces chondrocyte senescence [6]; oxidative DNA damage
has been demonstrated in osteoarthritic articular cartilage in both porcine [7] and human samples [8],
indicating that oxidative stress is one of the most important hurdles to overcome in order to increase
the efficacy of ACI.
Adult stem cells could be an excellent cell candidate not only because of their self-renewal
and multilineage differentiation capacity but also due to their antioxidant capacity [9]. A recent report
demonstrated that there were distinct DNA responses to damage and repair mechanisms in stem cells
that render them tolerant to stressors [10], making them superior to their more differentiated
counterparts [11,12]. Synovium-derived stem cells (SDSCs), a tissue-specific stem cell for
chondrogenesis, are an appropriate stem cell candidate for cartilage engineering and regeneration
[13,14]. The regenerative capacity of synovium has been demonstrated after surgical and chemical
synovectomy [15]. Synovium can be obtained in a minimally invasive fashion with few complications
during arthroscopy. Although stem cells exhibit some intrinsic degree of antioxidant capacity [16,17],
this intracellular defense system may be rapidly overwhelmed in an inflammatory environment,
resulting in poor cell survival and engraftment [18-20].
For successful cell therapy or tissue engineering, measures must be taken to control the
inflammatory and oxidative environment in which cartilage is regenerated. The regulation of
intracellular ROS is crucial for cell survival in the harsh environment and guarantees successful cell
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therapy.Our previous work suggested that decellularized stem cell matrix (DSCM) provides an in
vitro microenvironment for SDSC rejuvenation in terms of enhancing expanded cell proliferation and
chondrogenic potential [21-23]. It is possible that a small punch biopsy plus our DSCM approach
would be sufficient for growth of a clinically useful quantity of cells. Our recent findings indicated
that DSCM expansion decreases expanded cell ROS level [24,25]. In addition, our microarray data
suggested that DSCM expansion could upregulate SDSCs’ antioxidant gene levels, indicating that
DSCM expansion may benefit SDSCs by increasing the resistance to oxidative stress and promoting
cell chondrogenic capacity. In this study, we hypothesized that human SDSCs expanded on DSCM
acquired an ability to resist oxidative stress induced by hydrogen peroxide (H2O2) and enjoyed
expanded cell chondrogenic potential.

Materials and Methods
SDSC culture
Adult human synovial fibroblasts [4 donors, two male (39 and 42 years old) and two female (43 and
47 years old), average 43 years old with no known joint disease], referred to as hSDSCs [26], were
obtained from Asterand (North America Laboratories, Detroit, MI). Human SDSCs were plated and
cultured in a growth medium [Alpha Minimum Essential Medium containing 10% fetal bovine serum
(FBS), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 μg/mL Fungizone (Invitrogen,
Carlsbad, CA)] at 37C in a humidified 5% CO2 and 21% O2 incubator. The medium was changed every
three days.

DSCM preparation
The preparation of DSCM was described in our previous study [21]. Briefly, plastic flasks (Plastic)
were precoated with 0.2% gelatin (Sigma, St. Louis, MO) at 37C for 1 h and seeded with passage 3
(P3) hSDSCs. After cells reached 90% confluence, 50 μM L-ascorbic acid phosphate (Wako
Chemicals USA, Inc., Richmond, VA) was added for 8 days. The deposited matrix was incubated
with 0.5% Triton X-100 containing 20 mM ammonium hydroxide at 37C for 5 min and stored at 4C
in phosphate-buffered saline (PBS) containing 100 U/mL penicillin, 100 µg/mL streptomycin, and
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0.25 µg/mL Fungizone.

Global gene expression by microarrays and data analyses
A preliminary study was conducted to evaluate global gene expression changes in hSDSCs during
DSCM expansion and chondrogenic induction. P3 hSDSCs were expanded on either DSCM (Ecell) or
Plastic (Pcell) for one passage. Expanded cells were chondrogenically induced in a pellet culture
system (Ep and Pp, respectively) for 21 days. Total RNAs were isolated from expanded cells and 21day pellets using Trizol (Invitrogen) followed by additional purification using the RNeasy Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s instructions. The required amount of cDNA
(5.5 µg) was processed for fragmentation and biotin labeling using the GeneChip® WT Terminal
Labeling Kit (Affymetrix, Santa Clara, CA). The entire reaction of fragmented and biotin-labeled
cDNA (50 µL) with added hybridization controls was hybridized to the human GeneChip® 1.0 ST
Exon Arrays (Affymetrix) at 45C for 17 h in the GeneChip® Hybridization Oven 640 (Affymetrix).
Calculation of the scaling factor, background, noise, and percent present, etc. was performed
according to manufacturer’s procedures (Affymetrix). The raw data was uploaded into GeneSpring
(Agilent, Santa Clara, CA) and Partek (St. Louis, MO) software for initial analysis and Ingenuity
Pathway Analysis (IPA, Redwood City, CA) for pathway and functional analysis. Briefly, raw
intensity was background-subtracted, robust multi-array average (RMA) normalized, log-transformed,
and fold changes determined. The batch effects (scan date) were removed before fold change
calculation.

SDSC expansion and H2O2 treatment
P3 hSDSCs were cultured at 3000 cells/cm2 for one passage on two substrates: DSCM or Plastic. To
determine the effects of H2O2 on expanded cells, oxidative stress was induced 48 h after cell seeding
by exposing cells to 0.05, 0.5, and 5 mM H2O2 throughout the culture. Since higher concentrations
(0.5 and 5 mM) of H2O2 caused obvious cell death, 0.05 mM H2O2 was chosen for our cell expansion
study. Non-treated groups served as a control. The cell number was counted using a hemocytometer.
Expanded cells were also evaluated for proliferation index, apoptosis, and cell cycle using flow
cytometry.
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Cell proliferation, apoptosis, and cell cycle analysis
P3 hSDSCs were pre-labeled with CellVue® Claret (Sigma) at 2×10-6 M for 5 min according to the
manufacturer’s protocol. After a 7-day expansion, cells treated with or without 0.05 mM H2O2 in
DSCM and Plastic groups were collected and analyzed using BD FACSCalibur (BD Biosciences, San
Jose, CA). For each sample, 20,000 events were collected using CellQuestTM Pro Software (BD
Biosciences) and cell proliferation index was analyzed by ModFit LT 3.1 (Verity Software House,
Topsham, ME).
After cell expansion, an Annexin V-FITC Apoptosis Detection Kit (Biovision, Mountain View, CA)
was used to detect apoptosis. Briefly, 2×105 cells treated with or without 0.05 mM H2O2 in DSCM and
Plastic groups (n=3 each) were labeled with FITC annexin V and propidium iodide for 15 min. For
each sample, 10,000 events were collected; samples were analyzed using BD FACSCalibur. FCS
Express V3 (De Novo Software, Los Angeles, CA) was used to generate the histograms.
After hSDSCs were treated with 0.05 mM H2O2 for 2 h, the medium was switched to fresh medium
for cell recovery. Detached cells were washed with PBS containing 1% FBS, and then fixed with 80%
ethanol at 4C for 15 min. Fixed cells were stained with 20 μg/mL propidium iodide in PBS buffer
containing 1% FBS, 0.05% Triton X-100, and 50 μg/mL RNase. After a 30 min incubation at room
temperature, a flow cytometer was used to determine the percentage of cells in different phases of the
cell cycle (G1, S, and G2/M phase) with CFlow software (Accuri Cytometers, Inc., Ann Arbor, MI).

Chondrogenic differentiation
The effect of H2O2 treatment on SDSC-based chondrogenesis was evaluated in two phases. During
cell expansion on either DSCM or Plastic, 0.05 mM H2O2 was added to the medium throughout the
culture period. A 21-day chondrogenic induction followed in a pellet culture system. We also
evaluated the effect of H2O2 on premature SDSC pellets, in which both DSCM and Plastic expanded
SDSCs were incubated in a chondrogenic medium for 21 days, followed by the medium being
supplemented with 0.05 or 0.1 mM H2O2 for 7 days. The chonodrogenic induction protocol is briefly
described below: After in vitro expansion, 0.3×106 of SDSCs from each group were centrifuged at
500 g for 5 min in a 15-mL polypropylene tube to form a pellet. After overnight incubation, the
pellets were cultured in a serum-free chondrogenic medium consisting of high-glucose Dulbecco’s
Modified Eagle’s Medium, 40 μg/mL proline, 100 nM dexamethasone, 100 U/mL penicillin, 100
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μg/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate, and 1×ITSTM Premix [6.25 μg/mL insulin,
6.25 μg/mL transferrin, 6.25 μg/mL selenous acid, 5.35 μg/mL linoleic acid, and 1.25 μg/mL bovine
serum albumin (BSA), from BD Biosciences] with supplementation of 10 ng/mL transforming growth
factor beta 3 (TGF-β3, PeproTech Inc., Rocky Hill, NJ). Chondrogenic differentiation was evaluated
using histology, immunostaining, biochemical analysis, and real-time PCR.

Histology and immunostaining
The pellets (n=3) were fixed in 4% paraformaldehyde at 4C overnight, followed by dehydrating in a
gradient ethanol series, clearing with xylene, and embedding in paraffin blocks. Sections that were 5
μm thick were histochemically stained with Alcian blue (Sigma; counterstained with fast red) for
sulfated glycosaminoglycans (GAGs). For immunohistochemical analysis, the sections were
immunolabeled with primary antibodies against collagen II (II-II6B3; Developmental Studies
Hybridoma Bank, Iowa City, IA) and collagen X (Sigma), followed by the secondary antibody of
biotinylated horse anti-mouse IgG (Vector, Burlingame, CA). Immunoactivity was detected using
Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine as a substrate.

Biochemical analysis
The pellets (n=4) were digested for 4 h at 60C with 125 μg/mL papain in PBE buffer (100 mM
phosphate and 10 mM EDTA, pH 6.5) containing 10 mM cysteine, by using 200 μL enzyme per
sample. To quantify cell density, the amount of DNA in the papain digestion was measured using the
QuantiTTM PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor® Series 4000 (Applied
Biosystems, Foster City, CA). GAG was measured using dimethylmethylene blue dye and a
Spectronic BioMate 3 Spectrophotometer (Thermo Scientific, Milford, MA) with bovine chondroitin
sulfate as a standard.

Real-time PCR
Total RNA was extracted from samples (n=4) using an RNase-free pestle in TRIzol® (Invitrogen).
About 1 µg of mRNA was used for reverse transcriptase with a High-Capacity cDNA Archive Kit
(Applied Biosystems) at 37C for 120 min. Chondrogenic marker genes [collagen II (COL2A1I)
aggrecan (ACAN) and SRY (sex determining region Y)-box 9 (SOX9)] and hypertrophic marker gene
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[collagen X (COL10A1)] were customized by Applied Biosystems as part of the Custom TaqMan®
Gene Expression Assays (Li et al., 2011). Eukaryotic 18S RNA (Assay ID HS99999901_s1) was
carried out as the endogenous control gene. Real-time PCR was performed with the iCycler iQTM
Multi-Color Real Time PCR Detection (Perkin-Elmer, Waltham, MA). Relative transcript levels were
calculated as χ=2-ΔΔCt, in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s.

Western blot
To further determine potential mechanisms underlying DSCM-mediated cell proliferation and
differentiation under oxidative stress, the expanded cells from each group were homogenized and
dissolved in the lysis buffer (Cell Signaling, Danvers, MA) with protease inhibitors. Total proteins
were quantified using BCA™ Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL). Thirty
micrograms of protein from each sample were denatured and separated using NuPAGE® Novex® BisTris Mini Gels (Invitrogen) in the XCell SureLock™ Mini-Cell (Invitrogen) at 120 V at 4C for 3 h.
Bands were transferred onto a nitrocellulose membrane (Invitrogen) using an XCell II™ Blot module
(Invitrogen) at 15 V at 4C overnight. The membrane was incubated with primary monoclonal
antibodies in 5% BSA, 1×TBS (10 mM Tris-HCl, 150 mM NaCl, pH 7.5), and 0.05% Tween-20 at
room temperature for 1 h (β-actin served as an internal control), followed by the secondary antibody
of horseradish peroxidase–conjugated goat anti-mouse (Thermo Fisher Scientific) at room
temperature for 1 h. SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher
Scientific) and CL-XPosure Film (Thermo Fisher Scientific) were used for exposure. The primary
antibodies used in immunoblotting included the mitogen-activated protein kinase (MAPK) family
antibody sampler kit (catalog number: 9926) and phosphor (p)-MAPK family antibody sampler kit
(catalog number: 9910) as well as p21 Waf1/Cip1 (12D1) rabbit monoclonal antibody (catalog
number: 2947) were ordered from Cell Signaling.

Statistics
Numerical data are presented as the mean and the standard error of the mean. The Mann-Whitney U
test was used for pair-wise comparison in biochemistry and real-time PCR data analysis. All statistical
analyses were performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less
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than 0.05 were considered statistically significant.

Results
DSCM expansion promoted hSDSC antioxidation and chondrogenic potential
To explore the possible mechanisms of DSCM interaction with expanded cells, a microarray was
conducted for global analysis of gene expression in expanded hSDSCs and subsequent chondrogenic
differentiation in a pellet system. The top 100 genes (50 up- and 50 down-regulated) were analyzed
for gene-gene interaction networks and signaling pathways (Fig. 1A). The top associated networks
included: a) antigen presentation, cell-to-cell signaling and interaction, and inflammatory response; b)
cellular development; and c) cell death, cellular growth, and proliferation, etc. Top molecular and
cellular functions with p values ranging from 1.59E-08 to 5.07E-03 included: a) cellular movement
and development; b) cellular growth and proliferation; and c) cell-to-cell signaling and interaction, etc.
The top pathways included: a) endothelin-1 signaling; b) acute phase response signaling; and c) Gprotein coupled receptor signaling, etc.
During the cell expansion phase, we found DSCM expansion upregulated the genes for antioxidation
including prostaglandin F2alpha receptor (PTGFR), heme oxygenase (decycling) 1 (HMOX1),
superoxide dismutase 2 (SOD2), selenoprotein P, plasma, 1 (SEPP1), and interleukin 6 (IL-6). In the
meantime, DSCM expansion also downregulated the genes for oxidative stress including
nephroblastoma overexpressed (NOV), insulin-like growth factor binding protein 5 (IGFBP5),
connective tissue growth factor (CTGF), A disintegrin and metalloproteinase with thrombospondin
motifs 5 (ADAMTS5), and thioredoxin reductase 1 (TXNRD1) (Fig. 1B). In the subsequent
chondrogenic differentiation, the genes of antioxidation as above were downregulated in DSCM
pretreated hSDSCs; chondrogenic marker genes were also upregulated including collagen 9 alpha 1
(COL9A1), collagen 2 alpha 1 (COL2A1), aggrecan (ACAN), SOX9, and collagen 11 alpha 1
(COL11A1) (Fig. 1C).

DSCM expansion alleviated oxidative stress-mediated proliferation reduction through lowering the
apoptosis rate and elevating the G1 transition
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To determine an appropriate concentration of H2O2 for this study, a series of concentrations (0, 0.05,
0.5, and 5 mM) were chosen to evaluate toxicity in hSDSCs (Fig. 2A). After hSDSCs were plated on
either DSCM or Plastic for 48 h, the medium was added with varying concentrations of H2O2. When
treated with high concentrations of H2O2 (0.5 and 5 mM), a number of floating cells and attached
round cells were in both groups, indicative of cell death. At a low concentration of H2O2 treatment
(0.05 mM), both DSCM and Plastic groups showed that a decrease in cell number compared with the
non-treated group despite a similarity in cell morphology. Human SDSCs grown on Plastic displayed
random arrangements and flattened shapes while DSCM expanded hSDSCs exhibited an ordered
arrangement and glistening “fiber-like” shapes. Thus, 0.05 mM of H2O2 was chosen for cell expansion
to evaluate its effect on cell proliferation and subsequent multi-lineage differentiation.
To determine the effect of DSCM on cell proliferation under oxidative stress, expanded hSDSCs were
evaluated using both proliferation index (Fig. 2B) and cell number counting (Fig. 2C) approaches.
Under treatment with H2O2, proliferation index in the DSCM group was 9.20 compared to 4.36 in the
Plastic group; without H2O2 treatment, the proliferation index in the DSCM group was 18.75
compared to 10.62 in the Plastic group. Despite the fact that H2O2 treatment affected the proliferation
index in both groups, DSCM expanded cells retained more than twice the proliferation compared to
Plastic expanded cells, which is also consistent with cell number counts. Despite the same initial
seeding density (0.525 × 106 in a 175 cm2 flask), after a seven-day incubation under H2O2 treatment,
DSCM expansion yielded 1.99 × 106 cells compared to 1.21 × 106 cells in the Plastic group; without
H2O2 treatment, the cell number in the DSCM group was 4.69 ×106 compared to 3.24 ×106 in the
Plastic group. The proliferation difference in both DSCM and Plastic groups may be related to a lower
apoptosis rate in the DSCM group (Fig. 2D). There was a slightly lower apoptosis rate in the DSCM
group (3.30%) compared to the Plastic group (4.40%); under treatment with H2O2, the apoptosis rate
in the DSCM group decreased to 2.87% compared to an increase in the Plastic group (8.77%).
The discrepancy in cell proliferation may also be explained by cell cycle data (Fig. 2E). Flow
cytometric analysis revealed concomitant cell cycle arrest at the G1 checkpoint when expanded on
Plastic versus DSCM and incubated in the medium supplemented with versus without 0.05 mM H2O2.
After hSDSCs were treated with 0.05 mM H2O2 for 20 hours, we found that Plastic-expanded cells
were 85.00% (versus 75.20% without treatment) in the G1 phase, 8.63% (versus 18.18% without
treatment) in the S phase, and 6.36% (versus 6.62% without treatment) in the G2/M phase, suggesting
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that H2O2 treatment resulted in an arrest at the G1 phase of the cell cycle. In contrast, we found that
DSCM-expanded cells were 73.62% (versus 72.70% without treatment) in the G1 phase, 16.81%
(versus 16.76% without treatment) in the S phase, and 9.57% (versus 10.54% without treatment) in
the G2/M phase, suggesting that DSCM-expanded cells were able to resist the G1 arrest from H2O2.
We also found that, after 20 hours of H2O2 treatment, DSCM expansion could greatly enhance cell
proliferation ability, as evidenced by the cells either without H2O2 treatment (10.54% versus 6.62% in
the G2/M phase) or with H2O2 treatment (9.57% versus 6.36% in the G2/M phase), which was in
accord with the initial cells before H2O2 treatment (5.11% on DSCM versus 3.73% on Plastic in the
G2/M phase) (data not shown).

DSCM expanded hSDSCs acquired enhanced chondrogenic potential after treatment with H2O2 in
both proliferation and chondrogenic phases
The effect of oxidative stress on expanded hSDSC chondrogenic differentiation was evaluated in two
distinct phases: the proliferation phase (H2O2 was added during cell expansion followed by
chondrogenic induction) and the chondrogenic phase (H2O2 was added 21 days after expanded cell
chondrogenic induction). For the proliferation phase study, the expanded hSDSCs with or without
H2O2 treatment were incubated in a pellet system with a chondrogenic medium for 21 days. DSCM
expanded hSDSCs yielded pellets with larger size and intense staining of cartilage markers, in terms
of sulfated GAGs and collagen II, compared with Plastic expanded hSDSCs (Fig. 3A). Interestingly,
H2O2 treatment during cell expansion enhanced the resulting pellet in both size and chondrogenic
differentiation, especially for the DSCM group, which is supported by biochemical analysis data.
DSCM expanded hSDSCs yielded pellets with higher GAG amount and ratio of GAG to DNA
(chondrogenic index) when treated with H2O2 compared with the non-treated group. In contrast,
Plastic expanded hSDSCs yielded pellets with a relatively low GAG amount and chondrogenic index
when treated with H2O2, but did not show a significant difference when compared with the nontreated group (Fig. 3B). Despite enhanced chondrogenic differentiation in DSCM expanded hSDSCs
as evidenced by histology and biochemical analysis data, H2O2 treatment did downregulate
chondrogenic marker gene expression (SOX9, ACAN, and COL2A1) in the pellets after a 21-day
chondrogenic induction. On the other hand, for Plastic expanded hSDSCs, H2O2 treatment upregulated
chondrogenic marker gene expression, despite the fact that all chondrogenic marker genes from
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Plastic expanded hSDSCs were significantly lower than those from DSCM expanded hSDSCs under
treatment either with or without H2O2 (Fig. 3C).
For the differentiation phase study, expanded hSDSCs incubated in a pellet system with a
chondrogenic medium for 21 days were subsequently supplemented with H2O2 for an additional 7
days. DSCM expanded hSDSCs yielded pellets with larger size and intense staining of cartilage
markers, with or without H2O2 treatment, compared with Plastic expanded hSDSCs (Fig. 4A). There
was no difference in the size and chondrogenic staining of pellets from either DSCM or Plastic
expanded cells between H2O2 treated and non-treated groups. The histology data were supported by
biochemical data, in which DSCM expanded hSDSCs yielded pellets with a higher DNA ratio, GAG
amount, and chondrogenic index than those from Plastic expanded cells, despite no significant
difference from H2O2 treatment in either DSCM or Plastic expanded cells being found (Fig. 4B). Realtime PCR data showed that, compared to pellets from Plastic expanded cells, DSCM expanded cells
yielded pellets with a higher chondrogenic marker gene expression with or without H2O2 treatment.
DSCM expanded hSDSCs exhibited an upregulation of all three chondrogenic marker genes (SOX9,
ACAN, and COL2A1) when treated with a low concentration of H2O2 (0.05 mM) compared to an
upregulation of two chondrogenic marker genes (SOX9 and COL2A1) when treated with a higher
concentration of H2O2 (0.1 mM). In contrast, Plastic expanded hSDSCs displayed a dramatic decrease
of all three chondrogenic marker genes under treatment with H2O2 at both 0.05 mM and 0.1 mM (Fig.
4C).
Similar to the SOX9 mRNA level, for the proliferation phase study, DSCM expanded hSDSCs
exhibited a downregulation of the COL10A1 level compared to an upregulation in Plastic expanded
cells after H2O2 treatment followed by a 21-day pellet culture (Fig. 5A/C). For the differentiation
phase study, DSCM expanded hSDSCs displayed an upregulation of COL10A1 level compared to a
downregulation in Plastic expanded cells after a 21-day pellet culture followed by a seven-day H2O2
treatment (Fig. 5B/D).

Under oxidative stress, DSCM expanded hSDSCs exhibited an upregulation of p38 and Erk1/2 and a
downregulation of p21
To further determine potential mechanisms underlying DSCM mediated cell proliferation and
differentiation under oxidative stress, western blot was used to investigate the expression of the
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MAPK signaling pathway [extracellular signal-regulated kinases 1 and 2 (Erk1/2), p38] and a
senescence-associated marker (p21) in hSDSCs after exposure to 0.05 mM H2O2. Image J analysis
showed that, with H2O2 treatment, DSCM expanded cells exhibited higher levels of p-p38/p38 (Fig.
6A) and p-Erk/Erk (Fig. 6B) compared to those from Plastic expanded cells; in contrast, DSCM
expanded cells exhibited a lower level of p21 (Fig. 6C), a senescence-associated marker, compared to
those from Plastic expanded cells.

Discussion
Chondrocytes produce superoxide, hydrogen peroxide, and hydroxyl radicals under resting conditions
[27,28] and nitric oxide during chondrogenesis [29]. ROS are produced at a low level in articular
chondrocytes and play an important as integral actors of intracellular signaling mechanisms; they
modulate gene expression and are likely to contribute to the maintenance of cartilage homeostasis
[30]. Increased production of ROS contributes to the pathology observed in inflammatory joint
diseases [30], which is believed to be responsible for the fact that cartilage defects are difficult to
repair except in the presence of inflammatory factors [interleukin 1 beta (IL-1) and tumor necrosis
factor alpha (TNF-)] [5]. Our recent studies demonstrated that DSCM expansion enhanced SDSC
proliferation and chondrogenic potential [21,22]. It would be interesting to know if DSCM expansion
could resist H2O2-induced oxidative stress while enhancing cell expansion and chondrogenic capacity.
Our microarray data suggested that DSCM expansion not only dramatically enhanced hSDSC
chondrogenic potential but also promoted expanded cell antioxidation ability, indicating that DSCM
expansion could rejuvenate hSDSCs by decreasing the senescence-associated secretory phenotypes
[31].
Our study found that, during the cell proliferation phase, DSCM expansion decreased the decline in
cell proliferation and the increase in cell apoptosis in hSDSCs under H2O2-induced oxidative stress;
this finding may be because DSCM expanded cells were able to resist the G1 arrest from H2O2. In
contrast to the cell proliferation phase, expanded SDSCs were differently affected in chondrogenic
potential by oxidative stress in terms of an upregulation in Plastic expanded SDSCs compared to a
downregulation in DSCM expanded SDSCs. Our result differed from a previous report [32], in which
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H2O2 inhibited cartilage formation in chicken micromass cultures. This difference could be because
they used 1 mM H2O2 treatment for 30 min and we used 0.05 mM H2O2 as a continuous treatment.
Moreover, different types of cells have different responses and tolerances to H2O2-induced oxidative
stress [33]. In fibroblasts, low concentrations of H2O2 (<0.01 mM) stimulate cell proliferation;
intermediate concentrations (~0.15 mM) cause growth arrest or senescence; and high levels of H2O2
(>0.4 mM) induce rapid apoptosis [34]. Our dose of H2O2 causing growth arrest is also in accordance
with a previous study [35], in which inflammatory conditions (rheumatoid arthritis and osteoarthritis)
were imitated; synoviocytes were inhibited in both hyaluronan and DNA synthesis at concentrations
of H2O2 (10 – 100 µM), less than those which caused loss of cell integrity (>200 µM). The
preconditioned effect from 0.05 mM H2O2 might be responsible for the upregulation of chondrogenic
marker genes [36].
We also evaluated the effect of H2O2 on 21-day SDSC pellets in chondrogenic medium and found that
predifferentiated SDSCs in a pellet could better resist H2O2-induced oxidative stress, as evidenced by
comparable staining of sulfated GAGs and collagen II as well as stable cell viability and chondrogenic
index. Our data were in accord with a study investigating the effects of peroxynitrite (0.1-0.6 mM)
and H2O2 (0.1-4 mM) on poly (adp-ribose) polymerase (PARP) activation and extracellular matrix
production of high-density micromass cultures prepared from chick limb bud mesenchymal cells [37].
They found that both oxidative species strongly inhibited matrix formation of high-density micromass
cultures treated on day 2 but not on day 5. In micromass cultures, the major steps of cartilage
differentiation occur on days 2 and 3 when young cartilage cells start to secrete a specific extracellular
matrix (ECM) rich in collagen II and aggrecan [38], suggesting that ECM could protect
chondrogenically differentiated mesenchymal cells from oxidative stress. Despite resistance at the
protein level, DSCM expanded SDSCs yielded pellets with enhanced levels of chondrogenic marker
genes upon stimulation by H2O2; in contrast, Plastic expanded SDSCs yielded pellets with
downregulation of chondrogenic marker genes, indicating DSCM expansion renders SDSCs with
enhanced chondrogeneic potential.
Despite an enhanced antioxidation level in DSCM expanded cells, chondrogenic induction made these
cells lose their antioxidation capacity when compared with Plastic expanded cells. Since enhanced
endogenous antioxidant levels can protect cells from oxidative stress and inhibit chondrocyte
hypertrophy [39], a decline in the antioxidative level may explain why DSCM expanded hSDSCs
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exhibited a higher level of collagen X after chondrogenic induction compared to those grown on
Plastic. When H2O2 was used to treat chondrogenically differentiated SDSCs, it was also
understandable that DSCM expanded SDSCs exhibited an enhanced collagen X expression compared
with Plastic expanded SDSCs. Following H2O2 treatment during monolayer culture, Plastic expanded
SDSCs exhibited an increased ROS level, which is responsible for a higher level of collagen X
expression in these chondrogenically differentiated cells. Interestingly, we found DSCM expanded
SDSCs displayed a different response when incubated in a chondrogenic induction medium, while
H2O2 treated SDSCs had a lower level of collagen X than non-treated cells. The mechanism is still
under investigation.
The Erk cascade is a prominent component of the MAPK family that in particular plays an integral
role in both growth factor and stress signaling, although it preferentially regulates cell growth and
differentiation [40]. p38MAPKs are described as stress activated protein kinases because they are
frequently activated by a wide range of environmental stresses such as oxidative stress and cytokines
to induce inflammation, a key process in the host defense system [41]. The activation of Erk1/2 and
p38MAPK after treatment with H2O2 was demonstrated in different types of cells, such as PC12 cells
[42], skeletal myoblasts [43], alveolar epithelial cells [44], and ATDC5 cells [39], indicating that
Erk1/2 and p38MAPK have universal protection against oxidative stress in different cell types. Our
western blot data showed that the MAPK pathway was involved in the H2O2-mediated and DSCMmediated cell activities in terms of proliferation and differentiation; both Erk1/2 and p38MAPK were
upregulated in DSCM expanded SDSCs, indicating that DSCM expansion might activate the MAPK
signal pathway, helping combat H2O2-induced oxidative stress. A higher level of p38MAPK in
DSCM expanded SDSCs after H2O2 treatment might benefit subsequent differentiation due to its
positive role in mesenchymal stem cell chondrogenesis [45]. p21, a potent cyclin-dependent kinase
(CDK) inhibitor (CKI), functions as a regulator of cell cycle progression at G1 through binding and
inhibiting the activity of cyclin-CDK2 or CDK4 complexes. Compared to SDSCs grown on Plastic,
DSCM expanded SDSCs exhibiting a lower level of p21 might result from the observation that
DSCM expanded cells were able to resist G1 arrest from H2O2, demonstrating that DSCM expansion
could rejuvenate SDSCs from oxidative stress-induced cell senescence [46].
In the present study, for the first time, we demonstrated that DSCM could enhance human SDSC in
vitro expansion and chondrogenic potential; more importantly, we found that DSCM expansion could
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prevent human SDSCs from oxidative stress-induced cell senescence, in terms of cell proliferation
and differentiation. Since most patients with cartilage defects have diseased joints with oxidative
stress, this finding provides important information for the potential application of using DSCM in
cartilage engineering and regeneration. DSCM could be a promising cell expansion system to provide
a large number of high-quality hSDSCs for cartilage regeneration in a harsh joint environment. Our
DSCM model, as a new strategy and intervention aimed at reducing oxidative damage in implanted
cells, might be a promising alternative in the treatment of osteoarthritis patients with cartilage defects.
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Figure 6. 1 Effect of DSCM pretreatment on hSDSC oxidative stress and chondrogenic
potential.
In the heatmap (A), the expression intensity was log2-transformed and visualized by color ranging
from low expression (blue) to high expression (red). The comparisions of Ecell versus Pcell in the
genes (>2 fold change) related to oxidative stress and antioxidation (B) and Ep versus Pp in the genes
(>2 fold change) related to antioxidation and cartilage markers (C), were clustered by hierarchical
clustering methods.
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Figure 6. 2 Effect of DSCM pretreatment on hSDSC expansion under H2O2.
(A) Cell morphology of hSDSCs expanded on either DSCM or Plastic was shown under phase
contrast microscope after treatment with varying concentration (0, 0.05, 0.5, and 5 mM) of H2O2 for
four days. Scale bar is 200 µm. (B) The effect of 0.05 mM H2O2 on the proliferation of hSDSCs
expanded on either DSCM or Plastic was evaluated using proliferation index by flow cytometry. (C)
The effect of 0.05 mM H2O2 on the proliferation of hSDSCs expanded on either DSCM or Plastic was
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evaluated using cell count (n=8 flasks each group) by hemocytometer. (D) The effect of 0.05 mM
H2O2 on apoptosis of hSDSCs expanded on either DSCM or Plastic was evaluated using flow
cytometry. (E) The effect of 0.05 mM H2O2 on the cell cycle of hSDSCs expanded on either DSCM
or Plastic was evaluated using flow cytometry.
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Figure 6. 3 Effect of DSCM pretreatment with 0.05 mM H2O2 on expanded hSDSC
chondrogenic potential.
hSDSCs expanded on either DSCM or Plastic with H2O2 treatment were chondrogenically induced in
a pellet culture system for 21 days. Alcian blue (AB) was used to stain sulfated GAGs.
Immunohistochemistry staining (IHC) was used to detect collagen II (Col II). (B) Biochemical
analysis was used for DNA and GAG contents in the 21-day chondrogenically-induced pellets. Cell
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proliferation and viability was evaluated using DNA ratio (DNA content at day 21 adjusted by that at
day 0). Chondrogenic index at day 21 was evaluated using a ratio of GAG to DNA. (C) Real-time
PCR was used to evaluate chondrogenic marker gene expression (SOX9, ACAN, and COL2A1) in day
21 pellets. Data are shown as average ± SD for n = 4. * p < 0.05 compared with the corresponding
DSCM group. # p < 0.05 compared with the corresponding group without H2O2 treatment.
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Figure 6. 4 Effect of DSCM pretreatment on expanded hSDSC chondrogenic differentiation
with either 0.05 or 0.1 mM H2O2.
(A) hSDSCs expanded on either DSCM or Plastic with H2O2 treatment were chondrogenically
induced in a pellet culture system for 21 days and treated with H2O2 for the following 7 days. Alcian
blue (AB) was used to stain sulfated GAGs. Immunohistochemistry staining (IHC) was used to detect
collagen II (Col II). Scale bar is 1 mm. (B) Biochemical analysis was used for DNA and GAG
contents in the 28-day chondrogenically-induced pellets. Cell proliferation and viability was evaluated
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using DNA ratio (DNA content at day 28 adjusted by that at day 0). Chondrogenic index at day 28
was evaluated using ratio of GAG to DNA. (C) Real-time PCR was used to evaluate chondrogenic
marker gene expression (SOX9, ACAN, and COL2A1) in day 28 pellets. Data are shown as average ±
SD for n = 4. * p < 0.05 compared with corresponding DSCM group. # p < 0.05 compared with the
corresponding group without H2O2 treatment.

$

p < 0.05 compared with the corresponding group

treated with 0.05 mM H2O2.
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Figure 6. 5 Effect of H2O2 treatment in either cell expansion or chondrogenic differentiation
phase on expanded SDSC chondrogenic hypertrophy.
(A and C) hSDSCs expanded on either DSCM or Plastic with 0.05 mM H2O2 treatment were
chondrogenically induced in a pellet culture system for 21 days. (B and D) hSDSCs expanded on
either DSCM or Plastic were chondrogenically induced in a pellet culture system for 21 days and
treated with H2O2 for the following 7 days. Immunohistochemistry staining (IHC) was used to detect
collagen X (A and B). Scale bar is 1 mm. Real-time PCR was used to evaluate hypertrophy marker
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gene expression (COL10A1) (C and D). Data are shown as average ± SD for n = 4. * p < 0.05
compared with corresponding DSCM group.

#

p < 0.05 compared with the corresponding group

without H2O2 treatment. $ p < 0.05 compared with the corresponding group treated with 0.05 mM
H2O2.
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Figure 6. 6 Western blot was used to measure the levels of p38 and Erk1/2, p21 in the hSDSCs
expanded on either DSCM or Plastic after the treatment with 0.05 mM H2O2.
-actin served as an internal control. Image J software was used to quantify immunoblotting bands.
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Abstract
Chondrogenesis is a developmental process that is controlled and coordinated by many growth and
differentiation factors as well as environmental factors that initiate or suppress cellular signaling
pathways and transcription of specific genes in a temporal-spatial manner. As key signaling molecules
in regulating cell proliferation, homeostasis, and development, both mitogen-activated protein kinases
(MAPK) and the Wnt family participate in morphogenesis and tissue patterning and play important
roles in skeletal development, especially chondrogenesis. Recent findings suggest that both signals are
also actively involved in arthritis and related diseases. Despite the fact that the crosstalk between
MAPK and Wnt signaling has been implicated to play a significant role in cancer, few studies have
summarized this interaction and crosstalk in regulating chondrogenesis. In this review, we focus on
MAPK and Wnt signaling in reference to their relationships in different types of cells and particularly
how this crosstalk might influence chondrogenesis and cartilage development. We also discuss how
the interactions between MAPK and Wnt signaling might relate to cartilage related diseases such as
osteoarthritis and explore the potential therapeutic targets for disease treatments.

Key words
Chondrogenesis; MAPK signal; Wnt signal; Stem cell; Osteoarthritis
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Introduction
Chondrogenesis is a morphogenetic event that includes proliferation, condensation, and differentiation
of mesenchymal cells into chondrocytes with the production of a cartilage-specific extracellular
matrix (ECM) rich in type II collagen and sulfated proteoglycans [12]. Mitogen-activated protein
kinase (MAPK) is one of the conserved signal transduction systems in cartilage, which plays a crucial
role in chondrogenic differentiation. The MAPK cascades constituting three sequentially activated
kinase complexes, which include p38 MAPK, c-Jun N-terminal kinase (JNK), and extracellular
regulated kinase (ERK), are substrates for phosphorylation by MAPK kinases (MKKs) (Fig. 1). The
MKKs are in turn phosphorylated by MAPK kinase kinases (MEKKs). Regarding chondrogenesis and
chondrocyte differentiation, ERK and p38 MAPK have central roles in mediating chondrocyte
proliferation and related gene expression [55], whereas JNK has a minor role in chondrogenesis as
JNK phosphorylation is not affected during the process [66, 87]. p38 MAPK is usually
phosphorylated during chondrogenesis and is generally accepted as a positive regulator in
chondrogenesis and chondrocyte differentiation [73, 87, 101]; however, the role of the ERK MAPK
pathway (also known as the MEK-ERK kinase cascade) is still controversial. Murakami et al. reported
that ERK is a positive regulator in chondrogenesis, as the increase in SRY (sex determining region Y)box 9 (SOX9) levels induced by basic fibroblast growth factor (FGF2) was inhibited by a specific
ERK kinase (MEK) inhibitor (U0126) in primary chondrocytes. Co-expression of a constitutively
active mutant of MEK1 increased the activity of the Sox9-dependent enhancer in primary
chondrocytes and C3H10T1/2 cells [68]. However, some studies interpreted MEK-ERK as a negative
factor for chondrogenesis. For example, ERK1/2 activities were observed to decrease as
chondrogenesis proceeded and inhibition of ERK1/2 with PD98059 enhanced chondrogenesis [73];
other studies also showed similar results [7, 15].
The Wnt family of secreted glycoproteins are signaling molecules that play important roles in
controlling a wide range of developmental processes, including tissue patterning, cell proliferation,
and cell fate, through two distinct signaling pathways, in terms of the canonical and non-canonical
Wnt pathways (Fig. 2). In the canonical Wnt signaling pathway, binding of secreted Wnts to the
Frizzled family of cell surface receptors inactivates glycogen synthase kinase 3beta (GSK3β),
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resulting in stabilization and nuclear translocation of β-catenin and activation of Wnt target genes. The
non-canonical pathways also signal through the Frizzled receptors; the planar cell polarity (PCP)
pathway activates the rho family of GTPases and JNK and modifies cytoskeletal organization and
epithelial cell polarization. The Wnt/Ca2+ pathway stimulates the intracellular increase of Ca2+ through
activation of protein kinase C (PKC) and calmodulin-dependent kinase II (CaMKII) [1]. During
embryonic skeletogenesis, Wnt components act as both positive and negative regulators of key events,
including chondroblast differentiation, chondrocyte maturation, and joint formation [16].
In embryos, low levels of Wnt/β-catenin signaling stimulate chondrogenic differentiation of stem cells
whereas high levels of Wnt/β-catenin signaling inhibit that process [42, 49, 102]. Wnts have also been
shown to both inhibit and stimulate chondrogenic differentiation of adult progenitor cells [19, 43, 44].
Removal of β-catenin early in mesenchymal progenitor cells promoted chondrocyte differentiation
while ectopic expression of an activated form of β-catenin in early differentiating chondrocytes
induced ectopic joint formation both morphologically and molecularly [38]. In adult progenitor cells,
osteoblast precursors lacking β-catenin are blocked in differentiation and develop into chondrocytes
instead. Detailed in vivo and in vitro loss- and gain-of-function analyses reveal that β-catenin activity
is necessary and sufficient to repress the differentiation of mesenchymal cells into runt-related
transcription factor 2 (RUNX2) and SOX9-positive skeletal precursors [43], suggesting that Wnt/βcatenin signaling controls osteoblast and chondrocyte formation when they differentiate from
mesenchymal progenitors.
It has been reported that the MAPK pathway also regulates Wnt/β-catenin signaling. Wnt/β-catenin
signaling was activated by LIT1 and MOM4, which separately encode a homologue of the MAPKrelated Nemo-like Kinase (NLK) and a homologue of transforming growth factor beta (TGFβ)activated kinase (TAK-1) [66]. TAK-1, a MEKK activated by TGFβ, bone morphogenetic protein
(BMP), and other MAPK signaling components, plays a critical role in chondrogenesis. Deletion of
TAK1 in chondrocytes resulted in novel embryonic developmental cartilage defects including
decreased chondrocyte proliferation, reduced proliferating chondrocyte survival, delayed onset of
hypertrophy, and reduced matrix metalloproteinase-13 (MMP13) expression [36]. Since both MAPK
and Wnt signaling pathways play critical regulatory roles in the development of cartilage and bone
formation, studying their interactions and crosstalk is of extreme importance to elucidate the complex
signaling networks in chondrogenesis and to explore potential therapeutic targets for related diseases
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such as osteoarthritis (OA).

Influence of canonical Wnt signals on the MAPK pathway
In totipotent mouse F9 teratocarcinoma cells, the canonical Wnt-β-catenin-JNK signaling pathway
was found to be activated by G-proteins, which can propagate the signals downstream through
Dishevelled isoforms. Suppression of Dishevelled-1 or Dishevelled-3 abolished Wnt3a activation of
JNK [5]. Wnt3a treatment enhanced the mRNA and protein expression of c-Jun and stimulated the
phosphorylation of c-Jun and JNK. Furthermore, Wnt3a activation of activator protein-1 (AP-1) was
blocked by the inhibition of JNK with SP600125 and by the inhibition of AP-1 with N-acetyl-Lcysteine and nordihydroguaiaretic acid [45]. AP-1 was also activated by ERK1/2 in C3H10T1/2 cells
[83]. In NIH3T3 fibroblast cells, ERK pathway activation by Wnt signaling could occur at multiple
levels, including β-catenin-independent direct signaling resulting from a Wnt3a (Wnt3a-Raf-1-MEKERK) and a β-catenin-/Tcf-4-dependent post gene transcription event [108]. In addition to JNK and
ERK, p38 MAPK was strongly activated by Wnt3a in mouse F9 teratocarcinoma cells and the
activated p38 MAPK regulated canonical Wnt-β-catenin signaling through regulation of GSK3β.
Chemical inhibitors of p38 MAPK (SB203580) and expression of a dominant negative-version of p38
MAPK attenuated Wnt3a-induced accumulation of β-catenin, Lef/Tcf-sensitive gene activation, and
primitive endoderm formation [6]. The above evidence indicates the influence of canonical Wnt
signals on the MAPK pathway (Fig. 3).
It is known that reduced expression of adhesion molecules is associated with formation and
differentiation of cartilage nodules, which is supported by the fact that N-cadherin is expressed in
prechondrogenic mesenchymes during cell condensation but not in differentiated chondrocytes [72,
91]. One study indicated that inhibition of p38 MAPK results in sustained expression of N-cadherin
and eventually inhibits the chondrogenic differentiation in chick limb mesenchymal micromass
cultures [73]. Wnt regulation of limb mesenchymal chondrogenesis is also involved in the modulation
of N-cadherin. Wnt7a signaling has been shown to inhibit chondrogenic differentiation of limb
mesenchymal cells in vitro by modulating the expression of N-cadherin and the turnover of Ncadherin-dependent cell-cell adhesion complexes [98]. The combination of Wnt7a misexpression and
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ERK inhibition partially recovers Wnt7a inhibition of chondrogenic differentiation, whereas the
combination of Wnt7a misexpression and p38 inhibition acts in a synergistic chondro-inhibitory
fashion [97].
Wnt3a can also induce a rapid and transient activation of p38 MAPK, which in turn regulates alkaline
phosphatase activity and mineralization of nodules, directing the differentiation of mesenchymal cells
into osteoprogenitors. Dickkopf1, a selective antagonist of Wnt proteins, did not influence the
activation of p38 MAPK and ERK induced by Wnt3a [13], implying that non-canonical Wnt
pathways might participate in the regulatory process of mesenchymal cell differentiation into
osteogenic cells.

Influence of non-canonical Wnt signals on the MAPK pathway
As a non-canonical Wnt signal, Wnt5a specifically promotes entry into the prehypertrophic phase,
whereas it conversely blocks chondrocyte hypertrophy, acting in a stage-specific context [51, 106].
This finding was confirmed by a study showing that Wnt5a misexpression delays the maturation of
chondrocytes and the onset of bone collar formation [41]. Wnt5a increased chondrocyte
differentiation at an early stage through CaMK/calcineurin (CaN)/nuclear factor of activated T cells
(NFAT)-dependent induction of Sox9 while repressing chondrocyte hypertrophy via IкB kinase
(IKK)/nuclear factor-кB (NF-B)-dependent inhibition of Runx2 expression [9]. In mouse F9
embryonal teratocarcinoma cells, a strong activation of p38 MAPK was observed in response to
Wnt5a; treatment with SB203580 effectively abolished the stimulatory effects of Wnt5a [61]. Both
exogenous TGFβ3 and overexpression of Wnt5a stimulated PKCα and p38 MAPK activation early in
the culture, resulting in cellular condensation and chondrogenesis. Comparatively, inhibiting PKCα or
p38 MAPK activity abolished the promotion of chondrogenic differentiation by overexpressing
Wnt5a or exogenous TGFβ3. On the other hand, partial reduction of endogenous WNT5A by small
interfering RNA diminished TGFβ3-stimulated chondrogenesis through inhibition of PKCα and p38
MAPK activity [48]. Wnt5a was also found to promote ERK1/2 phosphorylation in endothelial cells
[62]; the expression of Wnt5a blocked canonical Wnt signaling in endothelial cells and other cell
types [95]. (Fig. 4)
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However, non-canonical Wnt signaling more commonly functions through the Wnt-JNK pathways
[59]. Activation of Wnt5a signaling by interleukin 1beta (IL-1β) induced the expression of MMPs via
the JNK pathways in rabbit temporomandibular joint (TMJ) condylar chondrocytes, whereas blockage
of JNK signaling impaired the Wnt5a-induced up-regulation of MMPs [31]. The highly homologous
non-canonical Wnt signals, Wnt5a and Wnt5b, have differential effects on cartilage development in
regard to cell proliferation and expression of type II collagen. Unlike Wnt5a, Wnt5b repressed
chondrocyte differentiation in both the initial stages of cartilage condensation and the late
hypertrophic stage [106]. Wnt5b activated JNK, a component of the PCP pathway, contributing to an
increase in cellular migration and Wnt5b-mediated decreases in cell-cell adhesion through an
activation of Src and subsequent cadherin receptor turnover [10]. (Fig. 4)
Wnt5a also plays an important role in osteoblast differentiation. The MAPK pathway was altered in
Wnt5a-deficient mouse calvarial cells, suggesting that Wnt5a signaling influenced the MAPK/JNK
pathway [37]. Other studies provide evidence for crosstalk between Wnt5a and MAPK. Ishitani et al.
found that overexpression of Wnt5a in HEK293 cells activated NLK MAPK through TAK-1;
furthermore, overexpression of Wnt5a antagonized the canonical Wnt/β-catenin pathway [46].
Through CaMKII-TAK1-TAB2-NLK, non-canonical Wnt signaling transcriptionally repressed
peroxisome proliferator-activated receptor gamma (PPARG) transactivation and induced RUNX2
expression, promoting osteoblastogenesis in preference to adipogenesis in bone marrow mesenchymal
progenitors [88]. Wnt4, conventionally regarded as a non-canonical Wnt class [103], was found to
potently enhance osteogenic differentiation of mesenchymal stem cells (MSCs) isolated from human
adult craniofacial tissue in vitro and bone formation in vivo, through activating p38 MAPK, which is
known to positively regulate osteogenic differentiation induced by BMPs and other growth factors
[30, 35]. The inhibition of p38 MAPK abolished osteogenic differentiation of MSCs promoted by
Wnt4.
Wnt11 belongs to the Wnt5a subclass which exerts diverse effects through activation of the noncanonical Wnt signaling pathway [25]. Recently, Rye and Chun demonstrated that Wnt11 stimulates
the accumulation of type II collagen in articular chondrocytes [78]. In three-dimensional alginate gels,
WNT11 expression peaked at the late stage of chondrogenic differentiation of human MSCs [105]. In
Xenopus laevis and mouse P19 cells, signaling cascades activated by Wnt11 were crucial for initiating
cardiogenesis; furthermore, Wnt11 not only inhibited β-catenin signaling, but also activated JNK,
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suggesting crosstalk between Wnt11 and MAPK signals [74]. In human hepatocellular carcinoma
(HCC) cell lines, overexpression of Wnt11 activated PKC signaling, which antagonized canonical
Wnt signling through phosphorylation of β-catenin and reduction of T-cell factor (TCF)-mediated
transcriptional activity [96]. However, few studies have been reported about the interplay between
Wnt11 and MAPK signaling in the regulation of chondrogenesis.

Influence of MAPK signals on the Wnt pathway
Many studies showed that MAPKs participated in the regulation of Wnt pathway activities (Fig. 5).
Expression of constitutively active MKK6, an upstream activator of p38 MAPK, in 293T cells was
sufficient to increase the expression of β-catenin proteins, through direct phosphorylation of GSK3β
protein both in vitro and in vivo; this phosphorylation was blocked by SB203580 or the knock-out of
MKK3 and MKK6 [25, 93]. Since MAPK signals were required for the phosphorylation of PPPS/TP
motifs of endogenous LDL-related protein 6 (LRP6), Wnt3a-induced phosphorylation of endogenous
LRP6 was significantly attenuated by knock-down of JNK1 and p38β. These results were further
confirmed by pharmacological inhibition of p38 MAPK by SB203580 and that of JNK by SP600125
[14]. Rac1 can activate JNK2 to phosphorylate β-catenin, which is responsible for controlling limb
outgrowth in mouse embryos [104]. In Xenopus embryos, activation of JNK antagonized the
canonical Wnt pathway through activating the nuclear export of β-catenin rather than its cytoplasmic
stability [58]. Many receptor tyrosine kinase (RTK) systems facilitated Wnt/β-catenin signaling by the
phosphatidylinositol 3-kinase (PI3K)/AKT (or alternatively Protein Kinase B, PKB) pathway through
inhibiting GSK3 activity [18]. Interestingly, RTKs were also found to utilize ERK/LRP6 pathways for
a direct phosphorylation of β-catenin to activate WNT/β-catenin signaling [50].
By changing key signals of the Wnt pathways, some critical transcriptional factor activities such as
Sox9 or Runx2 are regulated, and eventually determine the differentiation fate of cells. BMP2, for
instance, promotes chondrogenesis by activating p38 MAPK, which in turn down-regulates Wnt7a/βcatenin signaling. Inhibition of p38 MAPK using a dominant negative mutant led to sustained Wnt7a
increase and decreased Sox9 expression, with consequent inhibition of pre-cartilage condensation and
chondrogenic differentiation [47]. Similarly, TGFβ-1 mediated MAPK activation, which controls
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WNT7A gene expression and Wnt-mediated signaling through the intracellular β-catenin-TCF
pathway, likely regulates N-cadherin expression and subsequent N-cadherin-mediated cell-adhesion
complexes during the early steps of mesenchymal progenitor cell chondrogenesis [99].
Environmental factors such as mechanical stress and cytokines may also activate the MAPK pathway.
Static compressive loading of cartilage activates the MAPK pathway, which is also known as the
stress-activated protein kinase (SAPK) pathway [28, 94]. Wnt/β-catenin signaling was not only
involved in the bone response to mechanical loading [76, 81] but also associated with the response to
mechanical damage to cartilage, which results in an increase in Wnt16 expression [20]. In MC3T3-E1
osteoblastic cells, activation of the pathway by treatment with a GSK3β inhibitor resulted in an
anabolic bone formation response whereas the application of inhibitor combined with mechanical
loading produced a synergistic effect on the expression of Wnt/β-catenin pathway target genes [76].
These results indicated that mechanical loading activated the Wnt/β-catenin signaling pathway, at
least in part, through the MAPK signaling pathway [93].

Crosstalk of MAPK and Wnt signals in cartilage inflammation and
regeneration
Osteoarthritis is a common disease, clinically manifested by joint pain, swelling, and impairment of
joint function, which leads to disability and the need for joint replacement. Levels of β-catenin and
cyclooxygenase 2 (COX2) were increased in osteoarthritic and rheumatoid arthritic (RA) cartilage,
suggesting that accumulation of β-catenin may contribute to the inflammatory responses of cartilage
by inducing COX2 expression in chondrocytes of arthritis-affected cartilage (Kim et al. 2002).
Activation of β-catenin in mature chondrocytes stimulated hypertrophy and matrix mineralization,
evidenced by the expression of MMP13 and vascular endothelial growth factor (VEGF) [19, 90].
Overexpression of β-catenin in chondrocytes markedly increased expression of matrix degradation
enzymes such as MMP-2, MMP-3, MMP-7, MMP-9, membrane-type 3 MMP (MT3-MMP), and A
Disintegrin And Metalloproteinase with Thrombospondin Motifs 5 (ADAMTS5) [90]. Evidence from
animal and in vitro models showed that knock-out of FRZB, which encodes a secreted Frizzled-related
protein that can bind Wnt proteins, is more prone to lose proteoglycans from the articular cartilage in
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the knee [60]. Through β-catenin stabilization and its nuclear translocation, Wnt signaling is
associated with negative regulation of early chondrogenesis and stimulation of chondrocyte
hypertrophy during development. Overexpression of Frzb1 lowered the expression of β-catenin [26].
The FRZB-/- mice may induce OA formation through up-regulation and stabilization of β-catenin in
the canonical Wnt pathway. Interestingly, Frzb deficiency also resulted in thicker cortical bone, with
increased stiffness and higher cortical appositional bone formation after loading, seemingly
supporting the hypothesized inverse relationship between OA and osteoporosis [21]. In addition,
canonical Wnt signaling is influenced by local factors, including alterations in glycosaminoglycan
sulfation, cartilage matrix content, TGFβ, and vitamin D. It is interesting to note that the MMPs and
ADAMTSs boosted by experimental activation of the Wnt/β-catenin pathway are quite similar to
those triggered by treatment with IL-1β or tumor necrosis factor alpha (TNFα) in chondrocytes [11].
However, the role of β-catenin in the homeostasis of cartilage is still controversial, as suggested by
Zhu et al. that inhibition of β-catenin signaling in articular chondrocytes caused increased cell
apoptosis and articular cartilage destruction in COL2A1-ICAT-transgenic mice [110]. It is assumed
that the Wnt/β-catenin pathway may be part of integrated signal transduction mechanisms through
which chondrocytes respond to deranging and catabolic cues, activate the expression of MMP and
ADAMTS genes and corresponding proteolytic activity, and undermine their phenotypic status and
ultimate tissue function [107].
Accumulating evidence supports a central regulatory role of MAPK in mediating inflammatory and
matrix degrading processes that contribute to joint tissue destruction in OA. Both OA and normal
chondrocytes expressed p38 MAPK; however, OA chondrocytes showed a much higher
phosphorylated p38 MAPK level compared to normal chondrocytes [27, 89]. Activated JNK was
detected in the cytoplasm of OA chondrocytes, but not in healthy controls [17]. In a dog model of
surgically induced OA, p38 MAPK, JNK, and ERK1/2 were all activated to a greater degree
compared to those in normal tissue [8]. Among the possible MAPK therapeutic targets for OA or RA,
p38 MAPK is generally considered to be the most promising, as p38 MAPK isoforms have been
implicated in the regulation of processes (such as migration and accumulation of leucocytes and
production of cytokines and pro-inflammatory mediators and angiogenesis) which promote disease
pathogenesis [54, 82]. p38 MAPK inhibitors have been proven effective in reducing clinical severity,
paw swelling, inflammation, cartilage breakdown, and bone erosion in a rat streptococcal cell wall
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arthritis model [63, 64], a collagen-induced-arthritis (CIA) model in mice [65], and adjuvant and CIA
models in rats [2, 70]. JNK appears to be a critical MAPK pathway for IL-1-induced collagenase gene
expression in synoviocytes and joint arthritis (Han et al. 1999; Han et al. 2001). The JNK inhibitor
SP600125 completely blocked not only IL-1-induced accumulation of phosphorylated Jun and
induction of c-Jun transcription in synoviocytes but also the AP-1 binding and collagenase mRNA
accumulation [40]. ERK is known to be involved in the regulation of IL-6, IL-12, IL-23, and TNF-α
synthesis, suggesting a possible involvement of ERK in joint damage associated with proinflammatory cytokine production by macrophages [29, 34]. ERK inhibitors have been found to be
successful in reducing inflammation in an experimental OA model in rabbits [75]; therapeutic
intervention with the goal of MEK1/2 inhibition may have interesting potential for the development of
agents for the treatment of OA. Due to important roles in transducing inflammation and joint
destruction, MAPK signals are key molecular targets for therapeutic intervention in inflammatory
diseases such as OA and RA. However, inhibitors targeting ablation or reduction of MAPK activity
are likely to have serious side effects [92].
Recently, several non-canonical Wnt isoforms such as Wnt5a and Wnt11 were reported to be involved
in IL-1β-induced dedifferentiation of articular chondrocytes [78]. Wnt5a was detectably expressed in
OA and RA and was involved in IL-1β-induced up-regulation of MMP-1, MMP-3, MMP-9, and
MMP-13 in primary TMJ condylar chondrocyte via the JNK pathway, suggesting the role of Wnt5a in
arthritic pathology and regulation of cartilage destruction. Furthermore, blockage of JNK signaling
impaired the Wnt5a-induced up-regulation of MMPs [31]. This finding indicates that crosstalk
between Wnt5a and JNK contributes to the pathogenesis of OA; meanwhile, disturbance of or
intervention in the interaction between these signals might provide new targets for OA treatment.
Several studies have indicated that signaling pathways involving MAPKs mediate the catabolic
response of chondrocytes to those inflammatory cytokines; specific inhibitors to those pathways can
counteract cytokine effects on matrix protease gene expression [33, 45, 56, 57, 79].
Besides activation of inflammatory cytokines such as IL-1, the occurrence of OA may also take the
route in which articular chondrocytes lose their differentiated phenotype and obtain a behavior with
similarities to terminal differentiating chondrocytes (hypertrophy-like), as can be found in the growth
plate of growing individuals [24, 100]. Chondrocytes in OA cartilage show an aberrant phenotype and
actively produce cartilage-degrading enzymes, such as MMP-13 and aggrecanases [67, 85, 86]. The
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higher expression of hypertrophic chondrocyte markers, type X collagen and MMP-13 [53, 71] in OA,
suggests a correlation between hypertrophy and OA. Some studies demonstrated that Wnt signaling
promoted chick chondrocyte hypertrophy through induction of the bone and cartilage-related
transcription factor Runx2. Dong et al. reported that β-catenin is able to induce RUNX2 and COL10A1
transcription as the molecular mechanism through which Wnt signaling regulates chondrocyte
hypertrophy [23]. Protein levels of β-catenin, which accumulates in OA chondrocytes, are very low in
differentiated articular chondrocytes; however, low levels of β-catenin were up-regulated during
phenotypic loss after a serial monolayer culture. Ectopic expression or inhibition of β-catenin
degradation caused cessation of cartilage-specific ECM molecule synthesis via activation of βcatenin-Tcf/Lef transcriptional activity [79]. Activation of Wnt/β-catenin signaling is usually
accompanied by a shift in chondrocyte cytoarchitecture. This event may result from a reduction of
proteoglycan pericellular matrix, or interactions between chondrocyte surface and substrate or fibrillar
components such as collagen or fibronectin, which could change intracellular signaling and upregulate cell adhesion pathways such as that of MAPK [32]. Because the loss of a differentiated
phenotype of chondrocytes is associated with cartilage destruction during arthritis [80], the canonical
Wnt pathway-mediated cell phenotype change via crosstalk with MAPK signals is another pathway
through which OA forms. For the non-canonical Wnt signal pathway, Wnt5a has been reported as a
key parameter influencing the phenotypic stability of chondrocytes [4, 107]. Wnt5a inhibits type II
collagen expression in rabbit TMJ condylar chondrocytes [31], suggesting that Wnt5a signaling may
regulate pathologic cartilage degeneration by inducing chondrocyte dedifferentiation [78]. Increased
p38 activity is accompanied by type X collagen staining in osteochondrocytes and marginal synovial
cells in a mouse OA model [84]. During monolayer culture, p38 MAPK was responsible for the loss
of chondrocyte phenotypes including type II collagen and Sox9 while the blockade of p38 MAPK
enhanced chondrocyte phenotypes, which suggests a blockade of dedifferentiation (Rosenzweig et al.
2013). Inhibition of p38 signaling in chondrocytes resulted in decreased expression of the COL10A1
gene [3, 87, 109].
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Conclusion and Future Directions
Although there is an increasing awareness of the importance of MAPK and Wnt signaling pathways in
regulating cell activities and relevant diseases such as cancer, their interaction networks and potential
roles in disease are still not fully appreciated, especially in the cartilage regeneration area (Table 1).
Cartilage differentiation and maintenance of homeostasis are finely tuned by a complex network of
signaling molecules; interplay of these signaling pathways leads to changes in cell activities and
eventually influences their differentiation fates. Over the past two decades, extensive studies on Wnt
and MAPK regulation of chondrogenesis and cartilage development have shown that Wnt and MAPK
signals have both positive and negative regulatory effects on cartilage development. Increasing
evidence indicates the involvement of Wnt and MAPK signals in the regulation of differentiated
chondrocyte functions and cartilage disease.
Recent evidence from both animal experiments and clinical samples demonstrated the role of both
Wnt and MAPK signaling in OA pathology, making these pathways attractive targets for therapy.
Some chemicals and drugs targeting MAPK or Wnt have been designed and applied clinically; while
some are effective in treatment of OA, their side effects have drawn concern. Direct targeting to Wnt
or MAPK has been reported to be too risky, because of the critical role of these signals in the
maintenance of articular chondrocyte stability. A promising method would be to identify the misregulated genes in the Wnt or MAPK pathways, and try to determine balanced therapeutic targets. The
ideal therapeutic goal would be treatment with few or even no side effects to patients. In order to
achieve the goal of clinical application, comprehensive appreciation and meticulous evaluation of
interactions of these signaling pathways are not only necessary but also required. Future research may
focus on elucidation of the network between MAPK and Wnt signaling interplays and exploration of
clinical application in cartilage regeneration by intervening in specific signaling pathways.
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Table 7. 1 Highlighted references related to the crosstalk between Wnt and MAPK pathways in
varied cell types, especially its influence in the regulation of chondrogenesis

Cell type
Mouse
F9
teratocarcino
ma cells

Approach
Gene knockout (siRNAs targeting p38α
MAPK) and chemical inhibitor (SB203580
targeting p38 MAPK)
Gene knockout (siRNA targeting Dvl-1,
Dvl-2, and Dvl-3) and chemical inhibitors
(SB203580
targeting
p38
MAPK,
SP600125 targeting JNK)

Signal
P38 MAPK
and Wnt5a

Result
Wnt5a activated p38 MAPK pathway, which feeds into
the Wnt5a/cyclic GMP/Ca2+/NF-AT pathway

Reference
Ma and Wang
2007

Wnt3a
JNK

and

Suppression of either Dvl-1 or Dvl-3 but not Dvl-2
abolished Wnt3a activation of JNK; SP600125 but not
SB203580 blocked Wnt3a activation of JNK

Bikkavilli
2008a

et

al.

Gene knockout (siRNA targeting Gα0,
Gαs, Gαq, Gα11, JNK1) and chemical
inhibitor (SB203580 targeting p38 MAPK)

Wnt3a
JNK

and

Wnt3a activated p38 MAPK while Gαs, and Gαq
knockout attenuated this effect; SB203580 attenuated
Wnt3a induced accumulation of β-catenin

Bikkavilli
2008b

et

al.

Mouse
C3H10T1/2
mesenchymal
cells

Gene transfection (dominant-negative p38,
MEK3, and MEK6) and chemical
inhibitors (SB203580 targeting p38
MAPK, MEK inhibitor U0126)

Wnt3a,
ERK
and
P38 MAPK

Wnt3a induced a rapid and transient activation of p38
MAPK and ERK; SB203580 and dominant-negative
p38, MEK3 and MEK6 led to inhibition of β-catenin
expression

Caverzasio
Manen 2007

Mouse
NIH3T3 cells

Gene transfection (recombinant Wnt3a)
and gene knockout (siRNA targeting βcatenin, ERK1, ERK2)

ERK
and
Wnt/βcatenin

Wnt3a stimulated the proliferation of fibroblast cells, at
least in part, via activation of the ERK and Wnt/βcatenin pathways

Yun et al. 2005

Mouse
Stromal cell
clone (ST2)

Gene transfection (retroviruses expressing
GqI, Dkk1, Dvl-2 derivatives, N17Rac1,
N17Cdc42, and V12Rac1) and gene
knockout (siRNA targeting β-catenin)

Wnt/βcatenin and
JNK2

JNK2 kinase activated Rac1 resulting in β-catenin
phosphorylation and canonical Wnt signaling activation

Wu et al. 2008

Chicken
mesenchymal
cells
from
embryo wing
buds

Gene transfection (dominant-negative Tcf4)

Wnt3a
JNK

and

Wnt3a inhibited chondrogenesis by stabilizing cell-cell
adhesion;
Wnt3a
caused
dedifferentiation
of
chondrocytes by activation of the β-catenin-Tcf/Lef
transcriptional complex and the c-Jun/Ap-1 pathway

Hwang et al. 2005

Gene transfection (retrovirus transfection
targeting Wnt5a, Wnt7a)

N-cadherin
(MAPKs)
and Wnt7a,
Wnt5a

Retrovirally mediated misexpression of Wnt7a inhibited
in vitro chondrogenesis whereas Wnt5a did not; Wnt
signaling in chondrogenesis was likely to involve
modulation of N-cadherin expression

Tufan
2001

Gene transfection (RCAS constructs of
Wnt5a or RCAS vector); gene knockout
(siRNA targeting Wnt5a); and chemical
inhibitors (PD169316 targeting p38
MAPK, GF109203X targeting PKC-α)

Wnt5a and
p38 MAPK

Overexpression of Wnt5a or treatment with TGFβ3
stimulated the activation of PKC-α and p38 MAPK,
both positively regulated chondrogenic differentiation;
inactivation of PKC-α and p38 MAPK by specific
inhibitors abrogated chondrogenesis stimulated by both
TGFβ3 and Wnt5a

Jin et al. 2006a

Gene transfection (dominant-negative p38
MAPK)

Wnt7a/βcatenin and
p38 MAPK

Jin et al. 2006b

Chemical inhibitors (SP600125 targeting
JNK, Src kinase inhibitor I targeting Src)

Wnt5b
JNK

BMP2 promoted chondrogenesis by activating p38
MAPK, which in turn down-regulated Wnt7a/β-catenin
signaling responsible for proteasomal degradation of
Sox9
Wnt5b not only inhibited chondrocyte hypertrophy but
also promoted cellular migration through the JNKdependent activation of Src and subsequent cadherin
receptor turnover

Gene transfection (GSK3β mutant
constructs, dominant-negative ERK1/2,
constitutively active GSK3β); gene
knockout (siRNA targeting β-catenin,
siRNA targeting ERK1/2); and chemical
inhibitors (PD98059 targeting MEK1,
LY294002 targeting PI3K, calphostin C
targeting PKC)

P38 MAPK;
ERK1/2; and
Wnt/βcatenin

ERK activation led to phosphorylation and inactivation
of GSK3β, resulting in release of β-catenin, which was
translocated into nucleus and facilitated cell
proliferation

Ding et al. 2005

Human
embryonic
kidney
293
(HEK
293)
cell line

and
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and

and

Tuan

Bradley and Drissi
2011

Human
trabecular
bone-derived
mesenchymal
progenitor
cells (MPCs)

Rabbit
temporomand
ibular
joint
(TMJ)
condylar
chondrocytes
Xenopus
embryo

Gene transfection (plasmids for wild type
p38 MAPK, constitutively active MEK6,
mutant GSK3β) and chemical inhibitors
(SB203580
targeting
p38
MAPK,
Wortmanin targeting PI3K)

Tak1 MAPK
and Wnt/βcatenin

p38
MAPK
inactivated
GSK3β
by
direct
phosphorylation at its C terminus; this inactivation led to
an accumulation of β-catenin in nucleus

Thornton
2008

Gene transfection (FGFR3 vectors, LRP6
variant vectors, plasmids expressing V5tagged FGFR2, EGFR, and TRKA) and
chemical inhibitor (U0126 targeting
ERK1/2)

Wnt/βcatenin and
ERK1/2

Wnt/β-catenin was activated by FGFR2/3, EGFR, and
TRKA kinases, which depend on ERK-mediated
phosphorylation of Wnt co-receptor LRP6

Krejci et al. 2012

Gene knockout (siRNAs targeting
MAPK1, MAPK3, MAPK8, MAPK11)
and chemical inhibitors (BIRB796 and
SB203580
targeting
p38
MAPK,
SP600125 targeting JNK, U0126 targeting
ERK1/2)
Gene transfection (plasmid containing
human type II collagen α1, plasmid of
pAGC1 containing human aggrecan
promoter) and chemical inhibitors
(SB203580
targeting
p38
MAPK,
PD98059 targeting ERK-1 specific MEK1,
SP600125 targeting JNK)

MAPKs and
Wnt/βcatenin

Several MAPKs, such as p38, ERK1/2, and JNK1, were
sufficient and required for the phosphorylation of
PPPS/TP motifs of LRP6, which is a co-receptor of
Wnts and a key regulator of Wnt/β-catenin pathway

Cervenka
2011

MAPKs and
Wnt7a

Tuli et al. 2003

Gene
transfection
(β-catenin-Tcf/Lef
expression plasmid, Wnt5a expression
vector)

Wnt5a
JNK

TGFβ1
treatment
initiated
and
maintained
chondrogenesis of MPCs through the differential
chondro-stimulatory activities of p38, ERK1, and to a
lesser extent, JNK; TGFβ1-mediated MAPK activation
controlled Wnt7a gene expression and Wnt-mediated
signaling through the intracellular β-catenin-TCF
pathway, which likely regulated N-cadherin expression
and subsequent cell-adhesion complexes during the
early steps of MPC chondrogenesis
Activation of Wnt5a signaling by IL-1β induced the
expression of MMPs via the JNK pathway

Gene transfection [constitutive-active JNK
plasmid (Flag-MKK7-hJNK1), antisense
oligo against Dsh] and chemical inhibitor
(SP600125 targeting JNK)

Wnt/βcatenin and
JNK

JNK antagonized the canonical Wnt pathway by
regulating the nucleocytoplasmic transport of β-catenin

Liao et al. 2006

and
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et

et

Ge et al. 2009

al.

al.

Figure 7. 1 The best characterized MAPK modules are the ERK pathway, the SAPK/JNK
pathway, and the p38 MAPK pathway.
The MAPK cascades consist of an MEKK, an MEK, and an MAPK. MEKKs are activated through a
large variety of extracellular signals such as growth factors, cytokine factors, and stress. The activated
MEKKs can phosphorylate and activate one or several MEKs, which, in turn, phosphorylate and
activate a specific MAPK. Activated MAPK phosphorylates and activates various substrates in the
cytoplasma and the nucleus of the cell, including transcription factors. These downstream targets
control cellular responses (e.g., apoptosis, proliferation, and differentiation).
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Figure 7. 2 Three Wnt-dependent pathways have been categorized: canonical Wnt/β-catenin
and non-canonical Wnt/PCP as well as Wnt/Ca2+ pathways.
Canonical Wnt/β-catenin pathway: In cells, with an inactive state of canonical Wnt signaling,
cytosolic β-catenin is targeted to proteolytic degradation through phosphorylation by the APC–Axin–
GSK3β complex and further ubiquitination through action of βTrCP-dependent E3 ubiquitin ligase
complex. On stimulation by Wnt ligands through binding to Fzd receptors and its co-receptor Lrp, Fzd
recruits and phosphorates Dsh, and inhibits APC–Axin–GSK3β complex formation by the recruitment
and inhibition of GSK3β. Consequently, β-catenin can accumulate in the cytoplasm and enter the
nucleus, activating transcription of target genes through association with the Lef1/Tcf transcription
factor family. Non-canonical Wnt/Ca2+ pathway: Interaction of Wnt ligands with Fzd receptors can
lead to an increase in intracellular calcium level, through possibly the activation of phospholipase C
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(PLC). Intracellular calcium will subsequently activate Ca2+/calmodulin-dependent protein kinase II
(CAMKII) and protein kinase C (PKC) in cells, as well as the transcription factor NFAT. This
pathway is particularly important for convergent-extension movements during gastrulation.
Additionally, Fzd receptors can also activate JNK, promoting expression of specific genes through
activation of AP-1. Non-canonical Wnt/PCP pathway: This pathway is characterized by an
asymmetric distribution of Fzd and related receptors, resulting in the polarization of the cell. Also,
Wnt-signaling activates Cdc42, RhoA, and Rac1 leading to cytoskeleton rearrangement. Rac1 can
also activate JNK, activating specific gene transcription through modulation of the AP-1 protein
complex.
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Figure 7. 3 Influence of canonical Wnt signals on the MAPK pathway.
Wnt3a treatment activated the Raf-1-MEK-ERK cascade and the JNK pathways. Furthermore, Wnt3a
activation of activator protein-1 (AP-1) was blocked by the inhibition of JNK with SP600125 and by
the inhibition of AP-1 with N-acetyl-L-cysteine and nordihydroguaiaretic acid. In C3H10T1/2 cells,
AP-1 was activated by ERK1/2. In totipotent mouse F9 teratocarcinoma cells, canonical Wnt-βcatenin-JNK signaling was found to be activated by G-proteins, which propagated the signals
downstream through Dishevelled (Dsh) isoforms; suppression of Dsh-1 or Dsh-3 abolished Wnt3a
activation of JNK. In addition to JNK and ERK, p38 MAPK was strongly activated by Wnt3a and the
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activated p38 MAPK regulated canonical Wnt-β-catenin signaling through regulation of GSK3β.
Chemical inhibitors of p38 MAPK (SB203580) and expression of a dominant negative (DN)-version
of p38 MAPK attenuated Wnt3a-induced accumulation of β-catenin, Lef/Tcf-sensitive gene
activation, and primitive endoderm formation.
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Figure 7. 4 Influence of non-canonical Wnt signals on the MAPK pathway.
In mouse F9 teratocarcinoma embryonal cells, a strong activation of p38 MAPK was observed in
response to Wnt5a and treatment with SB203580 effectively abolished the ability of Wnt5a’s
stimulatory effects. Wnt5a was also found to promote ERK1/2 phosphorylation, enhancing
endothelial cell survival and proliferation, and the expression of Wnt5a blocked canonical Wnt
signaling in endothelial cells and other cell types. However, non-canonical Wnt signaling more
commonly functions through the Wnt-JNK pathway. Activation of Wnt5a signaling by IL-1β induced
the expression of MMPs via the JNK pathway in rabbit temporomandibular joint (TMJ) condylar
chondrocytes, whereas blockage of JNK signaling impaired the Wnt5a-induced up-regulation of
MMPs. Wnt5a increased chondrocyte differentiation at an early stage through CaMK/NFATdependent induction of Sox9 while repressing chondrocyte hypertrophy via NF-κB-dependent
inhibition of Runx2 expression. Wnt5b activated JNK, a component of the planar cell polarity
pathway, contributed to an increase in cellular migration while Wnt5b also decreased cell-cell
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adhesion through an activation of Src and subsequent cadherin receptor turnover.
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Figure 7. 5 Influence of MAPK signals on the Wnt pathway.
Expression of constitutively active MKK6, an upstream activator of p38 MAPK, in 293T cells
increased the expression of β-catenin proteins through direct phosphorylation of GSK3β protein both
in vitro and in vivo; this phosphorylation was blocked by SB203580 or the knock-out (KO) of MKK3
and MKK6. Members of MAPKs such as ERK1/2, p38 MAPK, and JNK contributed to the
phosphorylation of PPPS/TP clusters of endogenous LDL-related protein 6 (LRP6) phosphorylation,
stimulating Wnt/β-catenin expression. Rac1, a small signaling G protein, could activate JNK2 to
phosphorylate β-catenin. In Xenopus embryos, activation of JNK antagonized the canonical Wnt
pathway through activating the nuclear export of β-catenin rather than maintaining its cytoplasmic
stability. Receptor tyrosine kinase (RTK) systems facilitated Wnt/β-catenin signaling by the
PI3K/AKT pathway through inhibiting GSK3 activities; RTKs could also phosphorylate β-catenin
through involving ERK/LRP6 pathways to activate Wnt/β-catenin signaling.
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Chapter 8: General discussion

The objectives of this dissertation were to develop a novel in vitro expansion system (decellularized
extracellular matrix) for harvesting a large amount of high-quality stem cells for cartilage
regeneration. Surface characterization and mechanical properties of dECM have been determined; the
in vitro chondrogenesis of human SDSCs following preconditioning using decellularized matrix was
delineated. Oxidative stress and inflammatory environment are commonly seen in the joints of
patients with OA. To overcome these obstacles, we further explored dECM’s anti-oxidant and antiinflammatory properties, and proved its effectiveness in a mini-pig model. MAP kinase signaling
pathways play important roles in dECM-mediated chondrogenesis; p38 MAP kinase inhibitor
(sb203580) also has anti-inflammatory properties and have been applied in an in vivo animal model.
dECM not only provides biochemical and molecular factors to influence cell differentiation, it also
provide physical support as a 3D nano-scale structure with micromechanical properties. Thus, we
conducted some preliminary studies about the potential biophysical mechanisms of dECM on stem
cells’ chondrogenesis by testing its mechanical properties such as elasticity. In the synthesis of dECM,
ascorbic acid is an effective agent to control the micromechanical properties of the dECM
microenvironment, providing the capability to manipulate micromechanical properties such as
elasticity of dECM to influence expanded stem cells’ chondrogenic fate. Our long-term goal is to
develop an efficient ex vivo matrix niche with anti-inflammatory and appropriate micromechanical
properties to provide a large quantity of qualified stem cells for chondrogenesis even under the
oxidative and inflammatory environment in OA patients. The central hypothesis is that dECM could
rejuvenate expanding stem cells for both proliferation and chondrogenic potential in a harsh
(oxidative, inflammatory) environment. Due to the need for a large quantity of high quality
chondrocytes for cartilage repair, there is increasing need for developing ex vivo matrix for stem cell
expansion. Although previous studies of dECM demonstrated promising results in promoting
chondrogenic differentiation of stem cells, its functionalities are not fully explored. By taking
advantage of its anti-oxidant and anti-inflammatory properties, dECM has demonstrated great
potentials for enhanced cell proliferation and chondrogenesis under harsh environment. In addition,
strategies for generating functional small molecules of synthetic and natural products targeting
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inflammatory signals have been considered effective in the suppression of inflammation. For instance,
inhibition of the p38 MAPK signaling pathway with SB203580 showed anti-inflammatory effects in
both cartilage explants and animal models. Preconditioning using SB203580 was assumed to
significantly enhance dECM-expanded human SDSC chondrogenic potential and acquired antiinflammatory characteristics. While biomechanics-driven approaches have greatly motivated the
development of functional cartilage tissue engineering at the tissue level, few studies reported the
influences of biomechanics on chondrogenesis from the cellular level, its molecular adaption, and its
signals on neo-cartilage formation. Although stem cell biologists have long appreciated the regulatory
roles of soluble stem cell niche signals (e.g., growth factors and cytokines) in regulating stem cell
fate, recent evidence demonstrated that mechanical and topographical cues existing in the stem cell
niche can also be sensed and transduced into intracellular biochemical and functional responses by
stem cells, a process known as mechanotransduction [1, 2]. Mechanical forces generated intrinsically
within the cell in response to its extracellular environment, and extrinsic mechanical signals from
extracellular environment, play a critical role in determining stem cell fate. By controlling dECM
elasticity or changing the nanotopography of dECM, stem cells could be steered specifically toward
chondrogenic differentiation.

dECM expanded stem cell applications in in vivo animal experiments
dECM-expanded SDSCs not only exhibited enhanced in vitro chondrogenesis, they also demonstrated
improved cartilage regeneration by repairing partial-thickness cartilage defects through intra-articular
injection in a minipig model. Intra-articular injection of dECM-expanded SDSCs yielded the most
improved cartilage resurfacing, evidenced by intensified staining of hyaline cartilage markers and
comparable depth of regenerated cartilage with surrounding host cartilage tissue. The existence of
collagen I in the regenerated cartilage suggested fibrocartilage, which was nondetectable in the
resurfacing cartilage in the group implanted with dECM-expanded SDSCs. These results might
suggest the existence of a harsh environment in minipig knees where the partial-thickness cartilage
defects were created. The harsh environment, including reactive oxygen species, inflammatory
cytokines, metalloproteinases, nitric oxide, or mechanical forces, might cause implanted cell necrosis
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or apoptosis [3]. Inflammatory stress reportedly causes dedifferentiation of chondrogenic cells to
fibroblast-like cells, resulting in the defects being filled with a mix of fibrous and cartilaginous tissues
[4].
In tissue engineering, mesenchymal stem cells or tissue constructs to be transplanted into the human
body for therapeutics often face a hostile environment. In order to prepare MSCs to better adapt to the
undesirable environment, many preconditioning strategies have been studied. Reconstruction of an in
vitro microenvironment is one preconditioning strategy. Other strategies such as controlling oxygen
concentration, mechanical stimuli, growth factors, or chemicals can be used for priming the MSCs.
Through application of basic fibroblast growth factor-2 (bFGF-2) and controlling oxygen
concentration, in addition to the 3D dECM, porcine SDSCs demonstrated dramatic enhancement of
both cell proliferation and chondrogenic potential [5]. Those environmental factors demonstrated
better effects than using dECM alone which proved to be a potential application strategy for cartilage
repair.

MAPK signal pathway with dECM in chondrogenesis of stem cells in an
inflammatory environment
Accumulating evidence supports a central regulatory role of the MAP kinases in mediating
inflammatory and matrix degrading processes that contribute to joint tissue destruction in
osteoarthritis (OA). Once activated, the MAP kinases in turn activate other protein kinases and several
transcriptional regulatory proteins [6]. Some characterized transcriptional regulatory proteins include
Elk-1 activated by ERK, c-jun activated by JNK, and ATF-2 and MEF2 activated by p38 MAPK.
These transcriptional factors regulate the expression of OA-related genes involved in the
inflammatory response, regulation of cell proliferation, and production of matrix degrading enzymes
such as MMPs.
In previous studies, we found that p38 MAPK inhibitor SB203580 was able to precondition hSDSCs,
dramatically enhancing chondrogenic differentiation. The pellets derived from DSCM and p38 MAPK
inhibitor preconditioning exhibited enhancements in resistance to IL-1β. This strategy successfully
solved the toxicity concerns of p38 MAPK inhibitors. Since JNK inhibitors are similar to p38 MAPK
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inhibitors in respect to safety profile, we wondered whether JNK inhibitor SP600125 would be able to
precondition hSDSCs with DSCM and to enhance chondrogenesis. Inhibition of JNK was once
reported to suppress chondrogenesis in ATDC5 cells [7, 8]; in chondrocytes, however, inhibition of
JNK resulted in slightly enhanced Safranin O staining and deposition of collagen type II as compared
with DMSO controls. At the molecular level, there was significantly higher mRNA expression of the
chondrogenic markers collagen type II (Col2α1), aggrecan, cartilage oligomeric matrix protein
(COMP), and Sox9 in chondrocytes treated with JNK inhibitors [9]. However, there are no studies
concerning the effects of JNK inhibitors on chondrogenesis in human mesenchymal stem cells;
additionally, we are also curious about the chondrogenic effects of JNK inhibition in a 3D
microenvironment derived from stem cells. We expect that preconditioning stem cells with JNK
inhibitor SP600125 and dECM would significantly enhance chondrogenesis and also be resistant to an
inflammatory environment.
As possible OA treatment strategies targeting c-jun and AP-1 component, specific JNK inhibitors such
as SP600125 have been developed and found to suppress IL-1-induced and JNK MAPK-mediated cjun phosphorylation and AP-1 up-regulation, resulting in consequent down-regulation of MMP-1
expression. An in vivo experiment demonstrated that SP600125 had a beneficial effect in rat adjuvant
arthritis and it modestly decreased paw swelling in rat model. Moreover, radiographic evaluation of
rats treated with JNK inhibitor showed significantly less joint damage and remodeling than control
groups [10].
Considering the effects of JNK inhibitor on chondrogenesis and its anti-inflammatory effects on OA,
we hypothesized that preconditioning stem cels with JNK inhibitor as well as 3D dECM would boost
the chondrogenesis in an inflammatory environment. The overexpression of mitogen-activated kinaseextracellular signal-regulated kinase (MAPK-ERK) has been reported in previous studies and these
findings have generated interest in MAPK-ERK as a potential target for OA therapies. Additionally,
the phosphorylated mitogen-activated protein kinase kinase-extracellular signal-regulated kinase
(MEK-ERK) was developmentally overexpressed in articular cartilage and subchondral bone in rat
OA models. Several in vitro studies also demonstrated that modulating the MEK-ERK1/2 signaling
pathway using pharmacological inhibitors proved to have beneficial effects on OA [11]. Inhibition of
ERK can enhance the cartilage phenotype by negatively regulating the hypertrophic [12] and
degradative changes [ 13, 14, 15].
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MEK inhibitor U0126 is a chemically synthesized organic compound that inhibits the activation of
MAPK (ERK1/2) by inhibiting the kinase activity of MAP kinase kinase (MAPKK or MEK1/2) and
has been widely used in in vivo and in vitro studies to explore the function of the ERK pathway.
U0126 has been demonstrated to attenuate the synthesis of inflammatory cytokines and MMPs in
cartilage cells in previous studies [16, 17]. Preclinical in vivo studies have shown that U0126
successfully reduced inflammatory rheumatoid arthritis [18].
Previous studies confirmed that ERK is a strong candidate for the discriminating switch point between
lineages and the integration of 3D information; the addition of ERK inhibitor induced a significant
amplification of osteogenic gene expression and matrix mineralization in 3D collagen I cultures [19].
ERK can be activated indirectly by matrix adhesion signaling, which can be a potential link between
matrix interaction and cellular behavior. It is therefore supposed that 3D cell matrix-induced
chondrogenesis requires the participation of ERK.
However, the study of the ERK1/2 kinase cascade has not progressed as rapidly as the development of
p38 inhibitors which have already been applied in clinical trials. In some anti-cancer therapies, ERK
inhibitors have revealed certain toxicities, with side effects being perhaps the most frequent amongst
them [20]. On the other hand, there are no studies about the influences of ERK inhibition in 3D
environment for the chondrogenesis of hMSCs. Considering the antioxidant and anti-inflammatory
effects of the dECM model, we hypothesized that the interference with ERK signals in the 3D dECM
microenvironment would significantly enhance chondrogenesis of stem cells; also, we expect such
chondrogenesis would perform better in an inflammatory environment.

Biomechanical stimulations influence stem cell behaviors and chondrogenic
differentiation fate
The control of stem cell fate via cell-exerted forces (e.g. by modulating substrate stiffness) and
exogenous mechanical stimulation is increasingly being explored as a possible differentiation strategy.
By changing the substrate stiffness, the resultant cell-exerted forces can be altered to control stem cell
lineage commitment. At the single cell level, differentiating stem cells exhibit altered mechanical
properties. For example, mouse stem cells demonstrate increased stiffness after 6 days of chemical
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differentiation, with up to 3-fold higher stiffness values compared to undifferentiated cells [21]. The
results from the González-Cruz et al. study indicate that cellular mechanical properties are predicative
of adipose stem cell (ASC) differentiation and synthetic potential. Significant correlations existed
between mechanical properties and lineage-specific metabolite production by ASC clones [22].
Mechanical forces play important roles in stem cell adhesion, spreading, proliferation, migration, and
differentiation [23]. It is difficult to precisely determine the biomechanical mechanisms in vivo related
to the cytoskeletal conformational changes. Therefore, biomimetic mechanical stimulation, including
compression, stretching, and fluid-induced shear stress, have been used to investigate the mechanism
in vitro [24]. Cyclic compression is able to alter MSC phenotype. MSCs subjected to dynamic
compression or hydrostatic pressure induced an increase of chondrocyte lineage markers and
enhanced ECM deposition [25, 26]. It was hypothesized that biomechanical stimuli can be transduced
into molecular signals during early chondrogenesis by a combination of positive and negative
effectors of cartilage specific extracellular matrix macromolecules. Although the underlying
molecular mechanisms remain elusive, it is believed that biomechanical signals converting into
biochemical signals might involve integrin or non-integrin ECM receptors, cell-cell adhesion
molecules, or alteration of cytoskeletal architecture mediated by MAP kinase [27], rho kinase [28], or
focal adhesion associated with tyrosine kinase signal transduction pathways [29, 30].
Mammalian cells not only sense applied mechanical forces, but also sense the mechanical properties
of their environment, such as the elasticity of the substrate on which they grow. Substrate stiffness
influences cell adherence and cell migration and spreading [31, 32]. Peyton et al. reported that cells
proliferate more quickly on stiff than soft substrates [33]; in addition, DNA synthesis proceeds more
rapidly in flattened, well-spread cells [34]. Furthermore, substrate stiffness also has fundamental
effects on cellular differentiation. Embryonic stem cell (ESC) differentiation has been shown to be
regulated by substrate stiffness. Engler et al. showed that mesenchymal stem cells (MSCs) grown on
soft substrates differentiated preferentially into neurons, while those on substrates with stiffness
similar to muscle and bone tissue differentiated into myocytes and osteoblasts, respectively [35]. In
regarding to chondrogenic differentiation, chondrocytes on PA gels with Young’s moduli of 4 to 100
kPa showed that chondrocytes on very soft substrates (4 kPa) promoted the maintenance of the
chondrogenic phenotype as indicated by a diffuse orientation of the actin in the cytoskeleton, low
proliferation, high collagen type II and aggrecan, and slightly lower collagen type I expression [36].
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Comparatively, chondrocytes cultured on stiff substrates showed an accelerated loss of differentiated
phenotype, which was also supported by the significant decrease of collagen type II and aggrecan
production on stiffer matrices compared to cells on soft substrates. These findings indicate that
chondrocytes sense the elasticity of the matrix and might be used for the design of scaffolds with
mechanical properties specifically tailored to support the chondrogenic phenotype in tissue
engineering applications. It was proposed that a cell does not have a predefined stiffness; rather, cells
increase their internal stiffness until they match that of the substrate. This way, cells mechanically
probe their microenvironment and change their corresponding behaviors, such as adhesion, migration,
and proliferation [37].
Ni and coworkers explained this phenomenon through proposing a mathematical model in which the
morphology of a cell adhering to a substrate is characterized by competition between strain energies
(cell and substrate) and interfacial energy (work of adhesion at the cell periphery) and that the final
configuration of cell morphology is determined by the minimum of total free energy of the cellsubstrate

system.

Thus,

the

cell

changes

into

its

energetically

favorable

shape

by

assembling/disassembling of focal adhesions distributed around the cell periphery [38]. Daniel et al.
reported that substrate elasticity modulated the TGF-β1 stimulated re-differentiation of expanded/dedifferentiated human articular chondrocytes (HAC). Specifically, human articular chondrocytes on
soft substrate were restricted cortically while, on the stiffer substrates, F-actin assembled into stress
fibers, while type II collagen mRNA expression on the soft substrate (Young’s modulus of
0.26 ± 0.08 kPa) was dramatically enhanced [39].
Cells attached to a substrate have been shown to exert contractile forces, resulting in tensile stresses in
the cytoskeleton. The relationship between these forces and the mechanical stiffness, or elasticity, of
the ECM can have a major influence on cell behaviors such as migration, apoptosis [24], and
proliferation [40]. Through changing a series of cell activities, ECM stiffness can influence cell
differentiation fate. MSCs grown on variably compliant polyacrylamide gel were found to alter their
properties in relation to the stiffness of the substrate (i.e., stiffer substrates induced stiffer cells). It is
well known that chondrocytes expanded on plastic usually experienced “dedifferentiation”, which
might hinder its subsequent differentiation capabilities. Cells can regain their differentiation
phenotype; however, in order to produce functional cartilage tissue, after transferring and expansion
into a 3D environment [41], the redifferentiation process needs to induce the production of a
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substantial amount of GAGs to enable load bearing of the developed tissue, and the stimulation of
collagen type II over type I secretion in order to avoid the formation of fibrocartilage [42]. While a 3D
environment plays a crucial role in regaining chondrogenic phenotype, few systematic studies
investigate the influence of isolated matrix properties on this process [43].
Aging is another important factor that might influence the cell cytoskeletal organization and focal
adhesion. The loss of tissue elasticity has a close relationship with aging, as observed in human
epithelial tissue. It is believed that the loss of tissue elasticity results from rigidification of the
extracellular matrix due mostly to an increase of polymerization of collagen and elastin [44].
Berdyyeva et al. reported that tissues become more rigid through intracellular changes that enhance
cell rigidity of individual cells [45], which might have a positive correlation with the surface density
of cytoskeletal fibers. In the past decade, increasing research has been reported about the benefits of a
young microenvironment to cell differentiation compared to an old microenvironment in different
types of cells [46, 47, 48]. However, most researchers tried to explain the potential mechanisms from
the biochemical and molecular perspective. How aging-related elasticity changes influence the cell
behaviors and differentiation fate has rarely been investigated.
The mechanical properties of tissues are not only important for maintaining macroscale mechanical
integrity but also essential regulators of cellular function. Cells sense stiffness using structures such as
integrins to attach to the ECM and often remodel their environment by generating traction forces via
actomyosin contractility. When alterations are made to the extracellular mechanical environment, cells
can react to these mechanical stimuli by influencing tissue development, cellular differentiation, or
disease progression. An understanding of how the mechanical properties of the dECM contribute to
cell responses and tissue formation will ultimately further the understanding of disease states
associated with aberrant mechanosensing and guide the design parameters of successful biomaterials
and tissue-engineered constructs. Future cartilage tissue engineering strategies should work to
produce biomaterials and implants that are not only chemically favorable, but also integrate
mechanical cues that dictate cellular behavior to aid in cellular differentiation and cartilage
regeneration.
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Conclusions
Cartilage defects, especially from trauma-induced cartilage injuries, do not heal or self-regenerate
well due to the absence of blood supply [1]. For the most commonly used autologous chondrocyte
implantation (ACI) technique, chondrocyte senescence and cell dedifferentiation are still bothering
clinicians in orthopaedics. The development of mesenchymal stem cell (MSC) may help to improve
the current situation. However, how to harvest a large amount of high-quality of stem cells for
cartilage repair remains a challenge for both stem cell biologists and orthopaedics surgeons.
Decellularized extracellular matrix provides an in vitro cell expansion system that applied to human
synovium-derived stem cells. In order to apply dECM cell expansion system for future clinical
treatment, the characterization of dECM and expanded cells using both SEM and AFM was compared
to the plastic control; Moreover, the proliferation and chondogenic capacity of adult human SDSCs
after expansion were compared. dECM expanded hSDSCs exhibited a fibroblst shape, a low level of
elasticity, enhanced proliferation, unique changes in stem cell surface markers and enhanced
chondrogenic capacity and hypertrophy, which are consistent with our previous findings [3]. These
results suggested that dECM holds the potential for stem cell expansion and for future cartilage
regeneration.
Furthermore, cartilage joint is a harsh environment where a lot of reactive oxygen species (ROS) and
inflammatory factors might exist. Clinical treatment of cartilage defects is challenging due to
concomitant post-traumatic joint inflammation [2]. A major source of destructive power of
inflammation is the direct and indirect generation of reactive oxygen species (ROS) and free radicals
after the inflammatory cytokine response [3]. For successful cell therapy or tissue engineering,
measures must be taken to control the inflammatory and oxidative environment in which cartilage is
regenerated [2]. The regulation of intracellular ROS and inflammatory factors is crucial for cell
survival in the harsh environment ad guarantee successful cell therapy. Novel properties of dECM in
respect to its antioxidant and anti-inflammation charcteristics have been defined. Our experiments
suggested that dECM-expanded hSDSCs acquired enhanced chondrogenic potential after treatment
with H2O2 in both proliferation and chondrogenic phase [2]. Without the IL-1β induced inflammatory
environment, dECM expanded hSDSCs yielded pellets with higher GAG amount per pellet and ratio
of GAG to DNA than those from plastic expansion. In the IL-1β induced inflammatory environment,
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both GAG amount per pellet and ratio of GAG to DNA decreased in a dose-dependent fashion;
however, dECM expanded hSDSCs yielded pellets with a significantly higher ratio of GAG to DNA
than those from plastic expansion [4]. After defining the anti-oxidant and anti-inflammatory roles of
dECM, some critical inflammation-related signals such as p38 MAPK has been proposed to copreconditioning with stem cells to positively influence its chondrogenesis. This biochemicallymodified dECM has proved its effectiveness in promoting chondrogenesis under the inflammatory
environment [4].
Thirdly, to obtain a maximal stem cell numbers with optimal chondrogenic potential, optimization of
the in vitro dECM niche is urgently needed. Driven by biomechanics research on stem cells, we
hypothesized that the Young’s modulus of dECMs could be designed by controlling the culture days
or changing ascorbic acid concentration in the normal growth medium. Stem cells expanded on
dECMs of varied elasticity were compared for their responses to expanded substrates, cell surface
phenotypes, proliferation and chondrogenic differentiation. Stem cells expanded on the D10 dECM
with higher Young’s modulus demonstrated enhanced chondrogenesis compared to D0 dECM.
Compared to 50 µM ascorbic acid prepared dECM, 250 µM ascorbic acid produced dECM showed
higher Young’s modulus value and consistently enhanced chondrogenesis. Furthermore, stem cells on
passage senescent stem cell-derived dECMs had decreased chondrogenesis but did not show statistical
significance in respect to their Young’s modulus values compared to stem cells on early passage stem
cell-derived dECM. Future work about proteomics analysis is desirable to further determine the
potential biochemical and molecular mechanisms that might contribute to chondrogenic
differentiation differences.
In conclusion, to overcome the dedifferentiation and aging problems during cell expansion and
successfully translated human adult stem cell into applications in regenerating cartilage, it is important to
recreate a functional stem cell niche in vitro. Cell-derived decellularized extracellular matrix (dECM)
scaffolds harvested from cultured cells have attracted attentions in respect to their rejuvenation and
regeneration effects on stem cell. Decellularized extracellular matrix deposited by stem cells also
demonstrated promising applications in cartilage tissue engineering, not only enhancing cell proliferation
but also promoting expanded stem cells’ chondrogenic potential instead of (or even against) hypertrophy,
which is undesirable for neo-cartilage formation. The dECM expanded stem cells also exhibited enhanced
anti-oxidant and anti-inflammatory properties, suggestive of its potential applications for the repair of
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cartilage defects in osteoarthritic patients. Therefore, the dECM approach combined with stem cells may
provide a novel and promising approach to overcome replicative senescence and chondrogenic
hypertrophy, which are two significant hurdles for cell-based cartilage engineering and regeneration. The
development of biomechanics has advanced the development of optimization of dECM in respect of its
elasticity, dECMs with appropriate Young’s modulus not only promote stem cell proliferation and
chondrogenic differentiation, but may also optimize stem cells to adapt to undesirable environment such as
oxidative or inflammatory environment. Our ultimate goal is to optimize the dECM from biochemical and
biophysical perspective to facilitate the cartilage engineering and tissue regeneration in an inflammatory
environment.
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